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Bipolar Disorder (BD) is associated with increased familial risk and alterations in the function 
of large neural networks. There have been several studies that have examined the neural 
underpinnings of BD. Of particular relevance to this thesis are functional magnetic 
resonance imaging (fMRI) studies that have examined the neural correlates of affect and 
working memory processing in BD.  
The first aim of my thesis was to examine the consistency and relative specificity of affect-
related networks in BD. Using quantitative meta-analytic techniques I examined the neural 
correlates of facial affect processing in BD compared to healthy individuals and patients with 
Major Depressive Disorder (MDD) and schizophrenia (SZ). Emotional facial stimuli elicited 
increased activation in BD patients within the parahippocampus/amygdala, anterior 
cingulate cortex (ACC) and thalamus compared to all other groups. Decreased activation of 
the lateral ventral prefrontal cortex (VPFC) was found only when BD patients where 
compared to healthy individuals. Compared to BD patients, those with MDD showed greater 
activation in the dorsal ACC while those with SZ showed hyperactivation in posterior 
associative visual cortices.  
The second aim of this thesis was to define the influence of key risk conferring single-
nucleotide polymorphisms (SNPs) on the neural underpinnings of BD. To this purpose I 
focused on the CACNA1C (rs1006737) and ANK3 (rs10994336, rs9804190) which have the 
best supported genome-wide association evidence in BD. I analysed fMRI data from 41 BD 
patients, 25 unaffected first-degree relatives (RELs) and 46 healthy unrelated individuals (HI) 
while they were performing working memory (N-back) and facial emotion labelling tasks.  
In the N-back task, HI carriers of the ANK3 rs10994336 risk-allele showed reduced activation 
in temporal regions while carriers of the ANK3 rs9804190-risk-allele showed inefficient 
overactivation in prefrontal regions. In BD patients and RELs, risk-alleles at either loci were 
associated with hyperactivation in the ventral ACC. Additionally, rs9804190 risk-allele 





In the facial emotion labelling task, for the ANK3 rs9804190 a significant group by genotype 
interaction was noted in the VPFC. The presence of the rs9804190 risk-allele was associated 
with reduced VPFC activation in BD patients and decreased activation in the RELs and HI. 
The ANK3 rs10994336 and CACNA1C rs1006737 risk-alleles were associated with increased 
activation in the inferior occipital and fusiform gyrus and the amygdala in all participants, 
regardless of group. A significant group by genotype interaction was again noted in the 
VPFC. The presence of the risk-alleles was associated with inefficient VPFC overactivation in 
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1.     Bipolar Disorder 
 
This Chapter provides a brief overview of Bipolar Disorder (BD). Specifically, it describes the 
clinical features of BD and presents estimates of the international prevalence of BD in the 
general population. 
1.1 Introduction 
Mood disorders include a broad range of psychopathological conditions whose clinical 
manifestation is characterized by affective disturbances. They are often associated with 
behavioural disturbances, cognitive impairments, thought disorders and other disruptions of 
sleep and appetite (American Psychiatric Association (APA), 2013). Moreover, it is important 
to point out that the increase in morbidity, mortality, and personal suffering associated with 
bipolar disorder is not simply a result of psychiatric symptoms. It has been shown that 
bipolar disorder is associated with a wide range of medical problems including 
cardiovascular disease, diabetes mellitus, obesity, and thyroid disease (Krishnan et al., 
2005). Moreover, Kilbourne et al. (2004) reported that in BD patients the accumulation of 
key medical risk factors related to excessive nicotine use, use of alcohol and other drugs, 
and co-occurring anxiety disorders and eating disorders lead to the early onset of medical 
diseases with poor long-term outcomes. Taken together, these evidence suggested that the 
shorter lifespan observed in BD patients (from 13.5 to 32 years shorter) (Piatt et al., 2010) 
may be due to the combination of poor mental health and these general medical problems  
associated with the disease. 
1.2 Clinical features of Bipolar Disorder 
BD is associated with high levels of disability, morbidity, mortality and increased suicidal risk 
(Oswald et al., 2007). BD is defined by the presence of episodes of mania or hypomania and 
major depression. The APA (2013) defines a major depressive episode as lasting at least two 
weeks and including depressed mood or a loss of enjoyment in everyday activities. Manic 
episodes are defined by abnormal and persistently elevated mood that must last at least 
one week and may occur in conjunction with other symptoms including decreased need for 
sleep, hyperactivity, racing thoughts and an inflated self-esteem. A less intense 





hypomanic. It shows the same clinical symptoms but it is not severe enough to cause social 
or work impairment or to require hospitalization (Table 1-1).  
The Diagnostic and Statistical Manual of Mental Disorders (DSM-5; APA, 2013) classifies BD 
in different categories that are not based on the underlying biology of the illness but rather 
on the consensus opinion of mental health professionals. The three major categories are:   
 
• BD type I comprises patients who experience at least one manic episode. The age of onset 
is between 15 and 40 years, with a greater onset frequency in the early 20s (Morgan et al., 
2005; Wittchen et al., 2003). In regard to the episode's polarity, women experience more 
depressive episodes, whereas manic and mixed episodes were equally frequent in both 
genders (Angst and Sellaro, 2000) (Table 1-2).  
• BD type II includes patients who present at least one major depressive episode and at 
least one hypomanic episode. Comparative studies indicate that, compared to patients with 
BD type I, BD type II patients have a later age of onset (Merikangas et al., 2011), a higher 
number of relapses, a greater risk of recurrence (Vieta et al., 2008), lower rates of recovery, 
and a more chronic outcome characterized by more frequent depressive episodes with 
shorter euthymic periods (Angst et al., 1987; Bora et al., 2011) (Table 1-2).  
• Cyclothymic Disorder is characterized by short periods of hypomania and short periods of 
mild depression. Cyclothymia refers to a milder form of BD, which manifestations do not 
reach levels that meet the diagnostic criteria for depression and hypomania (Table 1-2).  
1.3 Prevalence of BD 
Epidemiological studies have shown that BD is common in all cultures and ethnic groups 
(Weismann et al., 1996). A review of epidemiological studies in Europe suggests a 
prevalence of BD Type I of 1-2%, which rises to 6% when including bipolar spectrum 
disorders (Pini et al., 2005). Few studies have investigated the specific prevalence of BD type 
II; some suggest a greater prevalence of BD type II than BD type I (Vieta et al., 2008), others 
demonstrate the opposite (Faravelli et al., 1990; Sculli et al., 2004). 
In the US population, Kessler et al. (1994) reported a rate of 1.6% in a representative US 
national sample of 8,098 participating in the National Comorbidity Survey (NCS). Several 





in a sample of 9,282 US adults who participated in the National Comorbidity Survey 
Replication. These studies showed a lifetime prevalence rate for syndromal BD of 2.6% with 
a 12 month prevalence of 2.6% (Kessler et al., 2005) and 1.4% (Merikangas et al., 2007). 
Lifetime prevalence of BD increased to 4.5% when considering sub-threshold expressions 
(Merikangas et al., 2007).  
Finally, the World Mental Health Survey Initiative, involving 61,392 adults in eleven 
countries in North and South America, Europe, and Asia, reported lifetime prevalence 
estimates of syndromal BD of 1.4 %  (Merikangas et al., 2011). 
1.4 Comparison between the two major classification systems for Bipolar Disorder: the 
International Classification of Diseases (ICD-10) and the Diagnostic and Statistical manual 
of Mental Disorders (DSM-5) 
The prevailing diagnostic systems are the 10th revision of the International Classification of 
Diseases, ICD-10 (World Health Organization, 1993) and the 5th edition of the Diagnostic and 
Statistical Manual for Mental Disorders (DSM-5) (American Psychiatric Association, 2013). 
These two systems operate with diverging definitions of bipolar disorder. For the diagnosis 
of Bipolar type I, the DSM-5 requires at least one full-blown episode of mania and at least 
both a major depressive and a hypomanic episode for the diagnosis of Bipolar type II. On the 
other hand, the ICD-10 defines bipolar disorder by at least two episodes of altered mood 
state and activity level. Consequently, the ICD-10 system does not differentiate between 
bipolar type I and bipolar type II, and as long as there has been at least two hypomanic 
episodes, no major depressive episode is required for a diagnosis of bipolar disorder. Thus, 
the ICD-10 system can be said to define bipolar disorder in a broader manner than the 
DSM5, and patients with the same symptomatic picture can fall within different diagnostic 
groups, depending on the system being used (see Table 1-3 with the ICD-10 criteria for 
Bipolar Disorder).  
1.5 Economical and Societal Burden 
People living with BD suffer substantial functional impairment and as one of the top 10 
leading causes of disability worldwide its burden outranks all cancers and primary 
neurologic disorders (e.g. epilepsy and Alzheimer’s disease; Merikangas et al., 2011), with 
sufferers estimated to be unable to maintain proper work role function over 30% of the 





(e.g. excess unemployment, absenteeism and suicide) attributable to BD are almost 2 billion 
pounds per year (Das Gupta et al., 2002). These costs remain high as in 2009/2010 the 
annual cost of BD to the National Health Service (NHS) reached £342 million (Young et al., 
2011). Estimates of the total costs of BD in the USA may be even higher exceeding 45.2 
billion dollars (Wyatt & Henter, 1995). Emerging evidence also demonstrated the 
association between BD and psychosocial functioning with profound disruptions in work 
productivity and social functioning, including high unemployment rates and relationship 
breakdowns (Kessler et al., 2006; Ruggero et al., 2007; Zimmerman et al., 2010). Specifically, 
several studies reported impairments in psychosocial functioning in BD patients with 
reduced occupational, interpersonal and psychological adjustment associated not only with 
acute phases of the illness but even in fully remitted patients (Judd et al., 2008; Martinez-
Aran et al., 2007; Simonsen et al., 2010). One study, which followed‐up 128 patients with BD 
six months after admission for a manic episode, showed that 77% of patients achieved 
syndromal recovery whereas only 29% achieved functional recovery. Considering only those 
patients who achieved syndromal recovery, almost 65% failed to achieve functional 
recovery (Tohen et al., 2000). However, a study by Judd et al. (2008) also reported that the 
severity of psychosocial dysfunctions was associated with the level of affective symptom 
severity, with depressive symptoms considered more disabling than hypomanic ones and as 
















Table 1-1 DSM-5 criteria for the manic, hypomanic and major depressive episodes 
MANIC EPISODE HYPOMANIC EPISODE MAJOR DEPRESSIVE EPISODE 
SymptomD
uration 
Episode must last at least 1 
week, with symptoms 
present nearly every day  
 
Episode must last at least 4 
consecutive days, with 
symptoms present nearly 
every day  
 
Episode must last at least 2 
weeks, with symptoms 





mood, expansive, or 
irritable mood and 
abnormally and 
persistently increased goal 
directed activity or energy 
Abnormally and persistently 
elevated, expansive, or 
irritable mood and 
abnormally and persistently 
increased activity or energy 
Depressed mood  










 - Inflated self-esteem or    
   grandiosity 
 - Decreased need for sleep       
 - More talkative than usual    
   or pressure to keep talking 
 - Flight of ideas or     
   subjective experience that  
    thoughts are racing                
 - Distractibility  
 - Increase in goal-directed     
   or psychomotor agitation 
 - Excessive involvement in    
   activities that have a high  
   potential for painful  
   consequences 
 - Inflated self-esteem or    
   grandiosity 
- Decreased need for sleep       
 - More talkative than usual    
   or pressure to keep talking 
 - Flight of ideas or     
   subjective experience that  
   thoughts are racing                
 - Distractibility  
 - Increase in goal-directed     
   or psychomotor agitation 
 - Excessive involvement in    
   activities that have a high  
   potential for painful  
   consequences 
 - Weight/appetite loss/gain  
 - Insomnia/hypersomnia 
 - Psychomotor agitation or      
    retardation  
 - Fatigue/loss of energy 
 - Feelings of worthlessness 
 - Diminished ability to think/     
    Concentrate 
 - Recurrent suicidal thoughts  
Inclusion 
Criteria 
Core symptoms + 3 or 
more auxiliary Symptoms  
PLUS  
Significant distress  
OR  
Social Impairment  
Core symptoms + 3 or more   
auxiliary Symptoms  
 
At least one core Symptom + 4 
or more auxiliary Symptoms 
PLUS  
Significant distress  
OR  
Social Impairment  
Exclusion 
Criteria 
Not substance related (e.g., 
a drug of abuse, a 
medication, other 
treatment) 
Not associated with any 
other medical condition 
 
Not substance related (e.g., 
a drug of abuse, a 
medication, other 
treatment) 
Not associated with any 
other medical condition 
 
Not substance related (e.g., a 
drug of abuse, a medication, 
other treatment) 









Table 1-2 DSM-5 classification of Bipolar Disorder 
Bipolar I Disorder 
A. Criteria have been met for at least one manic episode (see Table 1-1). 
B. The occurrence of the manic and major depressive episode(s) is not better explained by 
schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, 
or other specified or unspecified schizophrenia spectrum and other psychotic disorder. 
Bipolar II Disorder 
A. Criteria have been met for at least one hypomanic episode (see Table 1-1) and at least 
one major depressive episode (see Table 1-1). 
B. There has never been a manic episode. 
C. The occurrence of the hypomanic episode(s) and major depressive episode(s) is not 
better explained by schizoaffective disorder, schizophrenia, schizophreniform disorder, 
delusional disorder, or other specified or unspecified schizophrenia spectrum and other 
psychotic disorder. 
D. The symptoms of depression or the unpredictability caused by frequent alternation 
between periods of depression and hypomania causes clinically significant distress or 
impairment in social, occupational, or other important areas of functioning. 
Cyclothymic Disorder 
A. For at least 2 years (at least 1 year in children and adolescents) there have been 
numerous periods with hypomanic symptoms that do not meet criteria for a hypomanic 
episode and numerous periods with depressive symptoms that do not meet criteria for a 
major depressive episode. 
B. During the above 2-year period (1 year in children and adolescents), the hypomanic and 
depressive periods have been present for at least half the time and the individual has not 
been without the symptoms for more than 2 months at a time. 
C. Criteria for a major depressive, manic, or hypomanic episode have never been met. 
D. The symptoms in Criterion A are not better explained by schizoaffective disorder, 
schizophrenia, schizophreniform disorder, delusional disorder, or other specified or 
unspecified schizophrenia spectrum and other psychotic disorder. 
E. The symptoms are not attributable to the physiological effects of a substance (e.g., a 
drug of abuse, a medication) or another medical condition (e.g., hyperthyroidism). 
F. The symptoms cause clinically significant distress or impairment in social, occupational, 










Table 1-3 The ICD-10 Criteria for Bipolar Disorder 
F31 Bipolar affective disorder is a disorder characterized by two or more episodes in 
which the patient’s mood and activity levels are significantly disturbed, this 
disturbance consisting on some occasions of an elevation of mood and increased 
energy and activity (hypomania or mania) and on others o a lowering of mood and 
decreased energy and activity (depression). Repeated episodes of hypomania or 
mania only are classified as bipolar. Includes: manic-depressive illness,  psychosis 
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2.    Emotion and Cognition in Bipolar Disorder: Evidence from Neuroimaging  
and Neuropsychological findings 
 
2.1 Structural Brain changes in BD 
Neuroanatomical studies have illustrated significant differences between BD patients and 
healthy individuals in several cortical and subcortical regions. Among the most consistently 
reported abnormalities are the ventricular enlargement and the presence of white matter 
hyperintensities (Kempton et al., 2008; Strakowski et al., 2002). Lateral ventricles were 
found to be increased in BD patients and notably this feature seemed to correlate with the 
number of manic episodes (Strakowski et al., 2002). The lateral ventricular enlargement has 
also been reported by an International collaborative mega-analysis of published and 
unpublished data on 321 BD patients and 442 healthy individuals. This study also reported 
that BD patients compared to healthy individuals showed increased temporal lobe (mean 
volume estimated between 2.1 and 12.6 mm larger) and putamen volumes (Hallahan et al., 
2011). In addition to these findings, gray matter (GM) abnormalities have been observed in 
the prefrontal cortex, with GM reductions in BD patients compared to healthy individuals 
(Strakowski et al., 2005). The study by Lopez-Larson et al. (2002) found that BD patients 
showed smaller GM volumes in the left superior, middle and right prefrontal regions and 
suggested that the longer duration of affective illness was associated with smaller left 
inferior prefrontal GM volumes. Similarly, reductions in GM volumes was also found by 
Brambilla et al. (2002) in the left dorsolateral prefrontal cortex (DLPFC) in unmedicated BD 
patients compared to healthy individuals. 
Additionally, a recent review reported GM volumes reductions in the subgenual ACC in BD 
patients who were in remitted or euthymic states of the illness which persisted even during 
antidepressant treatment (Drevets et al., 2008). GM volumes reduction in the ACC was also 
suggested by a meta-analysis by Bora et al. (2010) together with the evidence of decreased 
GM volumes in the fronto-insular cortex.  
Anatomical studies investigating GM volumes in subcortical regions have not yielded 
consistent findings. A review by Strakowski et al. (2005) reported both increased and 





analysis by Ng et al. (2009) reported no significant GM changes in the thalamus and 
amygdala-hippocampal regions, with few studies associated with either increases or 
decreases in these structures. These inconsistent evidence may be due to variations in age 
and in lithium use across studies (Usher et al., 2010a, Usher et al., 2010b). It has been 
widely shown that lithium has neurotrophic effects (Manji et al., 1999) and it has been 
supported by several findings that showed the association of lithium with increased GM 
volumes in BD patients (Bearden et al., 2007; van Erp et al., 2012). The mega-analysis by 
Hallahan et al. (2011) further supported these evidence by reporting increased hippocampal 
and amygdala volumes in BD patients taking lithium compared with BD patients not treated 
with lithium and healthy individuals. Finally, an international collaboration for the study of 
BD (ENIGMA consortium-bipolar group) performed one of the largest studies exploring the 
subcortical volumes in a sample of 1,745 BD patients and 2,613 healthy individuals. The 
authors reported that BD patients showed significantly lower volumes in the hippocampus, 
thalamusand amygdalaas well as larger lateral ventricles compared to healthy individuals 
(Hibar et al., under revision). 
2.2 Functional MRI 
FMRI provides an indirect measure of neuronal activity by measuring changes in blood-
oxygen-level dependent (BOLD) signal. Over the last two decades, fMRI studies have shown 
functional alterations in specific brain areas that are closely related to BD. This chapter 
provides a critical appraisal of the findings to date in patients with BD while performing 
affective and non-affective tasks. 
2.2.1 Affective cognition 
The affective processing network 
From a neurobiological perspective, it has been proposed that the normal perception of the 
emotions is performed by two neural circuits (Phillips et al., 2003). A ventral system that 
includes the hypothalamus, the insula, the amygdala, the ventral striatum, the ventral 
anterior cingulate cortex (ACC) and the prefrontal cortex, and a dorsal system that is 
composed by the hippocampus, the dorsal ACC and the prefrontal cortex. According to this 
model, the ventral system is responsible for the evaluation of the emotional stimuli as well 





the cognitive aspect of the emotion and in the regulation of the affective state. Between 
these two systems there is a reciprocal functional relationship due to their reciprocal 
anatomical connections (Fig. 2-1). 
Figure 2-1 Schematic model of the dorsal and ventral systems underpinning the 




Although the ventral and dorsal systems are essential for normal emotional response, there 
are key regions within these systems that deserve more attention. Specifically, the amygdala 
is the core region of the limbic system. It integrates external and internal information and 
has direct output connections to nuclei that control physiologic, autonomic and behavioural 
fear-induced responses (Duvarci et al., 2014). It also has extensive connections with the 
prefrontal cortex and thus to neocortical circuits involved in cognitive processes which 
integrate the emotional content of the stimuli (Ghashghaei et al., 2007). A recent voxel-
based meta-analysis by Fusar-Poli et al. (2009) generated detailed neurofunctional maps of 
emotional facial processing in an overall sample of 1,600 healthy individuals. Specifically for 
the amygdala, the authors reported increased activation of the amygdala in response to the 
presentation of facial expressions of fearful, happy and disgusted faces. 
The ACC is extremely diverse and complex and can be divided into two components based 
on its functional organization: the ventral ACC and the dorsal ACC (Bush et al., 2000). The 





(Brodmann area [BA] 25), the pregenual BA 33 and the rostral ACC (BA 24) (Devinsky et al., 
1995). Further, the ventral ACC is widely identified as connected to several subcortical 
regions including the amygdala, the thalamus and the ventral striatum and is associated 
with the regulation of the emotional behaviour in response to emotional stimuli (Paus et al., 
2001). On the other hand, the dorsal ACC (dorsal BA 24 and BA 32) is connected with the 
prefrontal and parietal cortex and it is involved in emotional appraisal and cognitive conflict 
(Bush et al., 2000) (Fig. 2-2).  
Figure 2-2 Representation of the two components of the ACC: the cognitive dorsal ACC 




Finally, the prefrontal cortex with its extensive connections with motor, perceptual and 
limbic regions of the brain is considered a key region for the emotional processing, 
especially the DLPFC and orbito-frontal cortex (OFC). Positron emission tomography (PET) 
studies have shown that the DLPFC (BA 9, BA 46) was associated with increased activation in 
several experimental conditions, including sad mood (Pardo et al., 1993) and guilt (Shin et 
al., 2000) induction, and recall of emotional material (Reiman et al., 1997). By contrast, the 
OFC (BA 11, BA 47) has direct connections with the amygdala and appears to play a crucial 
role in representation of the reward value of a stimulus and therefore in goal-directed 
behaviours (Schoenbaum et al., 2011).  
The clinical features of BD, including mood lability and irritability, are suggestive of possible 





described above. The majority of neuropsychological and fMRI studies that investigated the 
emotional processing in BD patients used facial affect recognition tasks. This is because 
emotional facial expressions are an important part of social communication and play a 
crucial role in interpersonal interaction. Evidence form fMRI studies investigating the neural 
organization of facial emotion processing in healthy individuals suggested the involvement 
of the ventral and dorsal systems as well as occipital temporal regions (e.g, the fusiform 
gyrus and superior temporal gyrus) (Fusar-Poli et al., 2009; Vytal and Harmann, 2010), areas 
implicated in perception and recognition of face identity and emotional expressions 
(Adolphs et al., 2002). In these tasks, the participant is shown a picture of someone showing 
an emotional expression and the participant is asked to identify which emotion they think 
the person is expressing. These tasks may vary in the selection of the emotions, the stimuli 
used and the task format that involved either the implicit or the explicit recognition of a 
facial emotion. While the explicit tasks involve labelling the emotions, judging the intensity 
of the emotions or matching emotions, the implicit tasks refer to the judgment of other 
facial cues (e.g. gender).  
In the following sections I describe the main neuropsychological deficits and neuronal 
dysfunctions in BD patients observed while processing the aforementioned facial affect 
recognition tasks. 
Neuropsychological studies in BD 
Neuropsychological findings have suggested altered facial affect processing in BD patients in 
either depressed, manic or euthymic state compared to healthy individuals (Wessa et al., 
2009). Gray et al. (2006) investigated the sensitivity to the facial expressions of six basic 
emotions in a sample of 14 depressed BD patients and 9 manic BD patients. The authors 
found a significantly reduced sensitivity to happy facial expressions and a general negative 
effect in depressed but not in manic patients.Moreover, the study by Schaefer et al. (2010) 
reported deficits in the emotional expression multimorph task, characterized by facial 
emotions displayed in gradations from neutral to 100% emotional expression of happy, sad, 
surprised, fearful, angry, and disgusted. The authors showed that depressed BD patients 





individuals and required more intense facial expressions before they correctly identified the 
emotion. 
Getz et al. (2003) found that manic BD patients showed deficits in the facial affect labelling 
task where they made more errors than healthy individuals. In addition, Lembke et al. 
(2002) investigated the performance in the facial affect recognition task of manic BD and 
euthymic patients with BD-I and BD-II diagnosis. The authors reported that manic BD 
patients showed the greatest impairments overall in the facial affect recognition task with 
worse recognition of fear and disgust compared to healthy individuals whereas euthymic 
BD-II patients showed enhanced fear recognition compared to manic and euthymic BD-I 
patients. Moreover, Bozikas et al. (2006) explored the performance of euthymic BD patients 
in tests assessing identity (Kinney’s Identity Matching Test) and matching facial emotion 
expressions (Kinney’s Affect Matching Test). The authors found impairments in the affect 
matching task without, though, providing details on each of the different emotions. Martino 
et al. (2008) found that euthymic BD patients showed impairments in the recognition of fear 
and disgust compared to healthy individuals while processing a facial emotion recognition 
task. Hoertnagl et al. (2011) examined the facial emotion recognition abilities by using the 
facially expressed emotion labelling test in 47 euthymic BD patients. The authors showed 
that BD patients were significantly impaired in the recognition of happiness and disgust 
compared to healthy individuals. Finally, in a similar task, David et al. (2014) explored the 
performance of 110 BD patients in different mood states (depressive, manic and euthymic) 
during a facial emotion recognition test (FER) that included faces depicting happiness, 
sadness, surprise, disgust, anger and fear. The authors showed that BD patients has lower 
overall FER performance as well as lower FER scores in fear, happiness and surprise tests 
when compared to healthy individuals. 
FMRI studies in BD 
To date, several FMRI studies have investigated the processing of emotional information in 
BD patients (Townsend et al., 2012; Strakowski et al., 2012; Chen et al., 2011). Although the 
facial emotion recognition task is the most extensively used paradigm for exploring 
emotional processing in BD patients, this section also briefly describes the major findings 





the emotional Stroop and the Iowa Gambling tasks. These tasks aim to explore the impact of 
emotional factors on cognitive processes in order to investigate how emotions modulate 
brain activity in regions that subserve cognitive functions (Drevets et al., 1998). 
The Affective Go/no-go Task 
The affective Go/no-go task involves three conditions (positive, negative and neutral) and 
participants are instructed to indicate when a positive valenced stimuli (words or faces) 
appeared in the context of negatively valenced distracters (Jongen et al., 2007). It has been 
reported that this task engages regions within the prefrontal cortex and ACC (Shafritz et al., 
2006; Elliot et al., 2000). 
Neuropsychological studies reported that BD patients showed deficits in performing this 
task (Murphy et al., 1999; Rubinzstein et al., 2000). Murphy et al. (1999) explored the 
performance of manic and depressed BD patients by employing the Cambridge 
Neuropsychological Test Automated Battery (CANTAB) which also included an affective 
Go/no-go task. In this task, the authors reported that manic BD patients showed mood-
congruent biases for sad and happy targets; patients were slower when responding to the 
presentation of sad word compared to happy word targets and made more omission errors, 
with more happy missed targets than sad targets. On the other hand, depressed BD patients 
were slower when responding to the presentation of happy word as compared to sad word 
targets. In addition, Rubinzstein et al. (2000) suggested a tendency towards significance in 
response latency in the same affective Go/no-go task employed by Murphy et al. (1999), 
with slower reaction time in euthymic BD patients compared to healthy individuals. 
From a neurobiological point of view, three fMRI studies explored the neural activation 
associated with this task during euthymic (Wessa et al., 2007; Hummer et al., 2013), 
depressed (Hummer et al., 2013) and manic (Hummer et al., 2013; Elliot et al., 2004) states. 
However, while Wessa et al. (2007) and Hummer et al. (2013) used an affective Go/no-go 
task with emotional faces as stimuli, Elliot et al. (2004) employed an affective Go/no-go task 
with emotional words. These studies found no differences in reaction time and accuracy 
measures in the diagnostic group employed. Wessa et al. (2007) showed that euthymic BD 





caudate, the dorsal anterior and posterior ACC when inhibiting emotional stimuli compared 
to healthy individuals. In addition, Hummer et al. (2013) reported that euthymic BD patients 
showed increased insula and inferior frontal activation during happy and sad face inhibition 
respectively compared to healthy individuals. For manic and depressed BD patients, the 
authors also showed increased activation in the putamen, insula and prefrontal cortex while 
inhibiting sad faces compared to healthy individuals. In addition, increased putamen and 
insula activation was also found in manic BD patients while inhibiting neutral stimuli. Finally, 
Elliot et al. (2004) reported that manic BD patients compared to healthy individuals showed 
attenuated middle frontal gyrus response and increased activation in the inferior temporal 
and frontal gyrus, middle frontal gyrus and superior frontal polar region when all the 
emotional conditions were compared with a neutral condition. Manic patients showed also 
enhanced response to emotional relative to neutral distracters in the ventrolateral 
prefrontal cortex (VLPFC) and DLPFC.  
The Emotional Stroop (eStroop) Task  
In the eStroop task, participants are instructed to pay attention to the colour of the words 
and to inhibit the emotional content of the word presented. Slower responses are indicative 
of the interference effect of the words' content on the information processing abilities 
(Compton et al., 2003). Regions that have been consistently implicated in this task are the 
ACC (Whalen et al., 1998), the amygdala and the prefrontal cortex (Compton et al., 2003). 
Two fMRI studies explored the neural activation in euthymic BD patients while performing 
the eStroop task, and specifically while comparing emotionally valent and neutral words 
(Lagopoulos et al., 2007; Malhi et al., 2005). Both studies showed that euthymic BD patients 
have decreased activation in the VLPFC compared to healthy individuals. However, the two 
studies found different pattern of activation in subcortical regions. Malhi et al. (2005) 
reported decreased activation of the amygdala, thalamus and putamen whereas Lagopoulos 
et al. (2007) found significantly greater activity in the hippocampus and amygdala in 
euthymic BD patients compared to healthy individuals.  
In summary, the fMRI studies that employed the affective Go/no-go and the eStroop tasks 





emotional modulation of this cognitive process. With regard of neural activation, these 
studies demonstrated a cognitive-emotional interference in BD patients indicated by altered 
prefrontal as well as subcortical activation, although the direction of these alterations is still 
not clear.  
The Iowa Gambling Task (IGT) 
The IGT is an affective decision making task which is composed by four decks of cards 
(A,B,C,D) that have to be chosen by the participant. Behind each deck there is a positive or 
negative monetary reward; decks A and B contain high risk cards as the reward and penalty 
money is higher, which results in net loss whereas deck C and D have lower gains but also 
lower penalties making them advantageous overall. The aim of this task is to make as much 
money as possible. It has been shown that the neural systems involved in reward processing 
engage the amygdala, striatum, thalamus and the prefrontal cortex, including OFC and ACC 
(Elliot et al., 2003).  
Neuropsychological studies suggested that manic BD patients underperformed in this task 
(Clark et al., 2001) and similar decision making tasks (Cambridge Gamble Task) (Murphy et 
al., 2001) as did unmedicated depressed BD-II patients compared to healthy 
individuals(Taylor Tavares et al., 2007).  
Two fMRI studies explored the neural activity in euthymic BD patients compared to healthy 
individuals while processing of the IGT (Frangou et al, 2008; Jogia et al., 2012). Jogia et al. 
(2012) suggested that euthymic BD patients showed increased activation in the ventro-
medial frontopolar prefrontal cortex as well greater activation of the ACC and the posterior 
cingulate cortex. No differences in reaction time and performance were found in this study. 
Frangou et al (2008) also reported a significant difference in neural responses but not in task 
performance. In this study, the authors found that euthymic BD patients showed attenuated 
neural activation throughout the prefrontal cortex and increased activation in lateral and 
polar temporal regions. Finally, a PET study by Rubinsztein et al. (2001) found that manic BD 
patients showed increased activation in the ACC and reduced activation in the frontopolar 
cortex and VLPFC compared to healthy individuals. The authors reported no group 





In summary, these studies suggest that while processing of an affective decision making 
task, BD patients showed altered activation of region within the prefrontal cortex, including 
the VLPFC and the frontopolar cortex, as well as increased activation in the limbic regions, 
such as the ACC. 
The Facial Emotion Recognition Task 
As mentioned in the previous paragraphs, the facial emotion recognition task has been 
employed by the majority of fMRI studies to investigate emotional processing in BD patients 
in different affective states compared to healthy individuals (Townsend et al., 2012). It has 
been reported that this task engages several brain regions linked to limbic, visual, 
temporoparietal and prefrontal areas (Fusar-poli et al., 2009).  
Specifically for manic BD patients, Lennox et al. (2004) showed decreased amygdala and 
ventral ACC and increased posterior cingulate and insula activation in response to sad but 
not happy facial expressions. Chen et al. (2006) suggested increased activation in the middle 
temporal gyrus, parahippocampal gyrus and thalamus to fearful faces and the fusiform 
gyrus to sad faces. For happy faces, the authors reported increased activation in left 
superior frontal gyrus, ventral prefrontal cortex and middle temporal gyrus.  
For depressed BD patients, Chen et al. (2006) reported overactivity in fronto-striato 
thalamic systems in response to happy faces whereas Altschuler et al. (2008) suggested 
reduced activations in the VLPFC and DLPFC as well as increased activation in the middle 
prefrontal cortex in response to faces with negative emotions. Almeida et al. (2010) 
reported increased amygdala activation in response to mildly sad emotional faces. Finally, 
Lawrence e al. (2004) explored neural responses to mild and intense expression of fear, 
happiness, and sadness in euthymic and depressed BD patients. The authors found a 
positive correlation with the degree of depression and increased activation in the 
hippocampus while viewing sad facial affects. 
For euthymic BD patients, the study by Hassel et al. (2008) reported decreased activation in 
the DLPFC in response to happy and fearful faces. Malhi et al. (2007) found decreased 
middle and inferior frontal gyrus, precuneus and insula as well as increased middle occipital 





gyrus in response to fearful faces. Surguladze et al. (2010) suggested increased medial 
prefrontal cortex activation in response to both fearful and happy faces as well as increased 
activation of the amygdala in response to happy faces. Moreover, two studies also found 
hyperactivation in striatal regions, including the caudate and putamen (Surguladze et al., 
2010; Hassel et al., 2008).  
In summary, these results suggested an increased activation of prefrontal regions and 
decreased activation of limbic regions, including the amygdala, in BD patients compared to 
healthy individuals. However, the valence of the emotions as well as the different mood 
states may vary this pattern of activation. 
2.2.2 Non affective cognition 
Over the last decade there has been increased interest in executive dysfunctions associated 
with BD. In this paragraph, I review the main findings with regard to the neuropsychological 
and fMRI dysfunctions that affect BD during the processing of a broad range of cognitively 
demanding tasks. 
The neural brain network underpinning executive functions 
Executive functions are of higher order cognitive abilities. They allow humans to organize 
and implement complex actions to achieve an adaptive behaviour. In humans, executive 
functions include: planning, judgement, abstract thinking, initiation and inhibition of 
behaviour, anticipation of outcomes, and the adaptation of behaviour to changing 
environmental situations (Alvarez et al., 2006). It is widely agreed that the neural substrate 
of the executive functions are frontal circuits that if damaged can lead to a "dysexecutive 
syndrome" (Duffy and Campbell, 1994). However, fMRI studies have also suggested the 
involvement of other areas activated during the performance of executive functional tasks 
including parietal and temporal regions (Szameitat et al., 2002).  
Although fMRI studies reported the presence of several neural networks across the brain 
(Power et al., 2011), the fronto-parietal network is one of the most recognized for the top-
down regulation of lower order processes and therefore on cognitive control operations 





functions are: the DLPFC, VLPFC, the dorsal ACC, the OFC and the parietal cortex. These 
regions are variously responsible for response inhibition, working memory, verbal fluency, 
signalling motivational salience, selective attention, error detection and conflict monitoring 
(Behrmann et al., 2004; Braver et al., 2001; Bush et al., 2000; MacDonald et al., 2000; Stuss 
et al., 2000).  
Neuropsychological studies in BD 
The presence of cognitive deficits during the acute phases of the disease is widely 
recognized in the literature (Latalova et al., 2011; Martinez-Aran et al., 2004; Quraishi and 
Frangou 2002). However, several meta-analyses demonstrated that neurocognitive deficits 
persist even during the euthymic phase (Arts et al, 2008; Bora et al, 2009; Mann-Wrobel et 
al., 2011; Robinson et al, 2006; Torres et al., 2007) and therefore contribute to the absence 
of a complete functional inter episode recovery with significant psychosocial difficulties also 
present during periods of euthymia (Martino et al., 2009).  
These studies obtained overlapping results, identifying worse performance (medium-large 
effect sizes) of euthymic BD patients in executive functions (working memory, verbal 
fluency), memory, sustained attention and verbal learning. The most recent meta-analysis 
by Mann-Wrobel et al. (2011) showed, in a sample of 1,026 euthymic BD patients and 1,384 
healthy individuals, that there is a generalized neurocognitive impairment with medium-
large effect sizes in BD patients compared to healthy individuals. Specifically, the authors 
explored several cognitive measures that can be grouped in seven cognitive domains, 
including speed of processing, episodic memory, executive functioning, working memory, 
ﬂuency, perceptual\problem-solving, and intellectual\verbal ability. They also reported the 
effect of possible confounding variables including sex, education, age and illness duration. 
Sex did not influence the neurpsychological functioning whereas higher education, age and 
illness duration were correlated with less neurocognitive impairment. Finally, a longitudinal 
study by Chaves et al. (2011) explored the performance on a neuropsychological test battery 
that covers a wide range of cognitive domains, including executive functions, attention, 
working memory and speed of processing, in euthymic BD patients over a period of three 
months. At baseline, the authors found that BD patients showed significant deficits in speed 





follow up, it was reported a significant interaction between change in neurpsychological 
performance and symptoms change scores in measures exploring the speed of processing as 
well as a trend towards significance in measures investigating executive functions and 
declarative memory. The authors suggested that increased in symptoms scores was 
associated with decreased task performance.  
For manic BD patients, it was found that the manic state is dominated by poorer 
performances in verbal recognition memory (Martinez-Aran et al., 2004), episodic and 
working memory, spatial attention and problem solving (Sweeney at al., 2000) as well as 
sustained attention and verbal learning (Clark et al., 2001).  
For depressed BD patients, it was suggested that the depressive state was characterized by 
poorer performances in visual immediate recall and phonemic fluency (Martine-Aran et al., 
2004; Malhi et al., 2007), working memory (Sweeney et al., 2000), sustained attention and 
verbal learning (Malhi et al., 2007).  
In summary, several strands of evidence from neuropsychological studies seem to support 
the presence of cognitive impairments in BD. The next paragraph provides an overview on 
the available evidence regarding the neural basis of these cognitive deficits in BD as 
examined using functional magnetic resonance imaging.  
FMRI studies in BD 
Working memory: The N-back 
The N-back paradigm is one of the most extensively used paradigms for assessing working 
memory in fMRI studies investigating the neural activation elicited by increased memory 
load (1-,2-,3-back). In this task, the subject is presented with a sequence of stimuli, and the 
task consists of indicating when the current stimulus matches the one from n steps earlier in 
the sequence. The load factor n can be adjusted to make the task more or less difficult. This 
task engaged several brain regions including lateral and medial premotor cortex, dorsal 
cingulate, DLPFC, VLPFC, frontal poles, and posterior parietal cortex (Owen et al., 2005; 





Nine fMRI studies exploring the working memory circuit by using the N-back task in BD 
patients have been published so far, eight on euthymic BD patients (Adler et al., 2004; 
Drapier et al., 2008; Frangou et al., 2008; Hamilton et al., 2009; Jogia et al.,2012; Monks et 
al., 2004; Thermenos et al., 2010; Townsend et al., 2010) and one on manic BD patients 
(Pomarol-Clotet et al., 2013), all matched for age and sex with healthy individuals. The 
results of these fMRI studies showed a high degree of heterogeneity with regard to accuracy 
scores and neural response, especially for the 2-/3-back condition of the N-back task. For 
task performance, four studies showed significantly decreased accuracy scores in BD 
patients compared to healthy individuals in both 2-back (Pomarol-Clotet et al., 2013; 
Drapier et al., 2008; Thermenos et al., 2010) and 3-back (Drapier et al., 2008; Jogia et al., 
2012) conditions.  
With regard to neural activation, there was a general consistency indicating a dysfunctional 
activation in BD patients in the prefrontal cortex while performing the 2-back and 3-back 
condition. Specifically, the prefrontal areas that were found consistently altered in BD 
patients compared to healthy individuals included the DLPFC and the frontal pole (BA10). 
Four of the studies reviewed showed decreased activation of the DLPFC in BD patients 
suggesting the key role of the DLPFC in the pathophysiology of BD in respect of working 
memory processing (Hamilton et al., 2009; Monks et al., 2004; Pomarol-Clotet et al., 2013; 
Townsend et al., 2010). Although Hamilton et al. (2009) found no significant difference in 
the DLPFC in the direct comparison between BD patients and healthy individuals, the 
authors suggested that healthy individuals activated more the DLPFC compared to BD 
patients.  
For the frontal pole, four studies have found the involvement of this area in BD patients. 
Depending on the N-back condition employed in these studies, BD patients showed 
increased (Adler et al., 2004; Drapier et al., 2008; Jogia et al., 2012) or decreased 
(Thermenos et al., 2010; Jogia et al., 2012) frontal pole activation compared to healthy 
individuals. Particularly, Drapier et al. (2008) was the only study that found the engagement 
of this area during processing of the 1-back condition, whereas all the others found it in 
either the 2-back (Adler et al., 2004; Jogia et al., 2012; Thermenos et al., 2010) or the 3-back 
(Jogia et al., 2012) conditions. Therefore, these differences may be due to the N-back 





could be explained by the cortical inefficiency theory reported by Jogia et al. (2012).The 
authors showed that BD patients hyperactivated the frontal polar cortex during the 2-back 
condition without achieving optimal performance and hypoactivated it during the 3-back 
condition, suggesting the inability of patients to recruit this region beyond a certain 
cognitive load. 
For the ACC, only one study by Monks et al. (2004) found decreased activation in BD 
patients compared to healthy individuals in the dorsal ACC (BA 24). 
For parietal regions, four studies showed increased activation in BD patients compared to 
healthy individuals in parietal regions expanding from the inferior parietal lobule (BA 40) to 
the superior parietal lobule (BA 7) (Adler et al., 2004; Frangou et al., 2008; Drapier et al., 
2008; Townsend et al., 2010). Only one fMRI study by Monks et al. (2004) reported 
decreased activation in the superior parietal lobule in BD patients compared to healthy 
individuals.  
For temporal regions, three fMRI studies (Adler et al., 2004; Jogia et al., 2012; Monks et al., 
2004) showed altered activation in BD patients compared to healthy individuals. Two of 
these studies reported increased activation in BD patients in the middle and superior 
temporal gyri (Adler et al., 2004; Jogia et al., 2012) whereas Monks et al. (2004) showed 
decreased activation in the middle temporal gyrus. 
Finally, increased activation was also found in the anterior insula (Adler et al., 2004; Jogia et 
al., 2012; Thermenos et al., 2010), area associated with the limbic system and involved in 
emotional arousal (Critchley et al., 2000) and not normally activated during working 
memory tasks. However, after controlling for performance the hyperactivation of the insula 
in BD patients in the study by Adler et al. (2004) was not significant.  
In summary, while performing this task BD patients failed to activate prefrontal regions 
which results in the engagement of several other brain regions, including areas within 







Response Inhibition: the Stroop Task 
The Stroop Test is a colour naming task used for assessing response inhibition. It is 
composed by three conditions: congruent, incongruent and neutral words. The neutral 
stimuli are those which are in the same text or colour as is displayed. In congruent stimuli 
colour and the colour name are the same. For instance, the word “RED” is written in “RED”. 
The incongruent stimuli are those where the colour named by the word and the font colour 
do not match. For example, the word “RED” is written in “BLUE” font. In this task, the 
subjects were instructed to ignore the word referent and name the font colour (MacLeod et. 
al., 1991). It has been reported that the Stroop task engaged specific brain regions with the 
prefrontal and parietal cortex and ACC (Bush et al., 1998; Egner and Hirsch, 2005; Gruber et 
al., 2002). 
Seven fMRI studies explored the neural activation of euthymic BD patients compared to 
healthy individuals by means of the Stroop task (Blumberg et al., 2003; Frangou et al., 2012; 
Gruber et al., 2004; Kronhaus et al., 2006; Pompei et al., 2011; Roth et al., 2006; Strakowski 
et al., 2005). Additionally, Blumberg et al. (2003) is the only study that included results 
related to BD patients also in acute manic and depressed state. 
Two versions of the Stroop task have been used in these studies: the counting Stroop and 
the colour-word naming Stroop tasks. With regard to task performance, all fMRI studies 
except for Strakowski et al. (2005) showed no difference in accuracy scores of BD patients 
compared to healthy individuals. For reaction time, two studies showed that BD patient 
were significantly slower in completing the interference condition compared to healthy 
individuals (Gruber et al., 2004; Kronhaus et al., 2006).  
On the neuronal level, the majority of these studies found evidence of hypoactivation in 
prefrontal regions in BD patients compared to healthy individuals, including the VLPFC, 
DLPFC, and the ACC. 
The decreased activation of the VLPFC in euthymic BD patients is the most consistent finding 
across all of the reviewed studies (Blumberg et al., 2003; Kronhaus et al., 2006; Pompei et 
al., 2011; Roth et al., 2006). The study by Blumberg et al. (2003) also showed that depressed 





response in the right VLPFC.Similarly, decreased activation was also found in BD patients 
compared to healthy individuals in subdivision of the cingulate cortex, including the 
posterior cingulate cortex (Roth et al., 2006) and the perigenual ACC (Gruber et al., 2004) 
during processing of the counting Stroop and the colour-word naming Stroop tasks.  
For DLPFC, two studies (Gruber et al., 2004; Kronhaus et al., 2006) showed opposite results 
with increased (Gruber et al., 2004) and decreased (Kronhaus et al., 2006) activation of the 
DLPFC.  
In summary, overall these studies suggest that BD patients showed decreased prefrontal 
and cingulate cortex activation compared to healthy individuals. Moreover, the only study 
that explored the neural activation during the Stroop task in BD patients in different 
affective states suggested that the decreased activation of the VLPFC is a common feature in 
euthymic and depressed but not in manic BD patients. However, more studies are needed 
for further replicate these results. 
Executive functions: Verbal Fluency task 
Three fMRI studies were carried out in euthymic BD patients during the performance of the 
phonological letter verbal fluency task which consists in generating a word beginning with a 
cue letter (Allin et al., 2010, Costafreda et al., 2011, Curtis et al., 2001). This task engages 
several brain regions, including the ACC, left middle and inferior frontal gyri, parietal cortex, 
and right cerebellum (Fu et al., 2002). Allin et al. (2010) employed two easy and hard sets of 
letter and showed that in both conditions BD patients had increased activation of the 
posterior cingulate cortex (PCC) compared to healthy individuals. Moreover, for the easy 
conditions they also reported decreased activation in the frontal cortex in BD patients. The 
authors found a significant difference in performance, where BD patients made more errors 
in the easy but not in the hard condition. Curtis et al. (2011) found increased activation in 
the superior medial parietal cortex, medial frontal cortex, cerebellum, lingual gyrus and 
inferior frontal gyrus in BD patients compared to healthy individuals. Finally, Costafreda et 
al. (2001) showed increased activation in the ACC, DLPFC and putamen as well as decreased 
activation in the precuneus and PCC in BD patients compared to healthy individuals. No 





Sustained attention: the Continuous Performance Task (CPT) 
The CPT involves continual monitoring of the information through visual attention. The task 
may use number, symbols or sounds and it engages different brain regions, including frontal 
and temporoparietal cortex, ACC and insula (Sepede et al., 2014). 
Three fMRI studies investigating the sustained attention in BD patients while performing a 
continuous performance test (CPT) in either manic (Fleck et al., 2012) or euthymic (Sepede 
et al., 2012; Strakowski et al., 2004) have been published so far. These studies have 
consistently reported altered activation in BD patients in the inferior frontal gyrus/insula 
with increased activation found by Strakowski et al. (2004) and reduced activation reported 
by Fleck et al. (2012). Sepede et al. (2012) reported both decreased and increased activation 
in this area during processing of correct or wrong target responses respectively. Two studies 
showed increased activation of the amygdala in both euthymic (Strakowski et al., 2004) and 
manic (Fleck et al., 2012) BD patients. 
2.3 Reliability of the N-back and the Facial Affect Labelling tasks 
Although the N-back and the facial affect labelling tasks have become a standard for 
investigating working memory and emotional processing respectively, it is vital to explore 
their construct validity and test-retest reliability. For the N-back, the behavioural study by 
Hockey et al. (2004) reported test-retest reliability measures of a visuospatial version of the 
N-back task at four levels of load (0-3-back) and yielded reliability measures between r= 0.49 
(1-back) and r= 0.73 (3-back) for accuracy, and even better values for reaction times (r= 0.69 
(2-back) and r= 0.86 (0-back). For the facial affect labelling task, behavioural studies 
reported that the test-retest reliability of facial emotional stimuli depends on the clarity of 
emotion expression (Rojhan et al., 2000; Limbrecht et al., 2012). These studies have shown 
that happy and sad items were easier to agree upon than neutral ones and that happy items 
had the highest validity, highest test–retest reliability, and highest item-total correlations.  
Moreover, the study by Plichta et al. (2012) investigated both within-subject and group-level 
reliability of brain regions associated with the N-back and facial emotion recognition task in 
a group of healthy individuals that have been scanned twice on an MRI scanner. The overall 
results showed a robust activation of the two tasks in their respective target regions 





the reliability of group level activation was excellent for the two tasks, with intraclass 
correlation coefficient of 0.89–0.98 at the whole brain level and 0.66–0.97 within target 
ROIs. 
2.4 Conclusion 
In conclusion, anatomical studies have consistently shown a ventricular enlargement in BD 
patients compared to healthy individuals but contrasting and limited findings in regards to 
GM volumes changes in cortical and subcortical regions have been reported. 
However, evidence from fMRI and neurpsychological studies in affective and non-affective 
cognition suggest that BD patients show extensive neurocognitive deficits as well as 
dysfunctions in several cortical and subcortical brain regions. For the affective cognition, the 
majority of fMRI studies in euthymic BD patients report an overall impairment in 
frontolimbic regions across all the emotional tasks described above; with hypoactivation of 
the dorsal system including the VLPFC and DLPFC and hyperactivation of the ventral system 
including the amygdala. On the other hand, for manic and depressed BD patients, most of 
the evidence originates from studies that employed facial emotion recognition tasks. These 
studies suggest increased activation of the amygdala in both manic and depressed BD 
patients as well as reduced prefrontal activation, including VLPFC and DLPFC, in depressed 
BD patients compared to healthy individuals in response to affective faces. For the non-
affective cognition, the majority of the fMRI studies use euthymic BD patients as a sample. 
Overall, these studies show dysfunctional activation in several cortical components including 
the DLPFC, VLPFC and ACC; with decreased activation in these areas in euthymic BD patients 
across the majority of cognitive tasks described. Interestingly, evidence from the few fMRI 
studies investigating manic BD patients suggest the same general reduction in prefrontal 
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3.    Neural correlates of emotional processing in Bipolar Disorder: a voxel-
based meta-analysis of functional magnetic resonance imaging studies 
 
This chapter aims to synthesize the evidence from two published meta-analyses 
investigating facial affect processing network in Bipolar Disorder (BD)(Delvecchio et al., 
2012; Delvecchio et al., 2013, published copies available in the Appendix) and discusses the 
common and distinct pattern of neural activation between BD, Major Depressive Disorder 
(MDD) and Schizophrenia (SZ). 
3.1 Introduction 
Our understanding of the neural circuitry involved in emotional processing in healthy 
individuals is mostly based on studies using facial affect as a probe (Phan et al., 2002; 
Murphy et al., 2003; Fusar-Poli et al., 2009; Vytal and Hamann, 2010). Facial aﬀect 
processing engages numerous neural systems with key nodes spatially distributed within the 
primary and extrastriate visual cortices (particularly within the fusiform gyrus) in the 
occipital and ventral temporal lobes, the superior temporal sulcus, the medial and 
ventrolateral prefrontal cortex (PFC), limbic (amygdala and insula, among others) and 
thalamic areas (Adolphs et al., 1996; Haxby et al., 2002; Phan et al., 2002; Murphy et al., 
2003; Fairhall & Ishai, 2007; Fusar-Poli et al., 2009; Vytal & Hammann, 2010; Dima et al., 
2011). We used Activation Likelihood Estimation (ALE) (Turkeltaub et al., 2002; Laird et al., 
2005; Eickhoff et al., 2009), a quantitative meta-analytic approach which allows integration 
of neuroimaging results across studies, to investigate the neural correlates of facial affect 
processing in BD and compared them to those of MDD and SZ.  
Recurrent depressive episodes and similar subsyndromal affective symptoms are shared 
features of MDD and BD (Judd et al., 2002, 2003; Angst et al., 2010). Evidence from genetic 
studies suggests both distinct and common contributions to their aetiology (McGuffin et al., 
2003). Current neurobiological models propose that mood disorders arise from disruption in 
prefrontal, limbic and subcortical regions (particularly the amygdala/hippocampus, and 
striatum) that support the adaptive regulation of affect (Savitz and Drevets, 2009). Within 
this general framework, much research effort in neuroimaging is directed towards 





reviews and meta-analyses have attempted to summarise and synthesise the available 
evidence. For example, the most recent quantitative meta-analysis of structural magnetic 
resonance studies (Kempton et al., 2011) showed that volume reductions in the basal 
ganglia and hippocampus appear specific to MDD patients and differentiated MDD from BD.  
BD and SZ also show signiﬁcant overlap in terms of clinical symptoms (Fischer & Carpenter, 
2009), genetic risk factors (International Schizophrenia Consortium, 2009; Lichtenstein et al., 
2009) and brain morphological changes (Ellison-Wright & Bullmore, 2010; Yu et al., 2010). 
Specifically, the reason whywe focused speciﬁcally on facial aﬀect processing and we 
examined whether diagnosis-related diﬀerences in the engagement of the corresponding 
neural network support a distinction between SZ and BD are threefold. 
First, diﬀerences in emotional processing have been highlighted as the most distinctive 
features diﬀerentiating SZ from BD. Both early descriptions and later investigations of the 
two syndromes (Bleuler, 1950; Kraepelin, 1971; Carpenter et al., 1973) emphasize avolition 
and restricted aﬀect in SZ and excess emotional reactivity in BD.  
Second, most of the regions involved facial aﬀect processing are also implicated in current 
models of BD and SZ that respectively highlight abnormal interaction within prefrontal–
subcortical–limbic (Strakowski et al., 2005) and prefrontal–temporal–subcortical–limbic 
networks (Gur et al., 2007a).  
Third, available ﬁndings in BD and SZ are suggestive of diagnosis-speciﬁc diﬀerences, 
particularly within limbic and posterior parieto-occipital regions. For example, viewing 
emotional faces compared to neutral faces is associated with increased engagement of the 
parahippocampus/amygdala in BD (Altshuler et al., 2005; Strakowski et al., 2005; Chen et 
al., 2006; Foland et al., 2008; Delvecchio et al., 2012) but not in SZ (Aleman & Kahn, 2005; 
Holt et al., 2006; Surguladze et al., 2006; Hall et al., 2008; Seiferth et al., 2009; Li et al., 2010; 
Anticevic et al., 2012). Additionally, recruitment in medial occipital and parietal regions 
involved in visual processing has been reported to be enhanced in SZ (Farkas et al., 1984; 
Taylor et al., 2012) and reduced in BD (Pavuluri & Passarotti, 2008).  
However, inferring potential diﬀerences or similarities between the BD, MDD and SZ from 





limited. Therefore, meta-analytic techniques are currently the best option to investigate 
brain regions diﬀerentially engaged in BD, MDD and SZ, and thus address questions of 
diagnostic speciﬁcity. 
The main goals are threefold. First, to consolidate neuroimaging findings associated with 
emotional processing in patients with BD and to examine whether meta-analytic synthesis 
of this empirical evidence aligns with current theoretical models of BD (Cerullo et al., 2009; 
Savitz and Drevets, 2009). Second, to determine whether stimulus valence modulates 
disease-related activity within the face processing network in BD patients. Third, to describe 
the distinct and common patterns of activation between BD, MDD and SZ. 
3.2 Methods 
3.2.1 Data sources and inclusion criteria contrasting BD to MDD and SZ 
Studies investigating facial affect processing in BD patients, MDD and SZ were identified 
through a comprehensive MEDLINE, EMBASE and PsycINFO search of the English-language 
literature covering publications between January 2000 and April 2012. The search keywords 
were “mania ”, “depression ”, “bipolar disorder”, " schizophrenia", “emotional processing”, 
"facial aﬀect labelling", "facial aﬀect matching", “fMRI” and their combinations as well as 
terms specifying individual facial affect (fear, happiness, sadness, anger and disgust). 
Additional articles were identified through the reference lists of these papers. 
Studies were included if they (a) reported comparisons between patients with BD, MDD or 
SZ with healthy individuals (b) employed functional magnetic resonance imaging (fMRI) (c) 
assessed brain activation by using human facial identities (d) used image subtraction 
methodology to identify foci of task-related neural changes contrasting an active (emotional 
faces) and control (neutral faces or shapes) condition, and (e) reported their results in 
standard stereotactic coordinates (either Talairach or Montreal Neurological Institute [MNI] 
space).  
We excluded studies that (a) used facial affect stimuli to investigate processes not directly 
involved in emotional processing (e.g. memory, attention), (b) involved non-facial identities 
such as emotional pictures, (c) grouped together stimuli displaying positive and negative 





patients. The threshold of statistical inference varied but we accepted the results reported 
as significant based on the criteria of the primary studies. 
3.2.2 Quantitative meta-analytical voxel-based procedure 
Facial affect processing was examined based on the contrast between facial affect and 
control conditions using Activation Likelihood Estimation (ALE) implemented in GingerALE 
2.0.4 (http://brainmap.org/Ale). The ALE method is a meta-analytical approach to 
neuroimaging that attempts to assess above chance clustering of activation probabilities 
across studies. In other words, the aim of ALE is to determine where overlap across the fMRI 
studies is significantly higher than expected when results are independently distributed 
(Eickhoff et al., 2009). In the ALE, the data imputed represent significant BOLD activation 
signals. The key advantage of ALE is that it has a neurobiologically and mathematically 
stringent concept based on probabilistic inference about activation coordinates. Instead of 
trying to model the activation map or even effect sizes, ALE coherently only deals with 
activation coordinates, which are represented in a probabilistic fashion to account for 
spatial uncertainty.  This ALE version uses a random effect model and weighting for sample 
size of the original studies (Eickhoff et al., 2009). The statistical approach used in these 
meta-analyses involved several steps. Firstly, coordinates of the foci of activation reported 
in the primary literature were transformed into Talairach space using the Lancaster 
transform (icbm2tal tool) in GingerALE. Secondly, smoothing took place, in which ALE 
generated a Gaussian probability distribution around the cluster coordinates reported in 
fMRI studies (Turkeltaub et al., 2002). Thirdly, whole brain modelled activation (MA) maps 
were generated in order to provide an estimate of the likelihood that any given voxel was 
involved in the disorder under investigation. ALE scores from the convergent MA maps were 
then calculated on a voxel-by-voxel basis to test for convergent (random-effects) rather 
than study specific foci (fixed-effects). Following, False Discovery Rate (FDR) technique was 
applied to define a threshold of significance (Laird et al., 2005). Neighbouring voxels that 
were marked as significant were grouped together as resultant clusters and the smaller 
clusters were filtered out to avoid noises in the result. Importantly, the foci that served as 
the input for the analyses were weighted by the number of participants in each study to 
assign more weight to the studies that carry more information. A similar approach for 





size. However, this approach is roughly proportional to sample size, but is a more nuanced 
measure, and serves to minimize the variance of the combined effect. Finally, an important 
drawback of the ALE method is that there is no weighting of foci by significance, design or 
demographic and clinical variables. However, the ALE algorithm identifies common 
activations, and thereby factors out effects not related to the process of interest, such as 
different methodologies that are used by different research groups. Moreover, in my two 
meta-analyses most of the fMRI studies included were age and gender matched thus 
minimising the likelihood of a systematic sex- and age-related bias confounding the effect of 
diagnosis. With regard to clinical and behavioural variables, the ALE algorithm was not able 
to adequately address the impact of these variables on the results. Such questions would be 
ideally investigated in large neuroimaging data sets where the quantitative impact of these 
variables could be directly assessed (e.g. by including only BD or MDD patients in remission 
or in acute phase of the illness). All ALE data processing was performed using the BrainMap 
Search and View software (http://brainmap.org). 
First, three separate global meta-analyses were performed (a) all studies comparing BD 
patients to healthy individuals, (b) all studies comparing MDD patients to healthy 
individuals, and (c) all studies comparing BD to SZ patients. Differences between diagnostic 
groups were tested by computing the voxel-wise difference between the ensuing ALE maps. 
Statistical inference was based on a threshold of p< 0.05 with False Discovery Rate (FDR) 
correction and a minimum cluster size of 200 mm3. 
At a second stage, a series of subsidiary meta-analyses were conducted, based on data 
availability only for patients with mood disorders, focusing on fearful and happy facial 
expressions as exemplars of negative and positive valence. For all analyses, all ALE maps 
were imported into Mango and overlaid on an anatomical template 
(http://ric.uthscsa.edu/mango/) for representation purposes. Coordinates of the maximum 
ALE and corresponding Brodmann areas are reported. 
Moderator variables for the SZ and BD group comparison 
Demographic information about age and sex and clinical information about level of 





Mean antipsychotic dose was converted to chlorpromazine equivalents (Bezchlibnyk-Butler 
& Jeﬀries, 2010). The eﬀect of other medications (e.g. lithium) was not examined because 
dosage was not mentioned in a suﬃcient number of studies. We extracted information 
about participants’ scores on the Hamilton Depression Rating Scale (HAMD; Hamilton, 
1960), the Young Mania Rating Scale (YMRS; Young et al., 1978) and the positive and 
negative subscales of the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987). 
We tested for potential group diﬀerences in these moderator variables and examined their 
inﬂuence on the ALE results using meta-regression analyses. The impact of symptom 
severity was examined in each diagnostic group separately. Based on procedures 
implemented in previous studies (Van Snellenberg et al., 2006; Anticevic et al., 2012), we 
rescaled each psychopathology scale from 0 to 1, where 0 and 1 indicated respectively the 
minimum and maximum possible scores on each scale. 
3.3 Results contrasting BD to MDD 
We identified 37 studies that used facial affect paradigms in patients with BD or MDD of 
which twenty fulfilled all inclusion criteria, giving a total sample of 168 BD and 189 MDD 
patients and 344 healthy individuals (Table 3-1 and Table 3-3). Excluded studies (a) grouped 
mood disorder patients together with other diagnostic groups (Lau et al., 2009), (b) grouped 
positive and negative facial stimuli together (Matthews et al., 2008; Yang et al., 2010; 
Anderson et al., 2011), (c) did not provide coordinates of the case – control comparison 
(Yurgelun-Todd et al., 2000; Gaffrey et al., 2010; Liu et al., 2010; Versace et al., 2010) or of 
the emotional versus neutral facial expressions contrast (Victor et al., 2010; Frodl et al., 
2010), (d) did not include a control group (Keedwell et al., 2009), (e) implemented functional 
connectivity (Almeida et al., 2009) or pattern classification analyses (Fu et al., 2008), (f) used 
facial affect stimuli to examine other processes (e.g. interference) (Keedwell et al., 2005; 
Fales et al., 2008), and (g) examined the same patient group as other included studies 
(Haldane et al., 2008; Fu et al., 2004).  
Demographic details for all participants and clinical information about BD and MDD patients 
in the studies included are shown in Table 3-1, Table 3-3, Table 3-4 and Table 3-6. As the 
definitions of participants' mental state differed in the primary studies we provided the 





studies which included medication free patients, patients received combinations of different 
psychotropics. 
3.3.1 Facial Affect processing abnormalities in BD compared to healthy individuals 
BD patients compared to healthy individuals showed (a) increased activation in the 
parahippocampal gyrus (extending to the amygdala) bilaterally, in the left putamen and left 
pulvinar (14 studies; 50 foci; 379 subjects) (Table 3-7), and (b) decreased activation 
bilaterally in the ventrolateral prefrontal cortex, within the inferior frontal gyrus (BA47) 
(Table 3-7) (Fig. 3-1). 
There was evidence of valence specific differentiation in the facial affect network 
engagement in BD patients compared to healthy individuals with respect to fearful and 
happy facial stimuli.  
In the fearful > non emotional stimuli contrast BD patients, compared to healthy individuals, 
showed (a) increased activation in the left parahippocampal gyrus (BA 28/35), left putamen 
and left pulvinar thalamus (7 studies; 30 foci; 166 subjects), and (b) decreased activation in 
the inferior frontal gyrus (BA 47/45) bilaterally and in the left anterior cingulate gyrus (BA32) 
(7 studies; 23 foci; 170 subjects) (Table 3-8) (Fig. 3-1). 
With respect to the happy > non emotional stimuli contrast BD patients compared to 
healthy individuals (a) increased activation in the caudate bilaterally and left 
parahippocampal gyrus (BA 34) (4 studies; 16 foci; 132 subjects) and (b) decreased 
activation in the right anterior cingulate gyrus (BA 32) (3 studies; 23 foci; 95 subjects) (Table 
3-8) (Fig. 3-1). 
3.3.2 Facial Affect processing abnormalities in MDD compared to healthy individuals 
MDD patients compared to healthy individuals showed (a) increased activation in the right 
parahippocampal gyrus (extending to the amygdala) (7 studies; 24 foci; 280 subjects) (Table 
3-9), and (b) decreased activation in the right putamen, and left caudate (10 studies; 44 foci; 





There was evidence of valence specific differentiation in the facial affect network 
engagement in MDD compared to healthy individuals with respect to fearful and happy 
facial stimuli.  
In the fearful > non emotional stimuli contrast MDD patients showed decreased activation 
in sensorimotor cortices within the left precentral gyrus (BA 6) (4 studies; 14 foci; 97 
subjects) (Table 3-9)(Fig. 3-2). 
With respect to the happy > non emotional stimuli contrast, activation was decreased in the 
right pulvinar thalamus in MDD patients compared to healthy individuals (Table 3-9)(Fig. 3-
2). 
3.3.3 Facial Affect processing abnormalities in BD compared to MDD 
BD patients showed greater likelihood of activation than MDD patients in the 
parahippocampal gyrus (cluster included the amygdala), in the ventral anterior cingulate 
gyrus bilaterally and in the left pulvinar. Conversely, MDD patients had increased likelihood 
of activation than BD patients in dorsal anterior cingulate gyrus (Table 3-9) (Fig. 3-2). 
3.4 Results contrasting BD to SZ 
The study selection flowchart is shown in the PRISMA diagram provided in Fig. 3-S1. We 
included 29 studies that fulfilled all inclusion criteria, giving a total sample of 268 patients 
with SZ, 267 BD patients and 483 healthy individuals. Demographic details for all 
participants and clinical information of SZ and BD patients are shown in Table 3-1, Table 3-2, 
Table 3-4 and Table 3-5. There was a signiﬁcant diﬀerence between the two patient groups 
in age (SZ: mean=31.69 years, Standard Deviation (SD)= 6.1 years; BD: mean= 35.9 years, 
SD= 4.1; t=-2.33 p= 0.026) but not sex (SZ: 64.3% men, 35.7% women, BD: 56.2% men, 
43.8% women, χ2= 3.55, p= 0.06).  
3.4.1 Facial Affect processing abnormalities in BD compared to healthy individuals 
For this analysis we included two additional studies that have not been considered in the 
analyses contrasting BD to MDD. The results of this analysis are the same as described in the 
paragraph 3.3.1 except for the left anterior cingulate cortex (BA 32, x=-10, y=30, z=18, 





2368, ALE-value= 0.01) where BD patients showed decreased activation compared to 
healthy individuals.  
3.4.2 Facial Affect processing abnormalities in SZ compared to healthy individuals 
Compared to healthy individuals, patients with SZ showed an increased likelihood of 
activation in the right cuneus and a decreased likelihood of activation in frontal regions [left 
precentral gyrus (BA 6) and left medial frontal gyrus (BA 9)], in limbic and paralimbic regions 
[right amygdala, right insula and left parahippocampal gyrus (BA 28) and anterior cingulate 
cortex (ACC; BA 32)], in occipital and occipito-temporal regions [right inferior occipital gyrus 
(BA 17) and right fusiform gyrus (BA 37)], in the basal ganglia (right caudate nucleus) and in 
the right medial dorsal thalamus (19 studies; 103 foci and 645 subjects).Details are shown in 
Table 3-10 and Fig. 3-3. No eﬀect of gender was observed but age was positively correlated 
with the likelihood of activation in the left parahippocampal gyrus (BA 28) (x=20, y=26, z=8; 
r2= 0.66, p= 0.001, voxels= 227). A higher PANSS positive symptoms subscale score 
correlated with a reduced likelihood of activation in the hippocampus/parahippocampal 
gyrus (x=38, y=18, z=14; r2= 0.56; p= 0.001, voxels= 619). A higher PANSS negative 
symptoms subscale score correlated with a reduced likelihood of activation in the precentral 
gyrus (BA 6) (x=38, y=2, z=40; r2= 0.56, p= 0.001, voxels= 33). 
3.4.3 Facial Affect processing abnormalities in SZ compared to BD 
Compared to SZ patients, patients with BD were more likely to activate the left pulvinar 
thalamus (Table 3-10, Fig. 3-3). Conversely, patients with SZ were more likely to activate the 
cuneus bilaterally (BA 18) (Table 3-10, Fig. 3-3). Age and sex did not contribute to 
diﬀerences between diagnostic groups. Diﬀerences between the two disorders in amygdala 
activation were negatively correlated with antipsychotic dose (x=22, y=6, z=12; r2= 0.98, p= 
0.001, voxels= 832). 
3.5 Discussion 
These results provide evidence of the common and distinct patterns of activation between 
BD, MDD and SZ that can be summarized in seven key findings. First, both BD and MDD 
patients showed increased activation in limbic regions irrespective of stimulus valence while 





compared to healthy individuals. Second, BD and SZ was associated with reduced prefrontal 
cortical activation. Third, MDD showed decreased engagement of somatosensory cortices 
compared to healthy individuals. Fourth, activation in the pulvinar thalamus and basal 
ganglia was increased in BD compared to healthy individuals and MDD patients. Fifth, these 
findings showed evidence of modulation by stimulus valence. Sixth, SZ patients showed 
increased likelihood of activation in the cuneus (and adjacent posterior cortical regions) 
compared to healthy individuals. Seventh, additional diﬀerences were found when BD and 
SZ patients were compared to each other. BD patients showed greater likelihood of 
activation in thalamic regions compared to SZ patients; in the reverse comparison, SZ 
patients showed increased likelihood of activation in the posterior visual association 
cortices.  
3.5.1 Increased limbic engagement: a common feature of BD and MDD but not SZ 
Evidence in BD and MDD 
These findings broadly confirm the prevailing view that mood disorders are associated with 
increased limbic activation during emotional processing (Savitz and Drevets, 2009). These 
data question however the current “amygdalocentric ” models for mood disorders. Clusters 
of abnormal medial temporal activation in both BD and MDD centred on the 
parahippocampal gyrus although they extended to include the amygdala. Chen et al. (2011) 
reported a similar pattern in a previous meta-analysis of fMRI studies in BD (Chen et al., 
2011) and we now extend these observations to MDD. The parahippocampal gyrus and 
amygdala lie very close to each other and frequently co-activate during emotional 
processing (Fusar-Poli et al., 2009; Vytal and Hamann, 2010). Therefore the accuracy in 
locating the peak of activation within medial lobe structures could be influenced by 
smoothing and transforming data from individual subjects into a common stereotactic 
space. Other methodological considerations may relate to the type of paradigm or mood 
state. For example the amygdala become more engaged when facial expressions are 
processed outside the focus of attention (Hariri et al., 2003) and their activation may 
“normalise” with symptomatic remission, especially in MDD (Delaveau et al., 2011). 
Alternatively, it is possible that these results genuinely reflect greater parahippocampal 





the amygdala are thought to subserve partially segregated dimensions of emotional 
processing; amygdala engagement may signal salience or ambiguity (Gerber et al., 2008; 
Santos et al., 2010) while parahippocampal activation may reflect context appraisal (Gerdes 
et al., 2010). Whether these processes are differentially affected in mood disorders requires 
further investigation. In any case these results add to the emerging consensus that a more 
detailed evaluation of the role of limbic structures in mood disorders is warranted and this 
should crucially involve a revaluation of the central role currently ascribed to the amygdala. 
This is timely as within the field of affective neuroscience the role of the amygdala is 
undergoing major reappraisal with greater emphasis being placed on the contribution of 
other cortical and subcortical structures (Pessoa and Adolphs, 2010).  
Evidence in SZ 
On the other hand, in the contrast between emotional and neutral facial expressions, 
patients with SZ show the opposite pattern of activation observed in mood disorders, with 
reduced activation within the amygdala/parahippocampus compared to both BD patients 
and healthy individuals. This has been attributed to abnormally elevated responses to 
neutral facial stimuli (Aleman & Kahn, 2005; Holt et al., 2006; Surguladze et al., 2006; Hall et 
al., 2008; Anticevic et al., 2012) and is thought to reﬂect abnormal salience attribution 
(Kapur, 2003). However, Gur et al. (2007b) reported that limbic activation was abnormally 
elevated in patients with SZ when they failed to identify facial expressions. This information, 
combined with behavioural evidence that SZ is associated with deﬁcits in correct facial 
aﬀect identiﬁcation, suggests that patients ﬁnd these stimuli ambiguous regardless of 
valence (Pinkham et al., 2007). It could therefore be argued that it is ambiguity (Santos et 
al., 2010), rather than inappropriate attribution, that drives limbic recruitment in SZ. 
3.5.2 Prefrontal cortex involvement: a common feature in BD and SZ but not MDD 
BD, but not MDD, was associated with reduced engagement in ventrolateral prefrontal 
regions within the inferior frontal gyrus. The ventrolateral prefrontal cortex is involved in 
inhibitory control across a number of paradigms including emotional processing (Quirk and 
Beer, 2006). Dysfunction within this region is therefore thought to reflect reduced inhibitory 
capacity in BD (Cerullo et al., 2009; Chen et al., 2011). The degree of dysfunction in this 





processed negative facial expressions. Ventrolateral PFC engagement regulates stimulus-
driven action by modulating the influence of emotional stimuli on cognition with respect to 
contextually (or socially) appropriate behaviour (Quirk and Beer, 2006). In this respect 
ventrolateral PFC dysfunction may be relevant to stimulus-driven, socially inappropriate 
behaviour observed during mania. Similarly, SZ patients showed reduced activation in the 
dorsolateral prefrontal regions within the medial PFC compared to healthy individuals. The 
dorsolateral PFC modulates the generation, interpretation and regulation or identification of 
emotions and it is involved in cognitive control processes (Ochsner et al., 2005; Lesh et al., 
2011). This finding is in line with previous fMRI evidence showing a generalized 
hypofrontality in SZ patients in this region while viewing negative emotional stimuli 
(Williams et al., 2007; Takahashi et al., 2004). Given the role of the dorsal PFC in the 
integration of cognitive mechanisms with brain regions associated with emotion (Lesh et al., 
2011), a dysfunction within this region may be therefore related to dysfunctional top-down 
support from cognitive control processes.  
3.5.3 Increased thalamic engagement in BD compared to MDD and SZ 
Increased thalamic engagement was uniquely associated with BD, which indicates enhanced 
attention towards emotionally salient stimuli from the early stages of visual processing 
(Pessoa & Adolphs, 2010). However, the results in BD and MDD suggest that thalamic 
involvement in mood disorders is complex. Thalamic activation may be influenced by 
stimulus valence. Increased pulvinar activation was observed in BD during the processing of 
negative facial expressions while decreased activation in the same nucleus was noted in 
MDD during the processing of happy faces. The pulvinar is considered a “higher order” 
nucleus because of its widespread bidirectional cortical connections (Pessoa and Adolphs, 
2010). As mentioned above, the pulvinar is directly involved in visual perception (Pessoa and 
Adolphs, 2010), particularly in directing and maintaining attention towards salient stimuli 
(Desimone et al., 1990). Therefore, these results suggest that in BD the pulvinar 
overactivation may act to amplify neural engagement for emotionally salient, particularly 
negative stimuli. The reverse appears to be the case in MDD when processing happy faces; 
this is in line with current views that MDD may be characterised by reduced reactivity to 





3.5.4 Distinct basal ganglia involvement in BD and MDD 
Diagnosis related changes were also noted in the basal ganglia where increased engagement 
was observed in BD compared to healthy individuals while the reverse was the case for 
MDD. Specifically, BD patients expressed increased activation in the putamen and in the 
caudate in response to negative and positive facial expressions respectively. The putamen is 
mainly involved in sensorimotor processing and is thought to contribute to the motor 
production of facial expressions during negative affect recognition (Adolphs et al., 2002). 
Increased putamen activation in BD patients may reflect either greater facial mimicry or 
greater amplification of sensorimotor processing of negative facial affect. The latter 
interpretation is supported by the increased engagement of the pulvinar. During happy 
facial affect processing BD patients, compared to healthy individuals, expressed increased 
activation in the caudate nucleus. This is in line with findings implicating the caudate in 
processing rewarding stimuli (Schultz et al., 1997; O'Doherty et al., 2003) including happy 
facial expressions (Phan et al., 2002). As activation in reward-circuitry structures correlates 
positively with valence (Gerdes et al., 2010) these results indicate that happy facial stimuli 
may have greater reward value for BD patients. This observation may relate to the 
inappropriate and generalised activation of reward-related structures in mania (Abler et al., 
2008). 
3.5.5 Somatosensory corteces involvement: a unique feature of MDD 
MDD patients showed decreased responsiveness in the somatosensoty corteces compared 
to healthy individuals, particularly when viewing negative facial expressions. Somatosensory 
cortices contribute to the recognition of facial emotions (Adolphs et al., 2002) possibly 
through a process of invoking or “ mirroring ” internal representations of the pertinent 
emotional experience (Adolphs et al., 2000). Since MDD patients experience negative 
emotions frequently as part of the clinical syndrome of depression this finding could be 
suggestive of adaptive down-regulation of processing of negative stimuli. Similar 
observations of reduced emotional reactivity in MDD have been made previously in a 
variety of experimental settings and are thought to reflect emotion-context insensitivity 





3.5.6 Visual cortex involvement may typify SZ but not BD and MDD 
SZ was associated with increased likelihood of engagement within the cuneus compared to 
healthy individuals and patients with BD (Table 3-10). This was coupled to reduced 
engagement within the occipitotemporal cortices, including the inferior occipital and 
fusiform gyrus, compared to healthy individuals. The occipito-temporal cortices are involved 
in early stimulus categorization (Pizzagalli et al., 2002; Lachaux et al., 2005; Tsuchiya et al., 
2008) and therefore this cluster of hypo-activation in these areas in SZ may suggest an 
impairment in visual processing of facial stimuli (regardless of emotional expression) from 
the early stages of sensory perception (Chen et al., 2009). Diﬃculties in stimulus 
categorization are also likely to increase stimulus ambiguity. It is therefore possible that a 
more general dysfunction in visual perception contributes to abnormal facial aﬀect 
processing in SZ (Kumar et al., 2010; Green et al., 2011). 
The cluster of overactivation identiﬁed corresponds to the medial cuneus, which is part of 
the extrastriate visual cortex (Iaria et al., 2008) and thus involved in higher-order processing 
of visual information. The function most consistently ascribed to the cuneus relates to early 
stimulus categorization. In this respect the cuneus may enlist mnemonic and/ or attentional 
mechanisms towards features that distinguish categories and thus modulate the quality or 
quantity of visual information reaching later processing stages (Sergent et al., 1992; Vanni et 
al., 2001). This pattern of overactivation within higher-order visual cortices in SZ was also 
observed by Taylor et al. (2012) in a meta-analysis of fMRI studies of emotional perception 
and by Seiferth et al. (2009) in a study of facial aﬀect processing in adolescents with SZ.  
Taken together, these ﬁndings suggest a signiﬁcant role for the visual cortices in SZ that is 
probably already present at the earliest stages of the illness. The nature of this 
overactivation within higher-order visual regions in SZ is unclear but the prevailing view is 
that it represents a ‘compensatory’ response to deﬁcits in integrating visual information 
(Seiferth et al., 2009; Taylor et al., 2012). Visual abnormalities in SZ are not limited to the 
perception of facial expressions but have been reported in multiple paradigms including 
motion and form perception, spatial frequency and location discrimination, perceptual 






3.6 Methodological considerations 
Activation Likelihood Estimation represents a powerful approach for the meta-analytic 
treatment of neuroimaging data. Still, a number of factors should be considered in the 
interpretation of the current set of findings. 
 First, this initial review revealed great variability in the emotional processing paradigms 
used which coupled with small sample sizes impacts on the ability to draw statistically 
robust conclusions from this literature. To minimise variability due to study design we 
focused exclusively on studies using comparable versions of facial affect processing tasks.  
Second, we included results reported as significant in the original studies since ALE analyses 
do not allow weighting based on the threshold of significance employed in each individual 
study. 
Third, there was significant variability in the level of patients' symptomatology at the time of 
testing and in the definition of “remitted” or “euthymic” states (Table 3-4, Table 3-5 and 
Table 3-6). Separate analyses of the available studies according to mood states would not 
have been statistically feasible. Therefore, the changes in regional brain activity identified 
here cannot be clearly categorised as trait or state.  
Fourth, as shown in Table 3-4, Table 3-5 and Table 3-6, with the exception of five studies, 
patients were medicated and were prescribed combinations of psychotropics. Given the 
inter-study variability in medication regimes a systematic bias influencing these results is 
improbable. Additionally psychotropic medication predominantly acts to reduce case–
control differences in neural activity in mood disorders (Phillips et al., 2008; Delaveau et al., 
2011) and schizophrenia (Cabral-Calderin et al., 2010). In the study by Cabral-Calderin et al 
(2010) antipsychotic dose seemed to reduce group diﬀerences in amygdala/ 
parahippocampal engagement. Antipsychotic medication is known to inﬂuence the function 
of the amygdala (Aleman & Kahn, 2005) but the eﬀect observed here suggests that it 
minimizes diagnostic differences.  
Fifth, sex differences have been found during facial affect processing (Fusar-Poli et al., 
2009). Although it was not possible to examine this directly, the original studies included 





thus minimising the likelihood of a systematic sex-related bias confounding the effect of 
diagnosis.  
Sixth, since most original studies examined multi-episode BD patients (Table 3-4), further 
investigation is required to clarify the relevance of these results to the initial stages of mood 
disorders.  
Seven, current meta-analytic algorithms cannot adequately address the effect of 
demographic, behavioural or clinical variables on the distribution of the reported brain 
activation patterns. Such questions would be ideally investigated in large neuroimaging data 
sets where the quantitative impact of these variables could be directly assessed.  
Eight, a further limitation is the variability in the types of tasks used in individual source 
studies, which precludes separate analyses per task type because of small sets sizes. As the 
primary literature expands, more task-speciﬁc meta-analyses should be possible in the 
future. However, these results achieved a degree of robustness that suggests that we 
captured the most replicable diﬀerences between patients with BD, MDD or SZ.  
Finally, an important problem in traditional meta-analyses is publication bias especially  
reporting statistically significant results are more likely to be submitted for publication than 
those studies with non-significant results (Duval et al., 2000). This is because traditional 
meta-analysis are concerned with the effect size of the case control differences and that 
estimate can be affected by the non-publication of studies with non-significant (i.e. small 
effect size) results. This consideration does not apply in Activation Likelihood Estimation 
(ALE) meta-analysis as this method is concerned with the consistency of significant 
activations. Therefore, negative studies would not have contributed data to the ALE in any 
case whether they were published or not.  
In general, a common method  used to identify and estimate the extent of publication bias is 
the "funnel plot". This method plots the odd ratio on the horizontal axis and the sample size 
of each study in the vertical axis. Results from small studies will scatter widely at the bottom 
of the graph, with the spread narrowing among larger studies. In the absence of bias the 
plot will resemble a symmetrical inverted funnel. Conversely, if there is bias, funnel plots 





publication bias consists in the Egger regression test which indicates the presence of a bias if 
the intercept of a regression line of effect size/standard error against 1/standard error 
significantly deviates from zero. If the resulting value yields a significant p-value, then this 
test indicates the presence of publication bias in the collection of studies (Egger et al., 
1997). 
3.7 Conclusion 
In conclusion, we provided evidence for common and distinct neural correlates in BD, MDD 
and SZ in response to emotional faces. These results suggest (a) the need  for  more detailed 
examination of the relative contribution of medial temporal regions and particularly the 
interaction between amygdala and parahippocampus, (b) the contribution of cortical,  
thalamic  and  basal  ganglia regions to the pathophysiology of mood disorders and suggest 
that  examination  of  these  cortico-thalamic-basal  ganglia circuits  may  shed  light  to  
mechanisms  differentiating  BD from  MDD, (c) that stimulus  valence is an important 
modulator of activity within the neural networks underlying emotional processing in mood 
disorders, (d) that in SZ, aﬀective modulation was reduced in the amygdala and additionally 
we show the same eﬀect throughout the traditional face processing network, and (e) that 
facial aﬀect identiﬁcation deﬁcits in SZ may arise from abnormalities in visual perception 
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Table 3-1 Details of BD studies included in the meta-analysis (in alphabetical order) 
Reference Sample (M/W) Clinical Diagnosis Age  
Mean, years 
(standard deviation) 
Design Contrast   
Almeida et al. 
(2010) 
 
15 BD (remitted) (5/10)                                
15 BD (depressed) (1/14)                     
15 HI (3/12) 
Euthymic and 
Depressed 
BD (remitted): 33.2 (7.8)                    
BD (depressed): 36.5 (11.8)                                          
MDD: 32.7 (9.8)                                        
HI: 32.6 (8) 
Explicit facial affect labelling 
task, Event related 
Sad > Neutral   
Altshuler et al. 
(2008)  
11 BD (5/6)                                             
17 HI  (9/8) 
Depressed BD: 32 (7.3)                                                
HI: 29.5 (6.6) 
Explicit facial affect matching 
task, Block 
Fearful and angry > Shapes 
Blumberg et al. 
(2005)  
17 BD (10/7)                                        
17HI (7/10) 
Unspecified BD: 40 (12.3)                                                       
HI: 33.2 (10.8) 
Implicit facial affect 
recognition, Block 
Happy > Fixation 
Chen et al. 
(2006)  
8 BD (depressed) (5/3)                           
8 BD (manic) (8/0)                                    
8 HI (2/6) 
Depressed and 
Manic 
BD (depressed): 41.8 (12)                                                             
BD (manic): 39 (13.4)                                 
HI: 38.7 (12.5) 
Explicit facial affect labelling 
task and Implicit facial affect 
recognition, Event related 
Fearful > Neutral (explicit)        
Happy > Neutral (explicit) 
 
Foland et al. 
(2008)   
9 BD (manic) (3/6)                                  
9 HI (3/6) 
Manic BD: 34.6 (8.0)                                             
HI: 30.4 (7.6) 
Explicit facial affect matching 
task, Block 




24 BD (15/9)                                         
26 HI(15/11) 
Euthymic BD: 38.8 (12.8)                                                    
HI : 37.9 (13.4) 
Explicit facial aﬀect matching 
task; Block 
Label emotions> Shapes 
Hassel et al. 
(2008)   
19 BD (10/9)                                          
24 HI (11/13) 
Euthymic BD: 32.47                                                      
HI: 27.78 
Implicit facial affect 
recognition, Event related 
Happy  > Neutral 
Hulvershorn et 
al. (2012)1 
30 BD (depressed): 18/12)                           
30 BD (manic) (19/11)                          
15 BD (euthymic) (15/0)                     
30 HI (19/11) 
Euthymic, 
Depressed, Manic 
30 BD (depressed):35 (11)                                          
30 BD (manic): 34 (11)                                        
15 BD (euthymic):31 (11)            
30 HI: 32 (10) 
 
Explicit facial aﬀect matching 
task; Block









Reference Sample (M/W) Clinical Diagnosis Age  
Mean, years 
(standard deviation) 
Design Contrast   
Jogia et al. 
(2008)
2 
12 BD (5/7)                                                 
12 HI (5/7) 
Euthymic BD: 42.1 (11.8)                                             
HI: 41.8 (10.9) 
Explicit facial affect labelling 
task, Event related 
Sad > Neutral                                       
Angry > Neutral 
Killgore et al. 
(2008)  
14 BD (11/3)                                           
13 HI (12/1) 
Manic BD: 28.1 (11.2)                                         
HI: 25.5 (4.7) 
Explicit face perception task, 
Block 
Fearful > Fixation 
 
Lawrence et al. 
(2004)3 
20 BD                                                          
11 HI 
60% Male 
Euthymic Overall mean 41 (11) Implicit facial affect 
recognition task, Event 
related 
 
Fearful > Neutral                                   
Happy > Neutral                                              
Sad >  Neutral 
Lennox et al. 
(2004)  
10 BD (8/2)                                            
12 HI (6/6) 
Manic BD: 37.3 (12.8)                                             
HI: 32.6 (10.7) 
Explicit facial affect rating 
task, Event related 
 
Sad > Neutral 
Malhi et al. 
(2007)  
10 BD (0/10)                                         
10 HI (0/10) 
Euthymic BD: 33.5 (8.7)                                              
HI: 32.4 (6.4) 
Explicit facial affect labeling 
task, Event related 
 
Fearful > Neutral 
BD=Bipolar Disorder; HI=Healthy Individuals; M=Men; W=Women.                                                                                                                                                                                                                      
1= results of these studies have been used only in one meta-analysis (Delvecchio et al., 2013); 2= only baseline data used; 3= study also included 9 Major 





Table 3-2 Details of SZ studies included in the meta-analysis (in alphabetical order) 
Reference Sample (M/W) Age  
Mean, years 
(standard deviation) 
Design Contrast   
Das et al. (2007)  14 SZ (14/0)                    
14 HI (14/0) 
SZ:20.4 (3.3)                                          
HI: 23.1 (5.9) 
Implicit facial affect viewing and Explicit facial 
affect labeling task, Block 
Fearful > Neutral   
Dowd et al. (2010)  32 SZ (20/12)                      
40 HI (26/14) 
SZ:36.25 (10.85)                                    
HI: 36.8 (8.99) 
Explicit valence rating task, Event Related                                                         Fearful > Neutral
Fakra et al. (2008)  14 SZ  (9/5)                      
14 HI (9/5) 
SZ: 34.64 (5.96)                                  
HI: 37.29 (8.87) 
Explicit facial affect matching  task, Block Fearful and angry > Shapes 
Gur et al.(2002)  14 SZ  (10/4)                  
14 HI (10/4) 
SZ: 28.8 (8.9)                                   
HI:27.4 (7.3) 
Implicit emotional valence discrimination, 
Block 
Fearful, sad, angry, happy, 
disgust > fixation cross 
Gur et al. (2007)  16 SZ (12/4)                      
17 HI(12/5) 
SZ:30.1 (6.5)                                           
HI: 25 (3.9) 
Explicit facial affect  labeling task, Event 
related 
Fearful > Neutral                                           
Angry > Neutral   
Habel et al. (2010)  17 SZ                                   
17 HI                                        
Sex unspecified  
SZ: 34.4 (8.8)                                          
HI: 34.2 (7.7) 
Explicit facial affect labeling task, Event 
related 
 
Fearful > Baseline                                        
Angry > Baseline                                           
Happy > Baseline                                                   
Sad > Baseline 
Hall et al. (2008)  19 SZ (12/7)                      
24 HI (16/8) 
SZ:37.7 (8.4)                                          
HI: 35.1 (9.7) 
Implicit facial affect recognition, Block Fearful > Neutral   
Hempel et al. (2003)  9 SZ  (4/5)                        
10 HI (6/4) 
SZ: 28                                               
HI:26 
Explicit facial affect labeling task, Block 
 
Fearful, sad, angry, happy, 





Reference Sample (M/W) Age  
Mean, years 
(standard deviation) 
Design Contrast   
Holt et al.(2006)  15 SZ (15/0)                     
16 HI (16/0) 
SZ:47.7 (7.1)                                     
HI:  48.2 (9.6) 
Implicit facial affect recognition, Block Fearful > Neutral                                           
Happy > Neutral  
Kosaka et al. (2002)  12 SZ (6/6)                       
12 HI(6/6) 
SZ:26 (4.5)                                          
HI:  24.4 (2.4) 
Emotional intensity judgment task, Block 
 
Happy > Neutral  
Lapage et al. (2011) 26 SZ (11/15)                       
26 HI (14/12) 
SZ:31.8 (7.7)                                  
HI:28.3 (5.6) 
 
Implicit facial emotion perception, Event 
related 
 
Sad and happy > Neutral 
Li et al. (2012) 12 SZ (6/6)                             
12 HI (6/6) 
SZ: 29.8 (9.24)HI: 29.25 
(7.24) 
Explicit facial emotional valence 
discrimination, Event related 
Happy >Neutral 
Fearful >Neutral 
Michalopoulou et al. (2008)  11 SZ (9/2)                       
9 HI (5/4) 
SZ:35 (9)                                              
HI: 32 (6) 
Implicit facial affect recognition, Event related 
 
Fearful > Neutral  
Rauch et al.(2010) 12 SZ (7/5)                        
12 HI (9/3) 
SZ: 27.7 (7.5)                                        
HI: 26.9 (6.1) 
Implicit facial affect recognition, Block 
 
Happy > Neutral   
Sad > Neutral   
Reske et al.  (2009)  18 SZ (10/8)                        
18 HI (10/8) 
SZ:31.94 (6.41)                                       
HI: 31.94 (6.03) 
Explicit facial affect labeling task, Event 
related 
Sad > Neutral   
Williams et al.(2007)  13 SZ (8/5) 
paranoid                             
14 SZ (9/5) (non-
paranoid)                          
13 HI (8/5) 
SZ:26.9 (9.1) paranoid                    
SZ:27.8 (10.4) non-paranoid     
HI: 25.1 (8.1) 
Implicit facial affect recognition, Block 
 
Fearful > Neutral   






Table 3-3 Details of MDD studies included in the meta-analysis (in alphabetical order) 
Reference Sample (M/W) Age  
Mean, years 
(standard deviation) 
Design Contrast   
Fu et al. (2007)
1
 19 MDD (6/13)                        
19 HI (8/11) 
MDD:43.2                     
HI:42.8 
Implicit Facial Affect Processing, Event-Related Happy > fixation 
Gotlib et al. (2005)  18 MDD (5/13)                         
18 HI (5/13) 
MDD: 35.2                    
HI:30.8 
Implicit facial affect processing, Block Happy > neutral                                                    
Sad >  neutral 
Lawrence et al. (2004)  20 BD                                  
9 MDD                                         
11 HI 
60% Male 
Overall mean 41 (11) Implicit facial affect processing , Event-Related Fear>neutral                                                        
Happy >neutral                                                        
Sad > neutral 
Lee et al. (2008)  21 MDD (3/18)                             
15 HI (2/13) 
MDD= 46.8 (9.1)                 
HI= 48.7 (3.5) 
  Explicit facial affect rating , Block Sad> fixation 
Norbury et al. (2009)  16 MDD (7/9)                            
21 HI (11/10) 
MDD:36.2                       
HI:32.3 
Explicit facial affect matching, Block Fear vs Matching Shapes 
Scheuerecker et al. (2010)  13 MDD (10/3)                     
15 HI (10/5) 
MDD=37.9 (10.1)                    
HI= 35.5 (10.9) 
Implicit and explicit facial affect matching, Block Sad and angry > shapes 
Suslow et al. (2010)  30 MDD (17/13)                          
26 HI (12/14) 
MDD: 38.8 (11.4)                 
HI: 36.2 (13.4) 
Implicit facial affect processing , Event-Related Sad > neutral 
Thomas et al. (2011)  30 rMDD (7/21)                    
37HI (12/23) 
rMDD= 32.8 (10.4)               
HI= 31.7 (9.8) 
Implicit facial affect processing , Block Sad > neutral                                                       
















Reference Sample (M/W) Age  
Mean, years 
(standard deviation) 
Design Contrast   
Townsend et al. (2010)  15 MDD (9/6)                            
15 HI (9/6) 
MDD= 45.6 (11.2)               
HI= 44.8 (11.7) 
Explicit facial affect matching, Block Sad and angry > shapes 
Van Wingen et al. (2010)  18 MDD (first 
episode) (7/11)                                           
21 rMDD (4/17)                                           
30 HI (13/17) 
MDD (first episode): 
33.3 (11.7)                                               
MDD (recovered): 34.5 
(11.4)                                                 
HI: 35 (12) 
Explicit facial affect matching, Block Fear and angry Emotion Labelling 
> shapes 
HI=Healthy Individuals; MDD=Major Depressive Disorder; rMDD=remitted Major Depressive Disorder.                                                                                                                









Measures                                                                                          
Mean, total score 
(standard deviation)                  
Duration of 
illness Mean, 









Comorbidities                       
(number of patients 
with comorbid 
condition/total sample) 






Almeida et al. 
(2010)  
YMRS scores                                                        
BD (depressed): 
21.53 (6.40)                            
BD (remitted): 1.47 
(1.13)                              
MDD: 24.4 (6.1) 
BD (depressed): 
14.23 (9.82)                                        
BD (remitted): 
14.67 (5.48)                                       
MDD: 13.67 
(9.87) 
Unspecified SCID-P 9/30 BD substance abuse 
3/15 MDD substance 
abuse 
All patients had 
experienced at least two 
episodes of illness in the 
last 4 years 
Depressed 
and remitted 
Chen et al. 
(2006)  




(0.53)                                                  
HDRS scores                                                       
BD (manic): 2 (2.98)                                   
BD (depressed): 
18.38 (6.44) 
Unspecified Li (11), 
antiepileptics (9), 
antidepressants (2), 
typical (2) and 
atypical (3) 
antipsychotics 
Unspecified No comorbid axis I and II 
disorders 
All patients had at least 2 
previous episodes of 
mania and depression 
Manic and 
depressed 
Foland et al. 
(2008) 
YMRS scores                                                        
BD: 15.1 (3.7)                                                   
HDRS scores                                                           







SCID-I Excluded substance 
abuse No comorbid axis I 
disorders 
Patients had experienced 






YMRS scores                                                     
BD: 1.4 (1.9)                                            
HDRS scores                                              
BD: 4.6 (2.1) 
21.2 (14.8) Anticonvulsants 
(10), SGA (11), 
antidepressants (6) 
SCID-I No comorbid axis I 
disorders 
Patients had experienced 
an average of 9.6 (10.7) 










Psychopathology   
Measures                                                                                         
Mean, total score 
(standard deviation)                  
Duration of 










Comorbidities                       
(number of patients 
with comorbid 
condition/total sample) 




Hassel et al. 
(2008) 
YMRS scores                                                 
BD:<10                                                                
HDRS scores                                                          
BD: <7 
BD: 10.6 (6.61) 
 
Li (6), antiepilectics 






SCID-I 3/19 eating disorders                 
5/19 substance abuse               
11/19 anxiety 
Multi-episode unspecified Remitted 
Hulvershorn et 
al. (2012)1 
YMRS scores                                              
BD (depressed): 3 (3)                              
BD (manic): 16 (3)                                   
BD (euthymic): 2 (3)                                              
HDRS scores                                              
BD (depressed): 20 
(4)                                  
BD (manic): 6 (3)                                                    
BD (euthymic): 7 (4) 











abuse No comorbid axis I 
disorders 
BD patients (depressed) 
have experienced a 
median of 15 (range: 2-
186) depressive and 24 (1-
310) manic episodes                        
BD patients (manic) have 
experienced a median of 
15 (2-102) depressive and 
75 (3-447) manic episodes                                            
BD patients (euthymic) 
have experienced a 
median of 13 (0-100) 





Jogia et al. 
(2008)2 
YMRS scores                                                    
BD:<7                                                                    
HDRS scores                                                  
BD:<14 
Unspecified antiepilectics (12) SCID-I Excluded substance 
abuse No comorbid axis I 
and II disorders 
The patients had an 













Measures                                                                                          
Mean, total score 
(standard deviation)                  
Duration of 










Comorbidities                       
(number of patients 
with comorbid 
condition/total sample) 




Lawrence et al. 
(2004)
3 
BDI Scores                                                            
BD: 15.3 (9.2)                                                 
MDD: 31.8 (11.8) 
BD: 15.4 (13.4)                
MDD: 8 (5)




Unspecified Excluded substance 
abuse No comorbid axis I 
and II disorders 
Multi-episode unspecified Depressed 
and remitted 
Malhi et al. 
(2007) 
 
YMRS scores                                                  
BD: <6                                                                   




Li (3), antiepilectics 
(5) 
SCID-P Excluded substance 
abuse No comorbid axis I 
and II disorders 
Patients had experienced 
an average of 10.4 (8.7) 
depressive and 4.7 (3.4) 
manic episodes 
Remitted 
Altschuler et al. 
(2008) 
HRSD scores                                                            
BD (depressed):20.8 
(3.3)                                
HDRS (7 items 
extension) score                      
BD (depressed): 
31.27 (4.76)                        
YMRS score                                                      
BD:2.9 (1.9) 
Unspecified medication free (2), 




SCID-I Excluded substance 
abuse No comorbid axis I 
disorder 
Unspecified Depressed 
Killgore et al. 
(2008) 
YMRS scores                                                         
BD: 14.3 (8.9)                                                    
HDRS scores                                                           
BD: 15.6  (9.9) 
BD: < 1 year 
 


























Measures                                                                                          
Mean, total score 
(standard deviation)                  
Duration of 










Comorbidities                       
(number of patients 
with comorbid 
condition/total sample) 




Blumberg et al. 
(2005) 
HDRS                                                                  
ARSM                                                       
Unspecified scores 
Unspecified medication free (5), 




Unspecified 2/ 5 (unmedicated)                      





ASRM=Altman Self-Rating Mania Scale; BD=Bipolar Disorder; BDI=Beck Depression Inventory; HDRS=Hamilton Depression Rating Scale; Li= Lithium; 
SCID=Structured Clinical Interview for DSM-IV; YMRS=Young Mania Rating Scale.                                                                                                                                                                                                                                                                                                                                                                                 
aWe used the description of symptomatic state as in the original articles; 1= results of these studies have been used only in one meta-analysis (Delvecchio et 





Table 3-5 Clinical Description of SZ patients 
Reference Psychopathology Measures                                    
Mean, total score (standard deviation) 
Number of Episodes 








Das et al. (2007)  PANSS Positive: 16.07 (7.24)                                  
PANSS Negative: 21.14 (7.9) 
First episode psychosis;                       
Duration of illness: 1.21 (1.2) years 
SGA (9) No substance 
abuse 
Remitted 
Dowd et al. (2010)  SAPS: 1.83 (.93)                                                           
SANS: 1.81 (1.37) 
Unspecified;                                            
Duration of illness: 17.73 (11.25) 
years 




comorbid axis I 
disorders 
Remitted 
Fakra et al. (2008)  PANNS Positive: 24.71                                             
PANSS Negative: 13.14 (5.46) 





Gur et al. (2002)  SAPS: 0.5 (5)                                                                  
HDRS: 6.0 (4.7) 
Unspecified FGA (1), SGA (11) No comorbid axis I 
and II disorders 
 
Remitted 
Gur et al. (2007)  SAPS: 1.4 (0.6)                                                             
SANS: 1.3 (0.9) 
Unspecified;                                            
Duration of illness: 9.6 (7.1) years 
FGA (2), SGA (11), 
combination of FGA 
and SGA (2) 
No comorbid axis I 
and II disorders 
Remitted 
Habel et al. (2010)  PANSS Positive:18.0 (7.3)                                          
PANSS Negative:19.9 (8.8)                                         
PANSS General:76.5 (26.3) 
Unspecified FGA (2), SGA (12), 
combination of FGA 
and SGA (2), 
unmedicated (1) 
No comorbid axis I 




Hall et al. (2008)  PANSS Positive: 12.3 (4.5) Unspecified 
 
 
FGA (3) and SGA (16) No substance 
abuse, No 







Reference Psychopathology Measures                                    
Mean, total score (standard deviation) 
Number of Episodes 








Hempel et al. (2003)  PANSS Positive:13                                                      
PANSS Negative:13                                                     
PANSS General: 18 
Unspecified;                                           
Duration of illness: 13 months 




Holt et al. (2006)  PANSS total: 59.8 (10.3) Unspecified;                                           
Duration of illness: 21.6 (9.6) years 




Kosaka et al. (2002)  PANSS Positive: 11.3 (4.6)                                             
PANSS Negative: 16.3 (4.5)                                     
PANSS General: 28.8 (7.3) 
Unspecified;                                            









Lapage et al. (2011) 
 
 
SAPS: 9.6 (10.2)                                                                        
SANS: 15.6 (9.1) 
 
Unspecified;                                           
Duration of illness: 8.5 (6.5) 
 
SGA (18), combination 
of SGA and FGA (6), 
anticholinergic 
medication (1), 
combination of SGA 
/FGA and 
antidepressants (7) 




Li et al. (2012) 
 
 
PANSS Positive 16.08 (5.66)                                    
PANSS Negative: 13.41 (8.89)PANSS 
total: 28.42 (13.82) 
Unspecified;                                          




No comorbid axis I 
and II disorders 
 
Remitted 
Michalopoulou et al. 
(2008)  
PANSS positive: 16 (6.72)                                       
PANSS negative: 13.91 (5.54)                                  
PANSS total: 58.91 (17.72) 
 
Unspecified;                                         
Duration of illness: 12 (9) years 















Reference Psychopathology Measures                                    
Mean, total score (standard deviation) 
Number of Episodes 








Rauch et al.(2010)  
 
 
PANSS Positive: 14.4 (3.1)                                                            
PANSS Negative: 18.9 (5.2)                                               
PANSS General: 34.9 (5.9) 
Unspecified SGA (9), combination 
of FGA and SGA (3) 
No  substance 
abuse,  No 
comorbid axis I 
disorders 
Remitted 
Reske et al. (2009)  PANSS Positive: 8 (1.14)                                           
PANSS Negative: 13.61 (4.47)                                        
PANSS total: 23.11 (3.94) 
First episode psychosis;                  
Unspecified 
FGA (9), SGA (9) No comorbid axis I 
disorders 
Remitted 
Williams et al.(2007)  
 
PANSS delusions: 2.1 (1.1); excitement: 
1.6 (0.8) 
Unspecified;                                         








FGA=Frst-Generation Antipsychotic; HDRS=Hamilton Depression Rating Scale; HI=Healthy Individuals; PANSS=Positive and Negative Syndrome Scale; 
SGA=Second-Generation Antipsychotic; SANS=Scale for the Assessment of Negative Symptoms; SAPS=Scale for the Assessment of Positive Symptoms; 
SZ=Schizophrenia.                                                                                                                                                                                             





Table 3-6 Clinical Description of MDD patients 
Reference  Psychopathology Measures                                
M   Mean, total score                                    
(     (standard  deviation)                                                  
Duration of illness                    









Comorbidities                       










Fu et al. (2007)
1
 HDRS score                                  
MDD: 21.1 (2.3) 
Unspecified Medication free 
at baseline 
SCID No comorbid axis I 




Gotlib et al. (2005)  BDI score                                     
MDD: 24.6 (8.3) 
Unspecified Antidepressants 
(8) 
SCID No comorbid axis I 




Lee et al. (2008)  HDRS score                                
MDD: 22.2 (4) 
MDD: 14.9 (8.8) antidepressants 
(10) 
SCID No comorbid axis I 
and II disorders 
Mean depressive 
episodes: 1.9 (0.8) 
Depressed 
Norbury et al. (2009)  BDI score                                   
MDD: 3.5 (3.7) 
Unspecified medication free Unspecified 1/16 anxiety 
disorders                             
2/16 alcohol misuse 
Patients with at least 
2 previous episode of 
depression 
Remitted 
Scheuerecker et al. 
(2010)  
HDRS score                                 
MDD: 20.5 (4.7) 
MDD: 52.3 (71.5) medication free SCID No comorbid axis I 
and II disorders 
8 patients with first 
episodes and 5 with 
recurrent episodes                     
Mean depressive 
episodes: 1.4 (0.6) 
Depressed 
Suslow et al. (2010)  HDRS  score                                
MDD: 24.8 (4.9) 
MDD: 6 (6.2) antidepressants 
(30) 
SCID 13/30 anxiety 
disorders                             
3/30 dysthymia            
1/30 pain disorder 
Mean depressive 






Reference  Psychopathology Measures                                
M   Mean, total score                                    
(     (standard  deviation)                                                  
Duration of illness                    









Comorbidities                       










Thomas et al. (2010)  MADRS score                            
MDD: 2.3 (3.2) 
Unspecified antidepressants 
(3) 
SCID No comorbid axis I 
and II disorders 
Unspecified Remitted 
Townsend et al. (2010)  HDRS score                              
MDD: 20.1 (4.9) 
MDD: 14.7 (13.3) medication free SCID No comorbid axis I 
and II disorders 
Median  depressive 
episodes: 3 
Depressed 
Van Wingen et al.  
(2010)  
HDRS score                                
MDD (depressed): 21.8 (4.2)                                             
MDD (remitted): 3.3 (2) 
Unspecified medication free SCID No comorbid axis I 
and II disorders 
18 with first MDE and 




BDI=Beck Depression Inventory; HDRS=Hamilton Depression Rating Scale; MDD=Major Depressive Disorder; MDE=Major Depressive Episode; SCID=Structured 





Table 3-7 Results from the global Activation Likelihood Estimation (ALE) analyses of facial 
affect processing in Bipolar Disorder (p< 0.05 False Discovery Rate corrected) 
L =left; R=right; x=sagittal, y=coronal, z=axial coordinates according to Talairach and Tournoux. 
Table 3-8 Results from the valence Activation Likelihood Estimation (ALE) sub-analyses of 
facial affect processing in Bipolar Disorder (p< 0.05 False Discovery Rate corrected) 
L =left; R=right; x=sagittal, y=coronal, z=axial coordinates according to Talairach and Tournoux.









Bipolar Disorder > Healthy individuals 
Limbic 
Amygdala 
- Right 24 -4 -16 392 0.01 
 Left -18 -4 -16 1048 0.01 
Parahippocampal 28 Left -18 -18 8 1048 0.01 
Putamen - - Left -26 -6 -8 1048 0.01 
Thalamus Pulvinar - Left -6 -26 4 368 0.01 
Bipolar Disorder < Healthy individuals 
Frontal Inferior Frontal 
47 Left -34 26 -8 480 0.01 
47 Right 36 30 -8 872 0.01 










Bipolar Disorder > Healthy individuals 
Limbic Parahippocampal 28 Left -18 -12 -12 584 0.01 
Putamen - - Left -26 -6 -8 584 0.008 
Thalamus Pulvinar - Left -6 -26 4 346 0.01 
Bipolar Disorder  <  Healthy individuals 
Frontal Inferior Frontal 
47 Left -34 24 -8 480 0.01 
47 Right 44 22 -2 1080 0.01 




32 Left -8 34 12 424 0.01 
Happy 
Bipolar Disorder > Healthy individuals 
Limbic Parahippocampal 34 Left -26 6 -16 80 0.008 
Caudate 
- - Left -18 20 14 80 0.009 
- - Right 14 10 16 96 0.009 
- - Right 18 24 -6 80 0.008 









Table 3-9  Results from the global and valance Activation Likelihood Estimation (ALE) 
analyses of facial affect processing in Major Depressive Disorder and the direct 
comparison with Bipolar Disorder (p< 0.05 False Discovery Rate corrected) 
L=left; R=right; x=sagittal, y=coronal, z=axial coordinates according to Talairach and Tournoux.









Global Activation Likelihood Estimation (ALE) analysis 
Major depressive disorder > healthy individuals 
Limbic Amygdala 
- Right 28 0 -16 232 0.01 
 Left 30 -4 -20   
Major depressive disorder < Healthy individuals  
Basal ganglia 
Putamen - Right 28 -1 0 400 0.01 
Caudate - Left -36 -14 -10 256 0.01 




- Left -18 -4 -14 2984 0.01 
  -18 -30 -8  0.008 
  -24 6 -16  0.008 
Anterior 
cingulated  
32 Right 8 24 24 376 0.007 
 Right 6 30 28   
Thalamus Pulvinar - Left -6 -26 6 584 0.01 




24 Left -20 -18 46 416 0.007 
Valence Activation Likelihood Estimation (ALE) 
Fear 
Major Depressive Disorder > Healthy individuals 
No suprathreshold clusters 
Major Depressive Disorder  < Healthy individuals  
Frontal Precentral 6 Left -58 0 12 96 0.009 
Happy 
Major Depressive Disorder > Healthy individuals 
No suprathreshold clusters 
Major Depressive Disorder < Healthy individuals   





Table 3-10 Results from the global Activation Likelihood Estimation (ALE) analyses of 
facial affect processing in Schizophrenia and the direct comparison with Bipolar Disorder 
(p< 0.05 False Discovery Rate corrected) 























Schizophrenia > Healthy individuals 
Occipital Cuneus  18 Right 10 -88 20 416 0.01 




Medial Frontal 9 Left -8 46 22 360 0.01 
Precentral 6 Left -34 2 32 856 0.01 
Limbic 
Parahippocampal 28 Left -18 -2 -14 1104 0.01 
Anterior 
cingulated 
32 Left -12 26 22 408 0.01 
Amygdala - Right 20 -10 -8 384 0.01 
Insula 13 Right 40 -18 2 376 0.01 
Occipitotemporal Fusiform 37 Right 38 -48 12 592 0.01 
Occipital Inferior Occipital 19 Right 12 -92 -4 328 0.01 
Basal ganglia Caudate - Right 8 4 -4 408 0.01 
Thalamus Medial Dorsal - Right 10 10 18 1016 0.01 
Bipolar Disorder > Schizophrenia 
Thalamus Pulvinar  Left -5 -26 6 336 1.9 




Cuneus 18 Left -6 -92 18 1144 1.7 
 





Figure 3-1  Activation Likelihood Estimation (ALE) maps representing regional activity 
consistently associated with Bipolar Disorder. Clusters of relative overactivation or 
underactivation are shown in red and blue respectively; numbers represent axial (z) 
coordinates of each slice in Talairach space; p< 0.05 False Discovery Rate corrected for 
multiple comparisons. Top row: statistical map of significant ALE clusters for the 
comparison of BD patients to healthy individuals (HC). Middle row: statistical map of 
significant ALE clusters for the comparison of BD patients to healthy individuals (HC) 
during processing of happy stimuli. Bottom row: statistical maps of significant ALE 
clusters associated with the contrast of BD patients to healthy individuals (HC) during 





Figure 3-2 Activation Likelihood Estimation (ALE) maps representing regional activity 
consistently associated with Major Depressive Disorder (MDD). Clusters of relative 
overactivation or underactivation are shown in red and blue respectively; numbers 
represent axial (z) coordinates of each slice in Talairach space; p< 0.05 False Discovery Rate 
corrected for multiple comparisons. Top row: statistical map of significant ALE clusters for 
the comparison of MDD patients to healthy healthy individuals (HC). Bottom row: statistical 
















Figure 3-3 Activation likelihood estimation (ALE) maps representing regional activity 
consistently associated with schizophrenia (SZ). Top row: SZ patient compared to healthy 
healthy individuals (HC). Bottom row: SZ patients compared to BD patients. p<0.05 false 




























4.    Genetics of Bipolar Disorder 
 
4.1 Heritability of Bipolar Disorder 
Heritability is the proportion of trait variation that is accounted for by genetic factors, as 
opposed to trait variation due to environmental factors. Twin and family studies for bipolar 
disorder (BD) have placed heritability from 0.6 to 0.85 (McGuffin et al., 2003; Craddock and 
Sklar, 2009). To date, the single most significant predictor of BD expression remains genetic 
proximity to affected individuals; with first-degree relatives of BD patients showing a 10-fold 
increase in their risk to develop BD (Smoller et al., 2003). However, the majority of first-
degree relatives (around 60%) of BD patients do not develop any psychiatric disorder 
(Mowbray et al., 2006). Recent meta-analyses of cognitive functioning in unaffected first-
degree relatives of BD patients (RELs) have shown similar deficits to those observed in 
patients with BD, although milder, especially in verbal memory and some aspects of 
executive functions, including response inhibition, sustained attention and speed processing 
(Arts et al., 2008; Balanza-Martinez et al., 2008; Bora et al., 2009a). Moreover, a twin study 
by Christensen et al. (2006) compared several cognitive domains including attention, 
visuospatial abilities, language, learning and problem solving in a sample of 21 pairs of twins 
discordant for BD and 88 pairs of healthy twins. The results showed that also the unaffected 
twin pairs discordant for BD performed worse in comparison to healthy twins in working 
memory and declarative memory measures. Lastly, a recent study found that processing 
speed, long-term memory, verbal fluency, working memory, sustained attention and 
inhibitory controls are significantly heritable and that most of these measures are impaired 
in BD (Fears et al., 2014). 
4.2 FMRI studies in RELs of BD patients 
With regard to fMRI studies, the direct comparison between RELs and healthy individuals 
suggested that RELs showed impairment in several cortical and subcortical regions while 
processing of cognitive and emotional tasks.  
During an easy and hard condition of a verbal fluency task, Allin et al. (2010) showed that 





reduced activation in the frontotemporal areas compared to healthy individuals. A recent 
study by Sepede et al. (2012) showed that during a sustained attention task RELs shared a 
common pattern of activation with BD patients with increased activation in the posterior 
middle cingulate cortex and insula compared to healthy individuals. Linke et al. (2012) 
reported that during a reversal learning task, including a reward, punishment and reversal 
condition, RELs had increased activation in the medial orbitofrontal cortex (OFC) in all three 
conditions compared to healthy individuals. In the same study RELs also showed increased 
activation in the amygdala in response to reward compared to healthy individuals and BD 
patients. Two fMRI studies explored the neural activation (Pompei et al., 2011b) and 
functional connectivity (Pompei et al., 2011a) in BD patients, RELs and healthy individuals 
while performing the Stroop task. Together their findings suggested that RELs had 
decreased activation in the inferior and superior parietal lobule as well as reduced 
ventrolateral prefrontal cortex (VLPFC) connectivity with the ventral anterior cingulate 
cortex (ACC) and insula compared to healthy individuals. Two fMRI studies by Thermenos et 
al. (2010) and Drapier et al. (2008) explored brain activation in BD patients, RELs and healthy 
individuals while performing the 2-back version of the N-back task- a working memory task. 
The authors suggested that RELs showed increased activation in the insula, OFC, superior 
parietal lobule and postcentral gyrus (Thermenos et al., 2010) as well as in the frontal poles 
bilaterally (Drapier et al., 2008) compared to healthy individuals. Finally, in a facial 
emotional task, Surguladze et al. (2010) found increased medial PFC and putamen activation 
to fearful or happy faces in RELs compared to healthy individuals. In an additional region of 
interest analysis, the authors also reported an increased activation of the amygdala in RELs 
compared to healthy individuals in response to happy faces. Details of the original studies 








Table 4-1 FMRI studies in unaffected first-degree relatives of patients with BD 
 




Design Contrast   Results 
Allin et al. 
(2010) 
18 euthymic BD (7/11) 
19 RELs (11/8) 
19 HI (10/9) 
BD: 39.2 (11.5) 
RELs: 40.5 (13.9) 




Easy and hard verbal 
fluency condition 
 
RELs > HI, easy condition: increased activation in the  
retrosplenial/PCC and precuneus  and reduced 
activation in the left frontotemporal areas 
RELs > HI, hard condition: increased retro- 
splenial/posterior cingulate cortex, and reduced 
activation in the medial frontal cortex 
Drapier et al. 
(2008) 
20 euthymic BD (9/11) 
20 RELs (12/8) 
20 HI (10/10) 
BD: 42.7 (10.4) 
RELs: 43 (13.8) 
HI:41.9 (11.6) 
N-back, Block 1-,2-,3- back vs 0-back RELs > HI, 2-back vs 0-back: increased activation in 
the right and left frontal pole 
 
 
Linke et al. 
(2012) 
19 euthymic BD (8/11) 
22 RELs (11/11) 
22 HI matched to RELs (8/11) 
22 HI matched to BD (11/11) 
BD: 45 (10) 
RELs: 28 (11) 
HI (RELs): 45 (10) 




Win vs baseline (reward) 
lose/no shift vs baseline 
(punishment) 
 Lose/shift  vs baseline 
(reversal) 
RELs > HI, Reward, Punishment, Reversal: increased 
activation in the medial orbitofrontal cortex 





Pompei et al. 
(2011a)1 
39  euthymic BD (19/20) 
25 RELs (13/12) 
48 HI (25/23) 
BD: 39.43 (11.5) 






Incongruent vs neutral 
condition 
RELs < HI: reduced VLPFC connectivity with the vACC                     
 RELS < HI: reduced VLPFC connectivity with the 










Design Contrast   Results 
Pompei et al. 
(2011b)
1 
39 euthymic BD (19/20) 
25 RELs (13/12) 
48 HI (25/23) 
BD: 39.43 (11.5) 





Incongruent vs neutral 
condition 
RELs < HI: reduced activation in the the superior and 
inferior parietal lobule 
Sepede et al. 
(2012) 
24 euthymic BD (10/14)  
22 RELs (7/15) 
24 HI (8/16) 
BD: 34.8 (8.0) 





related   
Correct and Incorrect  
target condition vs correct 
response to non-targets 
RELs > HI, Incorrect  target condition:  
Increased activation in the posterior middle 
cingulate cortex and left insula 
Surguladze et 
al. (2010) 
20 euthymic BD (9/11) 
20 RELs (12/8) 
20 HI (10/10) 
BD: 42.7 (10.4) 
RELs:  43 (13.8) 




Moderate or intensive 
expressions  of fear vs 
neutral 
Moderate or intensive 
expressions  of happiness 
vs neutral 
RELs > HI, Happiness or Fear: increased activation in 
the medial prefrontal cortex and putamen. Region of 
interest analysis in the amygdala showed also 
increased activation in the amygdala in RELs in 
response to intensively happy faces 
Thermenos et 
al. (2010) 
19 euthymic BD (11/8) 
18 RELs (8/10) 
19 HI (9/10) 
BD: 41.1 (3.1) 
RELs: 36.3 (2.6) 
HI:39.2 (2.7) 
N-back, Block 2-back vs 0-back RELs > HI: increased activation in the insula, OFC and 
the right superior parietal lobule and the postcentral 
gyrus 
BD= Bipolar Disorder; HI= Healthy Individuals;M=Males; PPI= Psychophysiological interaction; RELs= Unaffected first-degree relatives of BD patients;W=Women. 





4.3 Genome-Wide Association Studies in Bipolar disorder 
After the human genome was first sequenced the genetics field has produced huge 
technological strides towards estimating heredity (Lander et al., 2001). The most common 
genetic marker is the single nucleotide polymorphism (SNP), a single subunit change in the 
DNA sequence. SNPs are located on a DNA chip, which is used to create a genetic profile for 
each individual. In turn DNA chips are used in genome-wide associations studies (GWAS) 
that estimate the heritability of a disorder throughout the genome by comparing healthy 
controls with patients, in a hypothesis-free way. The first disease upon which the GWAS 
technique was used was the age-related macular degeneration in 2005 (Klein et al., 2005), 
and since then many genes have been implicated in the disease (Fritsche et al., 2013). A 
schematic representation of GWAS analysis methodology is reported in Figure 4-1. 
Figure 4-1 Schematic representation of GWAS analysis methodology. 
 
        Ballouz et al., BMC Genet. (2011) 
      
With regard to BD, several independent GWAS studies reported numerous SNPs associated 
with BD, with the strongest confirmation of two loci, the CACNA1C and the ANK3, in both 
European/American (Baum et al., 2008; Dedman et al., 2012; Sklar et al., 2008; Ferreira et 
al., 2008; Scott et al., 2009; Sklar et al., 2011; Green et al., 2013; Mühleisen et al., 2014; 
Schulze et al., 2009) and Asian (Chen et al., 2013; Lee et al., 2011a; Takata et al., 2011) 
ancestry.  
Particularly for the CACNA1C gene, the majority of GWAS studies found one SNP, the 
rs1006737, to be strongly associated with BD (Sklar et al., 2008, 2011; Ferreira et al., 2008; 
Green et al., 2013). Moreover, these GWAS studies also identified another candidate gene 





rs10994336. Also in this case, the association between BD and ANK3 rs10994336 gene has 
been replicated by other research groups in independent samples from European (Scott et 
al., 2009; Schulze et al., 2009; Mühleisen et al., 2014) and Asian (Chen et al., 2011; Lee et al., 
2011) ancestry. Specifically, in the most recent and largest GWAS study of 9,747 BD patients 
and 14,278 healthy individuals, Mühleisen et al. (2014) found 56 genome-wide significant 
SNPs in five chromosomal regions, including risk loci within the ANK3 rs10994336. Finally, 
further evidence from GWAS studies reported the association of other SNPs within the 
CACNA1C and ANK3 genes but less consistently. For the CACNA1C, Sklar et al. (2011) 
reported a significant association of the CACNA1C rs4765913 with BD. For the ANK3, two 
SNPs have been found to be associated with BD, the ANK3 rs9804190 (Sklar et al., 2011; 
Baum et al., 2008) and the ANK3 rs1938526 (Dedman et al., 2012; Lee et al., 2011a; Takata 
et al., 2011).  
4.4 The relevance of the CACNA1C and ANK3 risk genes in Bipolar Disorder 
As mentioned in the previous paragraph, the most robustly identified SNPs associated with 
BD are located on chromosome 12p13 (CACNA1C rs1006737) and on chromosome 10q21.2 
(ANK3 rs10994336 and rs9804190). Specifically, the ANK3 rs10994336 and the ANK3 
rs9804190 are located at the 3' and the 5' end of the gene respectively and they lie very 
close to each other (about 340 kb apart in the gene). However, there is no evidence of 
linkage disequilibrium or other interaction between the corresponding SNPs (Schulze et al., 
2009). These two regions are therefore considered as two independent genetic risk factors 
for BD. Finally, the risk alleles within the CACNA1C (rs1006737) and ANK3 (rs10994336 and 
rs9804190) risk genes lie in the intronic, non-coding regions of the genome and therefore 
they probably regulate the expression of the protein rather than change its structure. In line 
with this statement is the study by Quinn et al. (2010) which showed that these genetic 
variants are integral to gene expression regulation through cis- or trans-regulatory 
mechanism and therefore may alter the transcription of nearby or distant genes 
respectively. Moreover, their specific biological role, described in the paragraph below,  may 
suggest a possible involvement of these genes in various aspect of neuronal development 






The biological functions of CACNA1C and ANK3 in brain neurons are linked to their effect on 
the efficiency of transmission of electrical impulses through the regulation of the voltage-
gated ion channels. CACNA1C encodes for the alpha subunit of the L-type voltage 
dependent calcium (Ca+2) channel Cav1.2. The ANK3 encodes for the Ankyrin G protein, 
found in the initial axon segment and the nodes of Ranvier, which are implicated in the 
generation and the amplification of action potentials (Lambert et al., 1997; Zhou et al., 
1998). Therefore, the biological role of these genes on the neuronal level could have an 
effect on brain networks that are affected in BD patients, such as mood and cognition. 
Supporting this hypothesis is the evidence provided by several animal studies both for the 
CACNA1C and ANK3 genes. Specifically for the CACNA1C gene, Moosmang et al. (2005) 
reported an impairment in the hippocampus-dependent spatial memory in mice with an 
inactivation of the CACNA1C gene in the hippocampus and neocortex, by using two different 
spatial learning memory tasks (water maze and labyrinth-maze tasks), as well as 
dysfunctions in hippocampal synaptic plasticity. Disruptions in spatial memory have been 
found also by White et al. (2008) in Cav1.2 knock-out mice while performing a water maze 
task. In addition, Lee et al. (2012) and Dao et al. (2010) investigated the impact of the 
depletion of the CACNA1C in mice with relevance to human mood disorders. The authors 
showed that heterozygous CACNA1C knock-out mice presented decreased exploratory and 
antidepressant like behavioursas well as increased anxiety-related behaviour compared to 
wild type mice. Likewise, also the ANK3 gene has been study in transgenic mice that 
provided relevant insight into the effect of this gene on the neural network (Leussis et al., 
2012). The authors suggested that in transgenic mice, in which brain-specific ANK3 isoforms 
were exclusively disrupted, showed changes in mood-related behaviours and elevated stress 
reactivity, functions that have been shown to be disrupted in BD patients (Leussis et al., 
2012). 
4.5 Population frequencies of the CACNA1C rs1006737, the ANK3 rs10994336 and the 
ANK3 rs9804190 
The three SNPs within the CACNA1C and ANK3 genes are considered common genetic 
variants and therefore their frequency in the population is expected to be above 1%. In 
particular, several databases (dbSNP, Ensembl) for nucleotide variations are now available 





variants in the population, including the risk genetic variants employed in this thesis. For the 
CACNA1C rs1006737 risk gene (risk-allele A), the dbSNP database 
(http://www.ncbi.nlm.nih.gov/SNP/) reported that the minor allele is "A" and is present in 
31% of European populations. For the ANK3 rs10994336 (risk-allele T), the minor allele is "T" 
and has a frequency of 12.3% whereas for the ANK3 rs9804190 (risk-allele C) the minor 
allele is "T" and has a frequency of 25.5%. 
4.6 The effect of CACNA1C gene 
Neuropsychological studies exploring the effect of the CACNA1C rs1006737 risk gene during 
processing of affective and non-affective cognitive tests 
For the CACNA1C rs10096737 gene (risk-allele A), Soeiro-de-Souza et al. (2012) employed 
facial emotion recognition (FER) tests in a sample of 39 BD patients and 40 healthy 
individuals. The authors reported lower FER scores in BD patients homozygous for the 
CACNA1C rs1006737 risk-allele compared to carriers of only one risk-allele or the non-risk 
allelic variant. In 2013, the same group published a study investigating executive functions 
in a sample of 109 BD patients and 96 healthy individuals. The authors employed four 
executive functions tests (Letter-Number Sequence test, digit span, trail making test, and 
Wisconsin Card Sorting Test) and they reported that BD patients carriers of the risk-allele 
showed worse performance on all four executive function tests compared to BD patients 
carriers of the non-risk allele (Soeiro-de-Souza et al., 2013). In the same year, Arts et al. 
(2013) showed, in a sample of 51 BD patients, 34 first-degree relatives and 50 healthy 
individuals, poorer cognitive performance in several cognitive tasks in subjects homozygous 
for the risk variant of the CACNA1C rs1006737 gene, especially in the speed of processing 
task. Zhang et al. (2012) found significantly higher error rates on two working memory tasks, 
the N-back and the dot pattern expectancy tasks (DPX), in BD compared to healthy 
individuals independently from the genotype. During the 1-back and the DPX tasks, healthy 
individuals carriers of the risk-allele had higher error rates than subjects with the non-risk 
variant whereas BD patients showed an opposite direction of association. Finally, two 
studies in healthy individuals showed no effect of genotype on episodic memory and verbal 
intelligent (Erk et al., 2010) as well as on executive functions and verbal/learning memory 





Evidence of the effect of CACNA1C rs1006737 risk gene in psychopathological measures and 
personality traits 
Four studies have provided evidence of the effect of the CACNA1C rs1006737 gene on 
psychopathological aspects and personality traits (Erk et al., 2010; 2014; Roussos et al., 
2011; Strohmaieret al., 2013). Erk et al. (2010) found that the CACNA1C rs1006737 risk-
allele was associated with higher scores in depression, anxiety, obsessive-compulsive, 
interpersonal sensitivity and neuroticism. Similarly, the study by Erk et al. (2014) showed 
that RELs of BD patients had increased scores of anxiety measures. Roussos at al.(2011) 
reported that the risk-allele was signiﬁcantly associated with low extraversion, higher harm 
avoidance, anxiety and paranoid ideation. Strohmaier et al. (2013) examined sex-speciﬁc 
effect of the CACNA1C rs1006737 gene in the population with a follow-up period of 10 
years. In men, the risk-allele was associated with higher emotional lability and lower 
resilience, and more depressive symptoms at follow-up. In women, the risk-allele was 
associated with lower emotional liability and stronger resilience and fewer depressive 
symptoms at follow-up. 
Neuroimaging studies exploring the effect of theCACNA1C rs1006737 risk gene 
Functional Magnetic Resonance Imaging studies 
Seven studies to date have looked into how the CACNA1C rs1006737 gene impacts brain 
function in healthy participants. During memory paradigms,the risk CACNA1C rs1006737 
was associated with increased (Bigos et al., 2010) and decreased (Erk et al., 2014; Paulus et 
al., 2014) prefrontal activity and reduced hippocampal function (Erk et al., 2010; Krug et al., 
2013). On the contrary, increased hippocampal activity was found during emotional 
processing in CACNA1C rs1006737 risk carriers (Bigos et al., 2010). Furthermore, increased 
activity in the right amygdala during a monetary reward paradigm was associated with the 
risk CACNA1C rs1006737 variant in healthy individuals (Wessa et al., 2010), as was increased 
activation in the left inferior frontal gyrus and precuneus during a semantic verbal fluency 
task (Krug et al., 2010). CACNA1C rs1006737 risk-allele carriers showed reduced neural 
activity in the right inferior parietal lobule during orienting and in the medial frontal gyrus 





Studies on the effect of the CACNA1C rs1006737 gene that include also BD patients and 
their RELs, have found increased right amygdala activity during a negative emotional faces 
task in CACNA1C rs1006737 risk carriers (Jogia et al., 2011; Tesli et al., 2013). In another 
study during an episodic memory task carrying the CACNA1C rs1006737 risk variant resulted 
in a stronger decrease of hippocampal and ACC activation in RELs, indicating an additive 
effect of CACNA1C rs1006737 variation on familial risk (Erk et al., 2014). Using Dynamic 
Causal Modelling (DCM) connectivity analysis, two studies found that, during emotional 
processing tasks, the presence of the CACNA1C rs1006737 risk-allele was associated with 
decreased effective connectivity between prefrontal and subcortical regions (Radua et al., 
2013) as well as  between visual and prefrontal cortices (Dima et al., 2013). In both studies 
the findings were significantly more marked in BD patients. Details of the studies have been 

























Bigos et al. 
(2010) 













































retrieval of aversive 
scenes > neutral 
scenes 
 




2-back > 0-back 
 
rs1006737 No Axis I 
disorder 
 
Erk et al. 
(2010) 




33.4 (10.7)   
32.0 (9.5)    




Face profession pairs 
> baseline  
 
rs1006737 No Axis I 
disorder 
 
Erk et al. 
(2014)1 
 
110 HI (See Erk et al. 
2010) 











memory > control 
condition 
 
rs1006737 No Axis I 
disorder 
 
Erk et al. 
(2014) 
Replication Sample: 
















Face profession pairs 
> baseline  
 





























Krug et al. 
(2010) 
62 HI (62/0) GG:32 
AG + AA: 30 









Reading aloud > 
semantic verbal 
ﬂuency 
rs1006737 No Axis I 
disorder 
 
Krug et al. 
(2013) 
94 HI (66/28) 
 
 








GG: 23.4 (3.3) 
AG+AA: 23.0 (2.5) 








Encoding/retrieval  > 
baseline 
rs1006737 No Axis I 
disorder 
 
Paulus et al. 
(2014) 
96 HI (66/28) GG: 43 
AG: 37 
AA: 12 
GG: 23.4 (3.3) 
AG: 23.0 (2.8) 
AA: 23 (1.6) 
N-back task, 
Block 
2-back > 0-back rs1006737 No Axis I 
disorder 
 
Thimm et al. 
(2011) 
80 HI (54/26) GG: 36 
AG: 34 
AA: 10 
GG: 23.3 (3.0) 
AG: 23.3 (3.2) 









rs1006737 No Axis I 
disorder 
 
Wessa et al. 
(2010) 
64 HI GG: 31 
AG: 26 








Reward > baseline 
 
rs1006737 No Axis I 
disorder 
 
BD= Bipolar Disorder; HI= Healthy Individuals; RELs= Unaffected first-degree relatives of BD patients. 































Jogia et al. 
(2011) 
41 euthymic BD 
(20/21) 
25 RELs (13/12) 




BD: 44.29 (11.87) 
RELs: 35.0 (13.67) 







rs1006737 HDRS: 4.77 (5.3) 
YMRS:1.44 (2.96) 





Dima et al.  
(2013) 
 
41 euthymic BD 
(20/21) 




BD: 44.3 (11.9) 




Fear, anger or 
sadness  > 
neutral   
 
rs1006737 HDRS: 4.8 (5.3) 
YMRS:1.4 (3.0) 





Tesli et al. 
(2013)1 
 
66  euthymic BD  
123 HI 
 
N/A N/A Faces matching 
task (fear or 
anger), 
Block 






BD= Bipolar Disorder; BDI= Beck Depression Inventory; BPRS= Brief Psychiatric Rating Scale; HDRS= Hamilton Depressive rating scale; HI= Healthy Individuals; 







Six studies have been published exploring the role of CACNA1C rs1006737 risk-allele on the 
integrity of gray matter volumes. Four of them used only healthy individuals (Wang et 
al.,2011; Kempton et al.,2009; Franke et al., 2010; Erk et al., 2010)while the other two 
included also BD patients (Soeiro-de-Souza et al., 2012; Perrier et al., 2011). Two studies 
have found increased gray matter volume (Kempton et al., 2009) and increased total cortical 
volume (Wang et al., 2011) associated with the risk CACNA1C rs1006737 variant. Perrier et 
al. (2011) using a regions of interest approach found increased gray matter density in the 
right amygdala and hypothalamus in participants with the risk CACNA1C SNP, while another 
study found that the CACNA1C rs1006737 gene influences the brainstem rather than gray 
matter volume (Franke et al., 2010). Two studies found no influence of CACNA1C rs1006737 
risk gene on hippocampal volumes in BD (Soeiro-de-Souza et al., 2012) and healthy 
individuals (Erk et al., 2010).   
4.7 The effect of the ANK3 gene 
Neuropsychological studies exploring the effect of the two allelic variations within the 
ANK3risk gene (rs10994336 and rs9804190) during processing of affective and non-affective 
cognitive tests. 
For the ANK3 rs10994336 gene (risk-allele T), Ruberto et al. (2011) employed several 
neurocognitive tests (Degraded Symbol Continuous Performance Task, Stroop Colour Word 
Test, Wisconsin Card sorting test, the Wechsler Memory Scale and the Iowa Gambling Task) 
in a sample of 47 BD patients, 74 RELs and 67 healthy individuals. The authors showed that, 
although carriers of the risk-allele underperformed in all the tests, no significant differences 
between genotype and genotype by affection status were found, except for the Symbol 
Continuous Performance Task in which carriers of the risk variant showed decreased scores 
for false alarm and sensitivity. Hatzimanolis et al. (2012) reported that in the Continuous 
Performance Test-Identical Pairs, healthy individuals carriers of the ANK3 rs10994336 risk 
gene showed reduced sensitivity in target direction and significant more errors of 
commission compared to healthy individuals carriers of the common allele. No significant 
association has been found in either healthy individuals (Roussos et al., 2011; Hori et al., 





Finally, for the ANK3 rs9804190 risk gene no neuropsychological evidence has been 
published yet.  
Neuroimaging studies exploring the effect of the two allelic variations (rs10994336 and 
rs9804190) within the ANK3risk gene.  
For the ANK3 gene only two studies investigated the effect of the ANK3 gene on brain 
activation (Dima et al., 2013; Roussos et al., 2012) and connectivity (Dima et al., 2013). 
During a facial affect labelling task, Dima et al. (2013) showed that the presence of the ANK3 
rs10994336 risk-allele was associated with increased VLPFC activation in healthy individuals 
and reduced VLPFC activation in BD patients. Additionally, the presence of the ANK3 
rs10994336 risk-allele was associated with decreased visual-prefrontal effective connectivity 
(Dima et al., 2013). The study by Roussos et al. (2012) explored the effect of the ANK3 
rs9804190 risk gene in healthy individuals while processing the 3-back condition of the N-
back task. The authors showed that carriers of the risk-allele showed increased activation in 
the left inferior frontal gyrus and in the left middle frontal gyrus (Table 4-4). Finally, a study 
by Linke et al. (2012) investigated the link between ANK3 rs10994336 risk gene and white 
matter integrity and showed that carriers of the risk-allele had reduced white matter 












Table 4-4 FMRI Studies exploring the effect of the effect of the two allelic variations (rs10994336 and rs9804190) within the ANK3risk gene in 
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4.8 Effect sizes of the risk variants within the CACNA1C and ANK3 risk genes on 
behavioural measures investigating emotion and cognition 
The behavioural results suggest that CACNA1C rs1006737 and ANK3 rs10998336 risk alleles 
were associated with cognitive and emotional impairments. However, the overall effect-size 
of these differences oscillates between small and moderate suggesting that the overall 
strength of these differences is low. This is in line with the notion that common genetic 
variants have just small effects on clinical phenotypes and consequently we can expect that 
the CACNA1C rs1006737 and the ANK3 rs10994336 might have small effects also in 
behavioural measures linked to BD. This consideration might also explain the absence of 
neuropsychological evidence for the ANK3 rs9804190 and the negative results found by two 
studies which showed no effect of the two SNPs within the CACNA1C rs1006737 and ANK3 
rs10998336 on episodic memory verbal intelligent (Erk et al., 2010) as well as on executive 
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Polymorphisms at the rs10994336 and rs9804190 loci of the Ankyrin 3 (ANK3) gene have 
been strongly associated with increased risk for bipolar disorder (BD). However, their 
potential pathogenetic effect on BD-relevant neural circuits remains unknown. We 
examined the effect of BD-risk polymorphisms at rs10994336 and rs9804190 on the working 
memory (WM) circuit using functional magnetic resonance imaging (fMRI) data obtained 
from euthymic patients with BD (n=41), their psychiatrically healthy first-degree relatives 
(n=25) and unrelated individuals without personal or family history of psychiatric disorders 
(n=46) while performing the N-back task. In unrelated healthy individuals, the rs10994336-
risk-allele was associated with reduced activation of the ventral visual cortical components 
of the WM circuit while the rs9804190-risk-allele was associated with inefficient 
engagement of the prefrontal cortical components of the WM. In patients and their healthy 
relatives, risk alleles at either loci were associated with hyperactivation in the ventral 
anterior cingulate cortex. Additionally, Rs9804190-risk-allele carriers with BD evidenced 
abnormal activation within the posterior cingulate cortex. This study provides new insights 
on the neurogenetic correlates of allelic variation at different genome-wide supported BD-
risk associated ANK3 locithat support their involvement in BDand highlight the modulatory 








Allelic variation in the Ankyrin3 (ANK3) gene located on chromosome 10q21.2 has been 
most convincingly associated with increased risk for bipolar disorder (BD). The first report 
concerned a genome-wide association between BD and a single nucleotide polymorphism 
(SNP) at rs9804190 identified in two independent samples from the US and Germany (Baum 
et al., 2008). This association signal within a 70 kilobase region at the 3’ end of the gene was 
later confirmed in a larger study by the Psychiatric GWAS Consortium Bipolar Disorder 
Working Group (Sklar et al., 2011).  Three linked susceptibility loci at rs10994336 (Ferreira et 
al., 2008; Lett et al., 2011; Tesli et al., 2011), rs10994397 (Sklar et al., 2011) and rs1938526 
(Takata et al., 2011; Lee et al., 2011; Dedman et al., 2012) have also been identified within a 
250 kilobase region at the 5’ end of the gene.  The association signals within the 3’ and 5’ 
regions do not overlap and there is no evidence of linkage disequilibrium or other 
interaction between the corresponding SNPs (Schulze et al., 2009). These two regions are 
therefore considered as two independent genetic risk factors for BD.  
The biological mechanisms linking allelic variation in the ANK3 gene to increased risk for BD 
have yet to be clearly defined. The ANK3 gene encodes for multiple protein isoforms of 
Ankyrin-G (AnkG) (Kordeli et al., 1995), a multi-functional protein with several distinct 
domains including spectrin- and trans-membrane binding domains. Brain-specific isoforms 
of AnkG are localized in the nodes of Ranvier and at axonal initial segments (AIS) (Kordeli et 
al., 1995). AnkG is involved in maintenance of neuronal polarity (Rasband, 2010) and in the 
clustering of ion gated channels required for action potential generation and propagation 
(Rasband, 2010; Zhou et al., 1998). Alterations in AnkG sequence or intracellular levels could 
disrupt these mechanisms and affect the function of neural circuits involved in mood and 
cognition. Congruent with this hypothesis, reduced ANK3 expression of brain-specific 
transcripts in mouse models affects AIS throughout the brain (Leussis et al., 2013). These 
mice also exhibit a number of traits considered relevant to BD, specifically increased risk 
taking behaviour (decreased latency in the elevated plus maze and light-dark transition), 
greater reward salience (decreased latency to approach food in the novelty-suppressed 
feeding and increased sucrose preference), and increased reactivity to chronic stress 
(increased forced swim test immobility and elevated baseline and reactive corticosterone 





In human post-mortem samples, the BD-risk-alleles have been associated with reduced 
neuronal ANK3 expression in multiple brain regions (Roussos et al., 2012; Rueckert et al., 
2013). However, in healthy individuals there are significant differences in the phenotypic 
traits associated with allelic variation at the 5’ compared to the 3’ ANK3 region. 
Behaviourally, 5’risk-allele carriers (rs10994336) show increased anxiety-related 
temperamental traits (Roussos et al., 2011) while 3’ risk-allele carriers (rs9804190) show 
abnormalities in psychosis-related traits (Roussos et al., 2012). White matter connectivity is 
reduced in 5’risk-allele carriers (rs10994336) but not in 3’ risk-allele carriers (rs9804190) 
(Linke et al., 2012). In terms of cognitive function, 5’risk-allele carriers (rs10994336), but not 
3’ risk-allele carriers (rs9804190), underperform in tasks of sustained attention and set 
shifting (Linke et al., 2012; Ruberto et al., 2011; Hatzimanolis et al., 2012; Zhang et al., 
2013). The one phenotypic trait shared by risk-alleles in both 3’ and 5’ ANK3 regions is 
working memory disruption (Roussos et al., 2012; Ruberto et al., 2011) which is also a 
documented feature of BD.  
Disruption in working memory (WM) circuitry in BD has been associated both with disease 
expression (Adler et al., 2004; Lagopoulos et al., 2007; Frangou et al., 2008; Townsend et al., 
2010; Jogia et al., 2012; Pomarol-Clotet et al., 2012; Fernández-Corcuera et al., 2013) and 
familial risk (Drapier et al., 2008; Thermenos et al., 2010; Thermenos et al., 2011). Disease 
expression is associated with diminished function in dorsolateral frontoparietal regions 
involved in information encoding and maintenance (Adler et al., 2004; Lagopoulos et al., 
2007; Frangou et al., 2008; Townsend et al., 2010; Jogia et al., 2012; Pomarol-Clotet et al., 
2012; Fernández-Corcuera et al., 2013) and with failure to deactivate the default mode 
network (DMN) as evidenced by aberrant activation within medial prefrontal cortex and the 
anterior cingulate cortex (ACC) (Jogia et al., 2012; Pomarol-Clotet et al., 2012; Fernández-
Corcuera et al., 2013).  The failure to suppress ACC activation during the N-back has also 
been reported in unaffected first-degree relatives of patients and is likely to represent a 
genetically mediated vulnerability trait for BD (Drapier et al., 2008; Thermenos et al., 2010).   
The current study examined the effect of SNP rs10994336 and rs9804190 on the neural 
circuitry subserving WM in a sample of 112 individuals comprising euthymic patients with 
BD (n=41), their psychiatrically healthy first-degree relatives (n=25) and unrelated healthy 





increased risk for BD conferred by the two independent loci. We tested whether the 
pathogenetic effect of the risk-alleles at rs10994336 and rs9804190 independently 
contribute to failure to suppress DMC activation during the n-back task in patients and their 
healthy relatives, and whether a similar effect would be observed in unrelated individuals 
without a personal or family history of psychiatric disorders.  
Subjects and methods 
Participants 
All participants were selected from the VIBES study cohort which comprises 75 families 
identified through a proband with BD type I and screened to exclude pedigrees with 
schizophrenia or schizophrenia spectrum disorders. Details of the VIBES rationale and design 
have been reported previously (Frangou, 2009). The sample considered in the present study 
comprised 41 euthymic patients with BD, 25 of their psychiatrically healthy first-degree 
relatives, and 46 healthy unrelated individuals, all of white British ancestry (Table 5-1). The 
study received institutional ethical approval. All individuals provided written informed 
consent prior to participation. 
All participants were assessed by trained psychiatrists with patient or non-patient versions 
of the Structured Clinical Interview for Diagnosis (SCID) (First et al., 2002a,b), the Hamilton 
Depression Rating Scale (HDRS) (Hamilton, 1960), the Young Mania Rating Scale (YMRS) 
(Young et al., 1978), the expanded Brief Psychiatric Rating Scale (BPRS) (Lukoff et al., 1986) 
and the Wechsler Adult Intelligence Scale-Revised (WAIS-R) (Wechsler, 1981). Patients 
fulfilled criteria for BD type I based on the Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition, revised (American Psychiatric Association, 1994). We included only 
psychiatrically healthy relatives of BD probands based on the absence of a personal lifetime 
history of any psychiatric disorder. Unrelated healthy individuals without a personal or 
family history of psychiatric disorders were selected to match patients and relatives on age, 
sex, and IQ. 
Exclusion criteria for all participants were current and hereditary neurological disorders, 
DSM-IV lifetime drug or alcohol dependence or drug or alcohol abuse in the preceding six 





patients were required to have been in remission, defined as scoring below 7 in HDRS and 
YMRS, for a minimum of one month based on prospective weekly assessments, and to have 
remained on the same medication type and dose for at least six months. There was a 
significant effect of group on all symptom rating scales (F(2,112)>9.82, p<0.001) with patients 
having higher scores than healthy relatives and unrelated healthy individuals; there was no 
difference between the latter two groups (Table 5-1). The HDRS, YMRS and BPRS were 
highly correlated with each other (all r=0.73, p<0.0001). As only the BPRS is suited for non-
patient populations (healthy relatives and unrelated healthy individuals) this scale was 
chosen to control for psychopathology in subsequent analyses. 
Thirty BD patients were on psychotropic medication; 12 on antipsychotics (7 on atypical, 2 
on typical and 3 on both), 21 on mood stabilisers (lithium =15, sodium valproate=6), and 13 
on selective serotonin reuptake inhibitors. None received anticholinergics or 
benzodiazepines. Medicated and unmedicated BD patients did not differ in age of onset, 
illness duration, IQ, HDRS, YMRS and BPRS total scores (all p> 0.31). 
DNA extraction and genotyping 
DNA was obtained from buccal swabs using conventional procedures. The ANK3 rs10994336 
(risk-allele T) as well as the ANK3 rs9804190 (risk-allele C) genotype were determined by the 
TaqMan allelic discrimination assay (Applied Biosystems, Assay ID C_31344821_10). 
Endpoint analysis was performed using the Applied Biosystems 7900HT Fast Real-Time PCR 
System. Genotypes were called with the SDS 2.3 software and the output was checked 
visually to ensure genotypes fell into distinct clusters. Call rate was 100% as buccal swabs 
were repeated for 7 individuals for whom initial genotyping was undetermined. Accuracy 
was assessed by duplicating 15% of the sample. Reproducibility was 100%.  
Within each group (patients, healthy relatives, unrelated healthy individuals) homozygote 
and heterozygote risk-allele carriers for each SNP were considered as detailed in 
Supplemental Tables 5-S1 and 5-S2. There was no effect of genotype or group-by-genotype 






Experimental Paradigm: The n-back task was employed in a block design incorporating 
alternating experimental and sensorimotor control conditions. A series of letters in yellow 
font were displayed on a blue screen for two seconds each. Participants were instructed to 
indicate by a button press whether the letter currently displayed matched the letter from 
the preceding n trials. In the sensorimotor control (0-back) condition, the letter “X” was the 
designated target. In the experimental conditions (1, 2, 3-back) the target letter was defined 
as any letter that was identical to the one presented in the preceding one, two, or three 
trials. There were 18 epochs in all, each lasting 30 seconds, comprising 14 letters with a ratio 
of target to non-target letters ranging from 2:12 to 4:10 per epoch. The entire experiment 
lasted 9 minutes and included a total of 49 target and 203 non-target stimuli. To avoid any 
systematic order effects the conditions were pseudo-randomised. Performance was 
evaluated in terms of reaction time to target letters and accuracy (% correct responses). 
Group differences in accuracy were examined using analysis of variance followed by 
pairwise comparisons with Bonferroni correction.  
Acquisition Parameters: Gradient echo planar magnetic resonance (MR) images were 
acquired using a 1.5-Tesla GE Neuro-optimised Signa MR system (General Electric, 
Milwaukee, WI, USA) fitted with 40 mT/m highspeed gradients, at the Maudsley Hospital, 
London. Foam padding and a forehead strap were used to limit head motion. A quadrature 
birdcage head coil was used for radio frequency (RF) transmission and reception. A total of 
180 T2*-weighted MR brain volumes depicting blood-oxygenation level-dependent (BOLD) 
contrast were acquired at each of 36 near-axial planes parallel to the inter-commissural (AC-
PC) plane; repetition time (TR) = 3000ms, echo time (TE) = 40ms, slice thickness = 3mm, 
voxel dimensions = 3.75 x 3.75 x 3.30mm, interslice gap = 0.3mm, matrix size = 64 * 64, flip 
angle=90°. Prior to each acquisition sequence, four dummy data acquisition scans were 
performed to allow the scanner to reach a steady state in T1 contrast. During the same 
session, a high-resolution T1-weighted structural image was acquired in the axial plane for 
subsequent co-registration (inversion recovery prepared, spoiled gradient-echo sequence; 
TR = 18ms, TE = 5.1 ms, TI = 450 ms, slice thickness = 1.5 mm, voxel dimensions = 0.9375 × 
0.9375 x 1.5 mm, matrix size 256 * 192, field of view = 240 x 180 mm, flip angle = 20°, 





Neuroimaging Data Analysis: All analyses were implemented using Statistical Parametric 
Mapping (SPM8) (www.fil.ion.ucl.ac.uk/spm/software/spm8/). The BOLD images were 
realigned to the fifth volume and corrected for interscan movements by means of a rigid 
body transformation with three rotation and three translation parameters. Subsequently, 
the 180 fMRI images were spatially normalized to the standard template of the Montreal 
Neurological Institute (MNI) and re-sampled to a voxel size of 2x2x2mm. Finally, the images 
were smoothed using an 8 mm full-width-half-maximum Gaussian kernel.  
The smoothed single-subject images were analyzed via multiple regression using a standard 
linear convolution model, with vectors of onset representing the 1, 2, 3-back and the 0-back 
condition as the sensorimotor control. Serial correlations were removed using an AR(1) 
model. A high pass filter (128s) was applied to remove low-frequency noise.  
As the effect of any single SNP on neural networks is expected to be subtle, all subsequent 
analyses were restricted to the 3-back condition because (a) individual differences in 
cognitive and neural efficiency are more apparent at high WM load (Gevins and Smith, 
2000), and (b) the effect of diagnosis in patients with BD and their relatives is also most 
consistently seen at high WM load (Jogia et al., 2012; Palaniyappan and Liddle, 2014). 
Images representing the 3-back vs. 0-back contrast from each subject were entered in 
second level random-effects.  
First, we investigated the main effect of each risk-SNP (rs10994336 and rs9804190) and 
their interaction on the WM circuitry in healthy unrelated individuals. This analysis allowed 
us to relate our findings to the literature that has examined the effect of ANK3 only in 
unrelated healthy individuals. Second, full factorial ANCOVA was used to the effect of each 
SNP and their interactions in patients, healthy relatives and unrelated healthy individuals 
with BPRS and accuracy as covariates. Suprathreshold clusters were identified using Family 
Wise Error (FWE) correction of P<0.05. Stereotactic coordinates of the peak maxima of the 
suprathreshold clusters were converted (www.mrc-cbu.cam.ac.uk/Imaging/mnispace.html) 
from the Montreal Neurological Institute spatial array (www.mni.mcgill.ca) to that of 
Talairach and Tournoux (Talairach and Tournoux, 1988). Mean signal change from 
suprathreshold clusters was extracted using the MarsBaR toolbox 





effect of age of onset, duration of illness, number of episodes, and medication dose at the 
time of scanning (lithium and antipsychotic). Threshold for statistical significance was set at 
p< 0.005 following Bonferroni correction. 
Results 
Effect of ANK3 allelic variation on clinical features 
Rs10994336 or rs9804190 risk associated patients had significantly higher HDRS, YMRS and 
BPRS scores compared to all other groups (F(2, 112)>6.5, p<0.02) (Supplemental Tables 5-S1 
and 5-S2). There was no effect of genotype on patients’ age of onset, duration of illness and 
number of mood episodes (t39<1.2, p>0.2). 
Effect of ANK3 allelic variation on cognitive task performance 
There was no effect of group, genotype or group by genotype interaction for either SNP on 
general intellectual ability or response time (p>0.1)(Table 5-1, Supplemental Tables 5-S1 and 
5-S2). In contrast, there was a significant effect of group on accuracy for the 3-back 
condition only, where relatives were significantly better than both other groups 
(F(2,112)>24.31, p<0.003)  (Table 5-1). Within the relatives group, non-risk associated relatives 
for either rs10994336 or rs9804190 had significantly higher accuracy (p<0.01) 
(Supplemental Tables 5-S1 and 5-S2).  
Effect of ANK3 allelic variation on WM-related activation in unrelated healthy individuals 
Healthy carriers of the rs10994336 risk-allele showed significantly decreased lateral 
temporal cortical activation within the middle (BA 21) and inferior (BA 20) temporal gyrus 
(Fig. 5-1). In contrast, healthy homozygotes of the rs9804190 risk-allele showed increased 
activation in the lateral prefrontal cortex within the inferior (BA 47/11) and middle (BA 46) 
frontal gyrus (Fig. 5-1). The coordinates of the peak height voxel of the corresponding 
suprathreshold clusters are presented in Table 5-2. 
Effect of ANK3 allelic variation on WM-related activation in BD patients and their healthy 
relatives 
An effect of group (patients, healthy relatives, healthy unrelated individuals) was observed 





and in the ventral ACC (BA 24/32). When compared to unrelated healthy individuals, brain 
activation in patients was significantly (a) reduced in the left (BA 9) and right middle frontal 
gyri (BA 10) and, (b) increased in the superior and middle temporal gyri (BA 21/22) on the 
right and in the ACC bilaterally (BA 24/32). In comparison to patients, healthy relatives had 
greater activation in the middle frontal gyrus bilaterally. No differences were observed 
between unrelated healthy individuals and healthy relatives. The coordinates of the peak 
activations of the suprathreshold clusters are shown in Supplemental Table 5-S3. 
In patients, there were no significant correlations between mean signal change in 
suprathreshold clusters and age of onset, duration of illness, mood episodes or medication 
dose (p> 0.1). 
For the ANK3rs10994336, we found a significant group by genotype interaction in the right 
ventral ACC (x=4, y=19, z=-3, cluster size=35, z-value=3.67) and left ventral posterior 
cingulate cortex (PCC; x=-28, y=-64, z=16, cluster size=166, z-value=4.10). In the right ACC, 
the risk T-allele was associated with increased activation in BD patients and their healthy 
relatives compared to unrelated healthy individuals. In the left PCC, the risk T-allele was 
related with increased activation in BD patients compared to their healthy relatives and to 
unrelated healthy individuals (Fig. 5-2).   
For the ANK3 rs9804190,  a significant group by genotype interaction was found in the right 
ACC (x=4, y=17, z=-4; cluster size= 58; z-value=3.95) in which patients and healthy relatives 
who were risk C-allele homozygotes showed increased activation compared to unrelated 
healthy individuals (Fig. 5-2). 
Discussion 
There are two key findings from this study. First, in healthy individuals without personal or 
family history of psychiatric disorders, the rs10994336 and rs9804190 BD-risk alleles had 
different effects on the working memory (WM) network, although neither affected task 
performance. Second, both BD-risk alleles were associated with failure to deactivate the 
default mode network (DMN) in patients and in their healthy relatives; accuracy was 





Unrelated healthy carriers of the rs10994336 risk-allele showed reduced engagement of the 
ventral visual cortex within the middle and inferior temporal gyri (Table 5-2). This accords 
with previous reports from two independent samples which found that the largest effect 
size of the rs10994336 risk-allele was on reduced sensitivity in target detection and 
increased errors of commission during the degraded symbol continuous performance task 
(Ruberto et al., 2011; Hatzimanolis et al., 2012). Although the ventral visual cortex is an 
integral part of the WM circuitry, the core WM network involves the frontoparietal cortices 
(Owen et al., 2005; Leech et al., 2011; Rottschy et al., 2012). These regions are also core 
components of the superordinate cognitive control network that supports a broad range of 
executive function tasks (Niendam et al., 2012). Unrelated healthy rs9804190-risk allele 
homozygotes evidenced greater activation within the prefrontal components of the WM 
network although their task performance was comparable to that of the non-risk associated 
unrelated individuals (Table 5-2). This pattern is typically interpreted as evidence of cortical 
inefficiency, and is consistent with behavioural data from an independent sample that also 
found that healthy rs9804190-risk-allele homozygotes underperform in a wide array of 
executive function tasks (Roussos et al., 2012).  
These findings suggest that in the absence of increased background genetic risk for BD or 
other psychiatric disorders the two ANK3 BD-risk loci affect different regions of the WM 
circuitry. The reason for these regional differences is unclear. Available data suggest that 3’ 
risk-alleles (rs9804190) are associated with reduced transcript levels of brain-specific AnkG 
isoforms. To date, the region most commonly implicated is the cerebellum where ANK3 
expression is generally highest (Rueckert et al., 2013). Information about other brain regions 
is incomplete because the available post-mortem studies have limited statistical power due 
to the small number of donors and provide incomplete brain coverage (Roussos et al., 2012; 
Rueckert et al., 2013). With regards to rs10994336, the effect of the risk-allele on ANK3 
expression in the brain is unknown. The rs10994336 polymorphism is located in an intronic 
region (Tesli et al., 2011) but could affect gene expression through cis- or trans-regulatory 
mechanisms (Quinn et al., 2010). Alternatively, rs10994336 may be in strong linkage 
disequilibrium with other, yet unidentified, genetic loci that drive the effects observed here.  
Rs10994336 or rs9804190 risk-associated patients and relatives showed hyperactivity within 





processing and generation (Critchley et al., 2003) and a key component of the anterior DMN 
(Raichle et al., 2001; Buckner et al., 2008). Activation within the ventral ACC is increased 
during the processing of arousing stimuli or during mental stress (Critchley et al., 2003). The 
n-back task is quite challenging and may engender mild mental stress but it is not expected 
to result in ventral ACC hyperactivation. In fact, deactivation of the ventral ACC is normally 
observed during the n-back task within the context of anticorrelated activity between the 
DMN and the frontoparietal cognitive control network (Leech et al., 2011; Esposito et al., 
2006).  
Accordingly, healthy unrelated individuals in this study showed deactivation of the ventral 
ACC during the n-back task regardless of genotype. As expected, hyperactivation within the 
ventral ACC was observed in the patients regardless of genotype (Jogia et al., 2012; 
Pomarol-Clotet et al., 2012; Fernández-Corcuera et al., 2013) but it was more pronounced in 
rs10994336 or rs9804190 risk associated individuals. Amongst the healthy relatives, ventral 
ACC hyperactivity was only present in risk associated individuals for either risk-allele. 
Additionally, BD carriers of the rs10994336 risk-allele also showed hyperactivity within the 
PCC, centred on the ventral and extending to dorsal regions (Vogt et al., 2006). The PCC has 
dense anatomical connections with multiple cortical and subcortical regions (Hagmann et 
al., 2008) and is a core component of the posterior DMN (Raichle et al., 2001; Buckner et al., 
2008). Healthy individuals performing the n-back task show deactivation in both dorsal and 
ventral PCC (Leech et al., 2011; Esposito et al., 2006) so the persistent PCC activation seen in 
patients suggests that the rs10994336 risk-allele compromises the ability to deactivate this 
brain region.  
Taken together, these findings suggest that aberrant hyperactivation within the ventral ACC 
is a key mechanism mediating the risk-conferring effects of rs10994336 and rs9804190 in 
connection to the WM circuitry. It is noteworthy that this effect appeared to require the 
concomitant presence of additional risk factors for BD as it was not observed in unrelated 
individuals who had no personal or family history of such risk factors. This is consistent with 
the multifactorial pathogenetic model of BD that involves interaction between multiple 
genetic and non-genetic risk factors (Sullivan et al., 2012). The effect of any individual factor 
depends on the relative prevalence of other risk factors that are part of the same 





reported here, several neuroimaging studies have shown differential effects of various 
susceptibility polymorphisms (e.g. DISC1, NRG1, COMT) on brain structure and function in 
patients, high-risk groups and unrelated healthy individuals (Addington et al., 2007; Mechelli 
et al., 2008; Prata et al., 2008; Tsuchimine et al., 2013; Narr et al., 2009; Whalley et al., 
2012).  
In conclusion, our results point to a differential effect of BD-risk associated polymorphisms 
at ANK3 rs10994336 and rs9804190 modulated by risk-status for the disorder. This suggests 
that the BD-risk conferring mechanisms associated with these genetic variants are 
influenced by other genetic and possibly non-genetic factors that contribute to risk status. 
Inability to suppress key nodes of the DMN emerged as a common final pathway through 
which either risk-allele may contribute to the pathogenesis of BD. Mood stabilizing 
medications such as Lamotrigine interact with the ANK3 system through ion channels bound 
by AnkG to the axonal initial segment. Our results therefore lend further support to our 
previous study on patients with BD treated with Lamotrigine that showed “normalization” 
of the WM circuitry (Lang et al., 1993; Haldane et al., 2008) and suggest that ANK3-related 
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Table 5-1 Study Sample 
 
 Unrelated Healthy 
Individuals 
N=46 







Age(years) 40.3 (13.2) 44.3 (11.9) 39.7 (13.7) 
Sex (Male/Female) 25/21 20/21 13/12 
Clinical Features 
HDRS total score a 0.1 (0.5) 4.8 (5.3) 0.14 (0.4) 
YMRS total score a 0.2 (0.6) 1.4 (3.0) 0.0 (0.0) 
BPRS total score a 24.3 (0.7) 27.5 (4.0) 24.1 (0.4) 
Age of onset (years) n/a 24.7 (8.0) n/a 
Duration of illness (years) n/a 20.2 (10.5) n/a 
Depressive episodes (n) n/a 5.7 (7.5) n/a 
Manic episodes (n) n/a 5.6 (7.7) n/a 
Cognitive task performance  
IQ 112.6 (14.5) 117.9 (17.9) 115.8 (18.5) 
1-back accuracy (% correct) 100 100 100 
1-back response time (sec) 0.6 (0.3) 0.5 (0.2) 0.5 (0.2) 
3-back accuracy (% correct)b 72.1 (17.2) 68.9 (19.7) 90.1 (15.4) 
3-back response time (sec) 0.8 (0.4) 0.8 (0.3) 0.7 (0.2) 
Except for sex, all data are presented as mean (standard deviation); BD= Bipolar Disorder; 
BPRS= Brief Psychiatric Rating Scale; HDRS=Hamilton Depression Rating Scale; YMRS=Young 
Mania Rating Scale. a Patients> healthy individuals and relatives (P<0.001); b Relatives> 







Table 5-2 Brain regions showing significant effects of allelic variation at 10994336 and 
rs9810490 in the 3-back vs 0-back contrast in unrelated healthy individuals 





Cluster size z-value 
X y z 
















-5 -15 90 3.76 
59 
 







-42 -12 -24 56 3.43 
Right 44 -11 -20 90 3.80 
ANK3 rs9810490: Risk Allele Carriers > Non-Risk Allele Homozygotes  









47/10 -46 48 -4 51 3.48 






Figure 5-1 Effect of genotype on regional brain activation in the 3-back vs 0-back contrast in unrelated healthy individuals. 
All the regions showed are ROIs which I used only for graphical purposes to present brain regions significantly activated 






Figure 5-2 Effect of genotype on regional brain activation in the 3-back vs 0-back contrast in patients with bipolar disorder and their 






Supplemental Table 5-S1 Effect of ANK3 rs10994336 genotype (risk-allele T)  

















N = 72 
Unrelated Healthy 
Individuals 



















N = 32 
BD patients 
 











21/19 34/38 7/7 9/7 4/6 18/14 11/14 7/8 
Clinical Features  
HDRS total score a 2.1 (4.3) 0.5 (0.81) 0.4 (0.9) 5.3 (4.6) 0.3 (0.6) 0.1 (0.4) 1.5 (0.9) 0.1 (0.5) 
YMRS total score a 0.7 (2.1) 0.1 (0.3) 0.2 (0.4) 1.6 (2.9) 0.0 (0.0) 0.2 (0.6) 0.7 (1.4) 0.0 (0.0) 
BPRS total score a 25.6 (3.2) 24.9 (1.0) 24.8 (1.1) 27.3 (4.3) 24.7 (1.1) 24.2 (0.6) 25.9 (1.9) 24.1 (0.3) 
Cognitive Performance 
IQ 117.2  (17.6) 116.9 (16.1) 110.7 (12.9) 112.3 (16.2) 112.0 (20.4) 116.7 (14.5) 121.7 (16.3) 118.3 (18.5) 
3-back accuracy 
(%) b, c 
78.7 (23.1) 66.9 (29.8) 70.5 (19.8) 73.3 (36.5) 83.8 (22.8) 75.1 (24.5) 67.2 (23.5) 90.78 (14.9) 
3-back response 
time (sec) 
0.84 (0.38) 0.77 (0.33) 0.99 (0.37) 0.68 (0.23) 0.54 (0.21) 0.86 (0.46) 0.94 (0.36) 0.75 (0.21) 
Except for sex, all data are presented as mean (standard deviation); BD= Bipolar Disorder; BPRS= Brief Psychiatric Rating Scale; HDRS=Hamilton Depression Rating Scale; 
YMRS=Young Mania Rating Scale. a BD carriers of the risk-allele > unrelated healthy individuals, relatives, P<0.02; b relatives> unrelated healthy individuals, P=0.003; 
relatives>  BD Patients, P = 0.003; 
c 






























N = 63 
 
 
N = 49 
Unrelated Healthy 
Individuals  
N = 28 
BD Patients   
 
N = 21 
Healthy 
Relatives 
N = 14 
Unrelated Healthy 
Controls   
 N = 18 
BD Patients  
 
N = 20 
Healthy 
Relatives 




38.8 (13.6) 43.9 (12.1) 40.1 (13.26) 43.5 (12.51) 40.2 (14.3) 40.1 (11.9) 44.8 (9.5) 39.2 (13.8) 
Sex (Male/Female) 
 
29/34 29/20 14/14 8/13 7/7 11/8 12/9 6/5 
Clinical Features 
HDRS total score a 1.7 (3.9) 2.1 (4.1) 0.1 (0.4) 5.5 (5.6) 0.1 (0.1) 1.2 (3.3) 4.5 (5.4) 0.07 (0.3) 
YMRS total score a 0.7 (2.1) 0.5 (1.8) 0.2 (0.5) 2.0 (3.5) 0.0 (0.0) 0.06 (0.25) 1.2 (2.7) 0.0 (0.0) 
BPRS total score a 25.8 (1.5) 25.1 (1.9) 24.3 (0.6) 29.3 (5.0) 
 
24.2 (0.6) 24.7 (1.0) 26.3 (2.7) 24.1 (0.3) 
Cognitive Performance 
IQ 111.8 (15.6) 120.4 (18.7) 117.6 (16.3) 114.1 (13.9) 108.5 (18.1) 119.4 (16.5) 118.3 (21.5) 122.9 (18.1) 
3-back accuracy 
(%)  b, c 
72.02 (25.9) 83.01 (23.1) 67.1 (25.7) 73.5 (30.5) 85.6 (17.0) 85.8 (26.1) 62.5 (23.2) 92.5 (14.2) 
3-back response 
time ( sec) 
0.76 (0.48) 0.58 (0.42) 0.85 (0.50) 0.61 (0.49) 0.70 (0.37) 0.81 (0.51) 0.41 (0.44) 0.60 (0.29) 
Except for sex, all data are presented as mean (standard deviation); BD= Bipolar Disorder; BPRS= Brief Psychiatric Rating Scale; HDRS=Hamilton Depression Rating Scale; 
YMRS=Young Mania Rating Scale. 
a
 BD carriers of the risk-allele > unrelated healthy individuals, relatives, P<0.02, relatives> unrelated healthy individuals, P = 0.003; relatives>  





Supplemental Table 5-S3 Brain regions showing significant effect of group in the 3-back vs 0-back contrast  
 
Gyrus Laterality Brodmann Area Talairach and Tournoux Coordinates z-value 
x y Z 
Patients with BD >  Healthy unrelated controls   
Anterior  
Cingulate 
Left  24/32 -14 46 6 3.56 
Right  10 26 -6 3.49 
Superior 
Temporal 
Right  22 54 1 -4 3.93 
Middle 
Temporal 
Right  21 62 -8 -4 4.25 
Patients with BD < Healthy unrelated controls 
Middle Frontal Left 
 
9 -34 14 40 3.70 
Right  10 38 56 -8 3.26 
Patients with BD  < Healthy relatives   
Middle Frontal Left  9 -42 20 34 4.46 
 Right  9 40 32 34 4.01 





Supplemental Figure 5-S1 Box plot with the mean signal change in the posterior Cingulate 
Cortex in subjects carriying the ANK3 rs10994336. 
 
Supplemental Figure 5-S2 Box plot with the mean signal change in the Anterior Cingulate 







Supplemental Figure 5-S3 Box plot with the mean signal change in the posterior Cingulate 





















6.    FMRI investigation on the effect of CACNA1C and ANK3 risk genes on 
brain regions during processing of facial affect labelling task in Bipolar 
disorder, their unaffected first-degree relatives and healthy individuals (in 
preparation for submission) 
 
This chapter aims to explore the influence of genetic polymorphisms within the CACNA1C 
and ANK3 risk genes for bipolar disorder (BD) during processing of a facial affect labelling 
task in 46 healthy individuals, 41 BD patients and 25 of their first-degree healthy relatives. 
The groups employed in this study derived from the same cohort (VIBES) employed in the 
previous chapter. 
Introduction 
BD is a high heritable disease (85-89%, McGuffin et al., 2003) characterized by periods of 
depression and mania (American Psychiatric Association, 2013).In the last twenty years, 
functional magnetic resonance imaging (fMRI) studies have tried to identify the link 
between the clinical phenomenology of BD and the underlying neural systems that subserve 
emotional processing and regulation in BD across mood phases (manic, depressive and 
euthymic). A consensus model for BD suggests a dysfunction within distributed neural 
networks that underlie abnormal emotional processing in BD patients (Strakowski et al., 
2012). Key regions within these networks involve the ventral prefrontal cortex (VPFC), the 
amygdala and other limbic areas (Chen et al., 2011). The pattern of activation in this 
network in BD patients seemed to be consistent across fMRI studies, with decreased 
activation in the VPFC (Altshuler et al., 2008; Jogia et al., 2008; Foland-Ross et al., 2012) and 
increased activation in the amygdala and other limbic associated regions(Foland et al., 2008; 
Jogia et al., 2008; Keener et al., 2012; Lawrence et al., 2004; Malhi et al., 2007).  
Genome-wide association studies (GWAS) consistently identified several single-nucleotide 
polymorphisms (SNPs) associated with BD (Baum et al., 2008; Ferreira et al., 2008; Sklar et 
al., 2011). Among the most significant loci, GWAS studies identified genetic variants 
associated with BD within the ANK3, on chromosome 10q21.2 (rs10994336 and rs9804190; 
Ferreira et al., 2008; Sklar et al., 2011) and the CACNA1C, on chromosome 12p13 





that these two genes have an effect on mood-related behaviours (Leussis et al., 2013; 
Shinnick-Gallagher et al., 2003). Specifically, the ANK3 gene encodes the ankyrin-G, a 
protein that is located at the nodes of Ranvier and the axonal initial segment and regulates 
the clustering of the voltage-gated sodium ion channels and neuronal excitability (Zhou et 
al., 1998; Pan et al., 2006). The CACNA1C gene encodes the alpha subunit of the L-type 
voltage-dependent calcium (Ca2+) channel Cav1.2 and influences neuronal ability to 
generate and transmit electrical signals (Moosmang et al., 2005).  
In healthy individuals, the CACNA1C rs1006737 risk-allele has been associated with 
increased amygdala activity (Bigos et al., 2010; Jogia et al., 2011; Wessa et al., 2010) and 
decreased connectivity between subcortical and prefrontal regions (Radua et al., 2012) as 
well as between visual and prefrontal cortices (Dima et al., 2013). For BD patients, two 
studies reported that the CACNA1C rs1006737 risk-allele was associated with significant 
decreased activation in the right VPFC compared to increased activation in healthy 
individuals (Dima et al., 2013; Jogia et al., 2011). Moreover, Jogia et al. (2011) reported that 
CACNA1C rs1006737 risk-allele was associated with significant increased activation of the 
VPFC in healthy relatives suggesting that this region may reflect the genetic pathway 
through which this BD-risk conferring SNP influence the emotional network in BD.  
On the other hand, evidence from the effect of the genetic variations within the ANK3 gene 
are scarce. Only three fMRI studies explored the effect of the ANK3 rs10994336 or the ANK3 
rs9804190 risk-alleles during processing of emotional or cognitive tasks (Dima et al., 2013; 
Delvecchio et al., 2015 (in press); Roussos et al., 2012). These studies suggested that both 
risk-alleles within the ANK3 gene modulate prefrontal regions, with reduced activation in 
the VPFC in BD patients and increased activation in healthy individuals during processing of 
emotional stimuli (Dima et al., 2013) as well as decreased activation in the inferior and 
middle frontal gyrus in healthy individuals during processing of a working memory task 
(Delvecchio et al., 2015 (in press); Roussos et al., 2012). Additionally, Delvecchio et al. 
(2015) also reported that BD patients and their healthy relatives carriers of either the ANK3 
rs10994336 or the ANK3 rs9804190 risk-alleles showed increased activation in the ventral 
anterior cingulate cortex (ACC) compared to healthy individuals as well as increased 
activation in the posterior cingulate cortex in BD patients carriers of the ANK3 rs10994336 





Based on these evidence, this study aimed to further explore the effect of CACNA1C 
rs1006737, ANK3 rs10994336 and ANK3 rs9804190 risk-alleles on brain activation during 
emotional processing in 41 euthymic BD patients, 25 of their healthy relatives and 46 
healthy individuals. Because it has been shown that the facial affect is processed mainly by 
right sided regions, including the inferior occipital gyrus (IOG) and fusiform gyrus (FG), the 
amygdala (AMY) and the VPFC (Dima et al., 2011; Dima et al., 2013; Fairhall et al., 2007), we 
focused our investigation on these four volume of interests (VOIs) that also overlap with 
regions implicated in BD (Strakowski et al., 2012).  
We tested the hypotheses that (a) the CACNA1C rs1006737, ANK3 rs10994336 and ANK3 
rs9804190risk-alleles will independently contribute to modulate the neural responses within 
the four predefined VOIs of the facial affect processing network, (b) BD patients will exhibit 
decreased activation within the VPFC compared to healthy individuals and healthy relatives, 
and (c) the CACNA1C rs1006737, ANK3 rs10994336 and ANK3 rs9804190 risk-alleles will 
independentlyamplify the abnormal brain de-activation in the VPFC in BD patients. 
Methods 
Participants 
All participants were selected from the VIBES study cohort which comprises 75 families 
identified through a proband with BD type I and screened to exclude pedigrees with 
schizophrenia or schizophrenia spectrum disorders. Details of the VIBES rationale and design 
have been reported previously (Frangou, 2009). The sample considered in the present study 
comprised 41 euthymic patients with BD, 25 of their psychiatrically healthy first-degree 
relatives, and 46 healthy unrelated individuals, all of white British ancestry (Table 6-1). The 
study received institutional ethical approval. All individuals provided written informed 
consent prior to participation. 
All participants were assessed by trained psychiatrists with patient or non-patient versions 
of the Structured Clinical Interview for Interview (SCID) (First et al., 2002a, 2002b), the 
Hamilton Depression Rating Scale (HDRS) (Hamilton, 1960), the Young Mania Rating Scale 
(YMRS) (Young et al., 1978), the expanded Brief Psychiatric Rating Scale (BPRS) (Lukoff et al., 





fulfilled criteria for BD type I based on the Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition, revised (American Psychiatric Association, 1994). Only psychiatrically 
healthy relatives were included based on the absence of a personal lifetime history of any 
psychiatric disorder. Unrelated healthy individuals without a personal or family history of 
psychiatric disorders were selected to match patients and relatives on age, sex, and IQ.  
Exclusion criteria for all participants were current and hereditary neurological disorders, 
DSM-IV lifetime drug or alcohol dependence or drug or alcohol abuse in the preceding six 
months and contraindications to MR imaging. Prior to cognitive and MRI evaluation, 
patients were required to have been in remission, defined as scoring below 7 in HDRS and 
YMRS, for a minimum of one month based on prospective weekly assessments, and to have 
remained on the same medication type and dose for at least six months. There was a 
significant effect of group on in all symptom rating scales (F(2,112)>9.82, P <0.001) with 
patients having higher scores than healthy relatives and unrelated healthy individuals; there 
was no difference between the latter two groups (Table 6-1). The HDRS, YMRS and BPRS 
were highly correlated with each other (all r=0.73, P <0.0001). As only the BPRS is suited for 
non-patient populations (healthy relatives and unrelated healthy individuals) this scale was 
chosen to control for psychopathology in subsequent analyses. 
Thirty BD patients were on psychotropic medication; 12 on antipsychotics (7 on atypical, 2 
on typical and 3 on both), 21 on mood stabilisers (lithium=15, sodium valproate=6), and 13 
on selective serotonin reuptake inhibitors. None received anticholinergics or 
benzodiazepines. Medicated and unmedicated BD patients did not differ in age of onset, 
illness duration, IQ, HDRS, YMRS and BPRS total scores (all P > 0.31). 
DNA extraction and genotyping 
DNA was obtained from buccal swabs using conventional procedures. The ANK3 rs10994336 
(risk-allele T), the ANK3 rs9804190 (risk-allele C) as well as the CACNA1C rs1006737 (risk-
allele A) genotype were determined by the TaqMan allelic discrimination assay (Applied 
Biosystems, Assay ID C_31344821_10). Endpoint analysis was performed using the Applied 
Biosystems 7900HT Fast Real-Time PCR System. Genotypes were called with the SDS 2.3 
software and the output was checked visually to ensure genotypes fell into distinct clusters. 





genotyping was undetermined. Accuracy was assessed by duplicating 15% of the sample. 
Reproducibility was 100%.  
Within each group (patients, healthy relatives, unrelated healthy individuals) homozygote 
and heterozygote risk-allele carriers for each SNP were considered as detailed in Tables 6-2, 
Table 6-3 and Table 6-4.  There was no effect of genotype or group-by-genotype interaction 
on age or sex. 
Neuroimaging 
Experimental Paradigm: The paradigm included 3 negative facial emotions (fear, anger, and 
sadness) in 3 separate experiments conducted in a single acquisition session in a 
randomized order. This paradigm consisted of 3 event-related tasks lasting 5 minutes each. 
In each task, 10 different facial identities (http://paulekman .com/) depicting 150% intensity 
of a negative (fear, anger, or sadness) or a neutral facial expression were presented in a 
pseudo random order interspersed with a fixation cross. The 150% level of intensity was 
chosen to minimize ambiguity about the nature of the stimuli. The stimuli (affective and 
neutral faces and the fixation cross) were each displayed for 2 seconds and repeated 20 
times. The inter stimulus interval followed a Poisson distribution and varied between 3 and 
9 (mean interval, 5) seconds. Participants were instructed to press the right or the left 
button with their dominant hand on an MRI compatible response box to indicate whether 
the face had an emotional or a neutral expression. Response time and accuracy data were 
collected. 
Acquisition Parameters: Anatomical and functional imaging data were acquired during the 
same session using a 1.5-T MRI system (GE Sigma; General Electric). Gradient echo planar 
magnetic resonance (MR) images were acquired at each of the 16 noncontiguous planes 
parallel to the intercommissural (anterior commissure–posterior commissure) plane. I 
acquired T2*- weighted MR images reporting blood oxygenation level– dependent contrast 
(repetition time, 2000 milliseconds; echo time, 40 milliseconds; flip angle, 70°; section 
thickness, 7 mm; section skip, 0.7 mm; matrix size, 64 × 64; voxel dimensions, 3.75 × 3.75 × 
7.7 mm). For each participant, 450 fMRIs were acquired. A high-resolution T1-Iighted 
structural image was acquired in the axial plane for coregistration (inversion recovery-





milliseconds; inversion time, 450 milliseconds; flip angle, 20°; slice thickness, 1.5 mm; matrix 
size, 256 × 192; field of view, 240 × 180 mm; voxel dimensions, 0.9375 × 0.9375 × 1.5 mm; 
number of excitations, 1). 
Demographic, Clinical and Task Performance Data Analysis: The groups were compared on 
demographic (age, gender and IQ) and clinical variables (HDRS, BPRS and YMRS total scores) 
using a univariate Analyses of Variance (ANOVA) with group or genotype as fixed 
factors.Similarly, task performance was examined using univariate ANOVA with accuracy or 
response time as dependent variables and group or genotype as independent factors. For all 
the statistical analyses, we controlled for possible confounding variables by including the 
BPRS total score as covariates. 
Neuroimaging Data Analysis: All analyses were implemented using Statistical Parametric 
Mapping (SPM8) (www.fil.ion.ucl.ac.uk/spm/software/spm8/). The BOLD images were 
realigned to the fifth volume and corrected for interscan movements by means of a rigid 
body transformation with three rotation and three translation parameters. Subsequently, 
the 180 fMRI images were spatially normalized to the standard template of the Montreal 
Neurological Institute (MNI) and re-sampled to a voxel size of 2x2x2mm. Finally, the images 
were smoothed using an 8 mm full-width-half-maximum Gaussian kernel. For each 
participant, the fMRI data from the 3 event-related tasks (fear, anger, or sadness vs neutral) 
were concatenated and modelled with a general linear (convolution) model. Serial 
correlations were removed using an AR(1) model. A high pass filter (128s) was applied to 
remove low-frequency noise. Six movement parameters were also entered as nuisance 
covariates. The means of the 3 sessions were also modelled, as was the transition at the end 
of each session. For each participant, contrast images (affective > neutral facial expressions) 
were produced.  
Group-level analyses were based on random-effects analyses of the single-subject contrast 
images using the summary statistic approach. To explore our hypotheses, four volumes of 
interest (VOIs) within the right IOG, FG, AMY and VPFC have been selected based on 
evidence of previous work that demonstrated the pivotal role of these regions during facial 
affect processing (Dima et al., 2011; Delvecchio et al., 2012; Dima et al., 2013). These VOIs 





Forest University PickAtlas (version 3.0.3;www.fmri.wfubmc.edu/software/PickAtlas). 
Measures of brain activation (weighted parameter estimates) (Kiebel et al., 2007) were 
extracted for each VOI from one-sample t-tests (contrast images affective>neutral facial 
expressions) for each group using a region-of-interest toolbox for SPM (MarsBaR; 
http://marsbar.sourceforge.net).  
These measures were analyzed in SPSS (version 20; SPSS, Inc). First, a multivariate ANOVA 
was performed to explore the effect of group on the four predefined VOIs (dependent 
variable: extracted weighted parameter estimates for each VOI; independent factors: 
group). Second, a two-sample t-test was carried out to investigate the independent effect of 
each genotype on neural activation in the four predefined VOIs. Third, a multivariate ANOVA 
was performed to explore the group by genotype interaction for each genotype separately 
(dependent variable: extracted weighted parameter estimates for each VOI; independent 
factors: group and genotype). All results were corrected by using the Bonferroni correction. 
The new critical value (a=0.01) for an individual test was found by dividing the family-wise 
error rate (0.05) by the number of tests employed (4). Threshold for statistical significance 
was then set at p< 0.01 following Bonferroni correction. 
Results 
Demographic and clinical data 
There was no effect of genotype or group by genotype interaction on demographic variables 
(P>0.2). However, BD patients, regardless of genotype, showed higher symptoms scores 
compared to all the other groups; rs10994336, rs9804190 or rs1006737 risk associated 
patients had significantly higher HDRS, YMRS and BPRS scores compared to all other groups 
(P<0.02) (Table 6-2, Table 6-3, Table 6-4). 
Task performance 
There was no effect of group, genotype or group by genotype interaction for either SNP 
within the ANK3 and CACNA1C genes on accuracy (P>0.6) (Table 6-2, Table 6-3, Table 6-4). 
BD patients had longer mean response time compared to their healthy relatives and healthy 
individuals (P<0.002) but there was no effect of genotype nor an interaction between group 






No significant suprathreshold clusters were found in the whole-brain analyses for each 
genotype.  
Multivariate ANOVA in the three groups regardless of genotype 
Multivariate ANOVA with weighted parameters from the four VOIs as dependent variables 
and group as independent factor showed a significant effect of group in the VPFC (all 
F(2,112)>9.5, all P<0.0001). Post hoc analyses showed that mean levels of activation were 
reduced in BD patients and healthy individuals compared to healthy relatives (P< 0.001). 
However, BD patients and healthy individuals did not significantly differ from each other (P> 
0.2) (Fig. 6-1). 
Two-sample t-test exploring the effect of each genotype regardless of group 
Two-sample t-tests with weighted parameters from the four VOIs as dependent variables 
and genotype as grouping factor showed the ANK3 rs10994336 and CACNA1C rs1006737 
risk-alleles were independently associated with greater activation in all four predefined 
VOIs, including the IOG, FG, AMY, and VPFC, while the ANK3 rs9804190 risk-allele carriers 
had an opposite pattern of activation (P< 0.05) (Fig. 6-2).  
Multivariate analysis of variance exploring the group by genotype interaction in the three 
genotypes separately 
For each genotype, we found a significant group by genotype interaction in the VPFC (all 
F(2,112)> 4, all P<0.001). The results showed that the ANK3 rs10994336, the CACNA1C 
rs1006737 and the ANK3 rs9804190 risk-alleles were independently associated with 
decreased activation in the VPFC in BD patients. In contrast, in healthy individuals and 
healthy relatives the ANK3 rs10994336 or the CACNA1C rs1006737 risk-alleles  were 
associated with increased activation in this brain region whereas the ANK3 rs9804190 risk-
allele carriers showed the opposite pattern of activation(all P<0.0015) (Fig. 6-3). 
Discussion 
It has been reported that psychiatric disorders, including BD, involved complex and 
polygenic modes of inheritance in which each gene might have only a small effect. 





the subtle effect of any single SNP on the neural networks. For this reason, to increase the 
power to detect the effect of any single SNP on brain activation we to extracted the BOLD 
signal from four VOIs that have been shown to have a pivotal role in the facial affect 
processing (Dima et al., 2013) and to perform statistics across only these regions.  This 
approach was used in order to reduce the severity of correction for multiple tests by 
correcting only for a small number of VOIs instead of correcting for the large number of 
voxels in the brain (Poldrack et al., 2007).  
In this study the effect of three SNPs within the ANK3 (rs10994336, rs9840190) and 
CACNA1C (rs1006737) risk genes on neural correlates of facial affect processing was 
explored using a VOIs approach in BD patients, their healthy relatives and healthy 
individuals. The key findings of this study are fourfold (a) a significant main effect of group 
was found in the VPFC, (b) a main effect of genotype was found in all four predefined VOIs 
with the ANK3 rs10994336 and the CACNA1C 1006737 risk-alleles showing the same effect 
on these regions compared to the ANK3 rs9804190 risk-allele, (c) a significant group by 
genotype interaction was found in the VPFC for each genotype independently, with the 
ANK3 rs10994336 and the CACNA1C rs1006737 risk-alleles showing the same modulation 
effect on the VPFC in the three groups compared to the ANK3 rs9804190 risk-allele. 
Independent effect of each genetic variation within the CACNA1C and ANK3 genes on 
facial affect processing network  
Results of this study supported the initial prediction that the three genotypes, regardless of 
group, independently modulated the brain activation in key regions of the facial affect 
processing network (Fig. 6-2). Specifically, we found that the ANK3 rs10994336 and 
CACNA1C rs1006737 risk-alleles were independently associated with increased activation in 
the four predefined VOIs. These findings partially replicated the results of a previous study 
by Dima et al. (2013) that reported increased activation in the IOG, AMY, FG in both healthy 
individuals and BD patients carriers of the risk-alleles within the CACNA1C rs1006737 and 
ANK3 rs10994336 genes. Moreover, these results are also in keeping with the evidence from 
two previous fMRI studies which reported that the CACNA1C rs1006737 significantly 
increased the activation of the AMY (Wessa et al., 2010; Jogia et al., 2011) and the VPFC 
(Jogia et al., 2011) in both healthy individuals and healthy relatives.The interpretation of 





such as the ones explored in this study, within the genome is still under investigation. 
However, what we do know is that since many of the GWAS hits for common diseases, 
including BD, lie in the non-coding regions of the genome it is likely that variation in these 
areas have an effect on gene expression (Hindorff et al., 2009; Chorev et al., 2012), including 
the genetic variants within the ANK3 and CACNA1C genes (Quinn et al., 2010). Moreover, 
because the CACNA1C and ANK3 genes regulate the voltage-gated ion channels that are 
involved in various aspect of neuronal development (Spitzer et al., 2006), alterations in gene 
expression may therefore affect brain structure, which could also affect brain function. 
Additionally, for the ANK3 rs9804190 risk-allele we observed the opposite pattern of 
activation, with risk-allele carriers showing a decreased activation in the four predefined 
VOIs. Also in this case, the reason for these differences, especially between the two SNPs 
within the same ANK3 gene, is still unclear as no fMRI studies exploring the effect of the 
ANK3 rs9894190 risk-allele on brain activation during emotional processing have been 
published yet.The rs10994336 and rs9894190 are over 340 kb apart and at the 5' and 3' end 
of the ANK3 gene respectively and with no evidence of linkage disequilibrium (LD) (Schulze 
et al., 2009). LD is defined as the non random association of alleles of two or more loci 
(Slatkin et al., 2008) and it is used to identify redundant tracts of the genome that carry the 
same genetic information (Meadows et al., 2008). More importantly, it has been reported 
that differences in LD can lead to differences in the effect of a SNP in different populations 
(Bastiaansen et al., 2014). Therefore, it may be plausible that the ANK3 rs10994336 and the 
ANK3 rs9840190 subserve different functions on molecular level and therefore may impact 
brain development or brain activity in different ways yet to discover. 
The role of the VPFC in the pathophysiology of BD 
Our results also fully support our initial prediction that BD patients would have a significant 
decreased activation in the VPFC compared to healthy individuals and healthy relatives (Fig. 
6-1) and also that the three risk-alleles within the CACNA1C and ANK3 genes would 
independently amplified this abnormal brain de-activation (Fig. 6-3). The VPFC has been 
considered the core regulatory centre of emotions (Ochner et al., 2005; Phillips et al., 2008) 
that has direct anatomical connections with the amygdala (Ray and Zald, 2012). The 





studies in healthy individuals that suggested the pivotal role of this region in the voluntary 
suppression of affect that could represent increasing effectiveness in emotion regulation 
(Phan et al., 2005; Levesque et al., 2003). Therefore, decreased activation in the VPFC found 
in BD patients may be considered as a dysfunction of the VPFC in exerting cognitive or 
inhibitory control on emotional response's areas (Hariri et al., 2003). This finding confirmed 
the evidence from previous meta-analyses that reported reduced activation in this region 
(Houenou et al., 2011; Delvecchio et al., 2012), especially when BD patients processed 
negatively valenced emotions (Delvecchio et al., 2012).  
Finally, our results also showed a significant group by genotype interaction in the VLPFC for 
the ANK3 rs9804190, the ANK3 rs10994336 and the CACNA1C rs1006737 (Fig 6-3). We 
found thathealthy individuals and healthy relatives carriers of the CACNA1C rs1006737 or 
the ANK3 rs10994336 BD-risk conferring SNPs had increased activation in the VPFC. These 
findings are in line with the evidence that genes have more penetrant power in detecting 
risk-associated alterations in brain function than clinical diagnoses (Hariri and Weinberg, 
2003) and therefore can be identified also in healthy risk-allele carriers. Our results can be 
interpreted as an indicator of prefrontal physiological inefficiency related to genetic risk 
(Callicott et al., 2003a). In other words, the increased activation of the VPFC in unaffected 
individuals might be considered in the light of an exaggerated, compensatory mechanism of 
the top-down cognitive modulation exerted by the VPFC over brain regions known to be 
involved in emotional processing, such as the amygdala (Jogia et al., 2012). Therefore, 
overactivation in this area may underlie and reflect a compensatory effect and a capacity for 
resilience of unaffected individuals in response to BD-related disturbance in the VPFC.This 
interpretation might be supported by a functional connectivity study by Pompei et al. 
(2011b) that found a significant positive connectivity between VPFC and the dorsal PFC in 
healthy relatives during the Stroop task. The authors reported that the increased dorso-
ventral prefrontal connectivity is related to an increased in task difficulty and therefore it 
may reflect a capacity for resilience in this group who engaged more prefrontal regions to 
compensate dysfunctions in other brain regions that are usually involved in a response 
inhibition task.  
In contrast, we found that the ANK3 rs9804190 risk-allele was associated with decreased 





opposite pattern of activation compared to the ANK3 rs10994336 and CACNA1C rs1006737 
risk-alleles. This finding is in line with a previous fMRI study (Delvecchio et al., 2015,in press) 
that explored the effect of the ANK3 rs10994336 and the ANK3 rs9804190 during a working 
memory task. The authors showed that in healthy individuals, the ANK3 rs9804190 risk-
allele had not only a different impact on neural activation but also modulated completely 
different brain regions compared to the ANK3 rs10994336 risk-allele. Nonetheless, the 
reason for these differences is still unclear especially because our knowledge of ANK3 
expression in the brain is still limited. 
Conclusions 
Taken together, these findings showed that the three genetic variants within the CACNA1C 
and ANK3 genes are associated with functional effects on human brain not only in BD 
patients but also in individuals who do not show an expression of BD, e.g. healthy 
individuals and healthy relatives. The effect of the ANK3 rs9804190, ANK3 rs10994336 and 
CACNA1C rs1006737 risk-alleles is more prominent in the VPFC, a core region of the 
emotional brain network, in all three groups. Moreover, the decreased activation of the 
VPFC in our sample of remitted BD patients, with and without the presence of genetic risk, is 
in line with prior hypotheses supporting that the abnormal activation in the VPFC is not only 
related to either the depressive or manic state but also to the euthymic phase of the illness 
and therefore a stable trait of BD (Townsend et al., 2012). Finally, we cannot exclude that 
our results may be due to the influence of other genetic or environmental factors 
interacting with each other (Geoffroy et al., 2013). In support of this statement is also the 
study by Cooper et al. (2013) that highlighted that the reason why healthy individuals 
harbour potentially disadvantageous variants but without suffering any obvious ill effects 
might be due to several reasons including the possible requirement of additional genetic 
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Table 6-1 Study Sample 
 
 Unrelated Healthy 
Individuals 
N=46 







Age(years) 40.3 (13.2) 44.3 (11.9) 39.7 (13.7) 
Sex (Male/Female) 25/21 20/21 13/12 
Clinical Features 
HDRS total score a 0.1 (0.5) 4.8 (5.3) 0.14 (0.4) 
YMRS total score a 0.2 (0.6) 1.4 (3.0) 0.0 (0.0) 
BPRS total score a 24.3 (0.7) 27.5 (4.0) 24.1 (0.4) 
Age of onset (years) n/a 24.7 (8.0) n/a 
Duration of illness (years) n/a 20.2 (10.5) n/a 
Depressive episodes (n) n/a 5.7 (7.5) n/a 
Manic episodes (n) n/a 5.6 (7.7) n/a 
Cognitive task performance  
IQ 112.6 (14.5) 117.9 (17.9) 115.8 (18.5) 
Correctly identified 
faces, % 
93.1 (4.8) 90.3 (4.1) 89.9 (8.4) 
Response time, msb 1109 (241) 1491 (209) 1107 (152) 
Except for sex, all data are presented as mean (standard deviation); BD= Bipolar Disorder; 
BPRS= Brief Psychiatric Rating Scale; HDRS=Hamilton Depression Rating Scale; YMRS=Young 
Mania Rating Scale.a Patients> healthy individuals and relatives (P<0.001); b Relatives and 









Table 6-2 Effect of ANK3 rs10994336 genotype (risk-allele T) 












N = 40 
 
 
N = 72 
Unrelated Healthy 
Individuals 












N = 16 
Healthy 
Relatives 
N = 10 
Unrelated Healthy 
Individuals 
N = 32 
Patients  with 
BD 
N = 25 
Healthy 
Relatives 




39.9 (13.1) 42.8 (12.3) 40.6 (12.2) 42.0 (10.7) 40.8 (8.3) 39.3 (12.3) 43.3 (12.3) 38.3 (13.7) 
Sex (Male/Female) 
 
21/19 34/38 7/7 9/7 4/6 18/14 11/14 7/8 
Clinical Features  
HDRS total scorea,b 2.1 (4.3) 0.5 (0.8) 0.4 (0.9) 5.3 (4.6) 0.3 (0.6) 0.1 (0.4) 1.5 (0.9) 0.1 (0.5) 
YMRS total score a,b 0.7 (2.1) 0.1 (0.3) 0.2 (0.4) 1.6 (2.9) 0.0 (0.0) 0.2 (0.6) 0.7 (1.4) 0.0 (0.0) 
BPRS total score a,b 25.6 (3.2) 24.9 (1.0) 24.8 (1.1) 27.3 (4.3) 24.7 (1.1) 24.2 (0.6) 25.9 (1.9) 24.1 (0.3) 
Cognitive Performance 




110.7 (12.9) 112.3 
(16.2) 
112.0 (20.4) 116.7 (14.5) 121.7 (16.3) 118.3 (18.5) 
Correctly identified 
faces, % 
90.2 (10.2) 89.6 (11.1) 95.0 (4.1) 91.2 (6.2) 88.01 (13.0) 92.8 (7.0) 90.0 (9.4) 90 (8.3) 
Response time, msb 1248 (237) `1137 (206) 1193(328) 1244 (221) 1196 (41) 1096 (185) 1252 (249) 1092 (148) 
Except for sex, all data are presented as mean (standard deviation); BD= Bipolar Disorder; BPRS= Brief Psychiatric Rating Scale; HDRS= Hamilton Depression 
Rating Scale; YMRS= Young Mania Rating Scale. a Scores for BD patients are significantly greater than those for healthy individuals and unaffected first-degree 













 Effect of Genotype Effect of Group by Genotype 











N = 63 
 
 
N = 49 
Unrelated Healthy 
Individuals 
N = 28 
BD Patients 
 






N = 18 
BD Patients 
 
N = 20 
Healthy 
Relatives 




38.8 (13.6) 43.9 (12.1) 40.1 (13.26) 43.5 (12.51) 40.2 (14.3) 40.1 (11.9) 44.8 (9.5) 39.2 (13.8) 
Sex (Male/Female) 
 
29/34 29/20 14/14 8/13 7/7 11/8 12/9 6/5 
Clinical Features 
HDRS total score a,b 1.7 (3.9) 2.1 (4.1) 0.1 (0.4) 5.5 (5.6) 0.1 (0.1) 1.2 (3.3) 4.5 (5.4) 0.07 (0.3) 
YMRS total score a,b 0.7 (2.1) 0.5 (1.8) 0.2 (0.5) 2.0 (3.5) 0.0 (0.0) 0.06 (0.25) 1.2 (2.7) 0.0 (0.0) 
BPRS total score a,b 25.8 (1.5) 25.1 (1.9) 24.3 (0.6) 29.3 (5.0) 
 
24.2 (0.6) 24.7 (1.0) 26.3 (2.7) 24.1 (0.3) 
Cognitive Performance 
IQ 111.8 (15.6) 120.4 (18.7) 117.6 (16.3) 114.1 (13.9) 108.5 (18.1) 119.4 (16.5) 118.3 (21.5) 122.9 (18.1) 
Correctly identified 
faces, % 
90.4 (12.8) 88.4 (9.4) 92.38 (6.9) 87.2 (12.7) 91.3 (6.9) 90.8 (10.4) 86.56 (15.8) 87.7 (10.0) 
Response time, msb 1152 (229) 1165 (185) 1090 (207) 1287 (262) 1083 (98) 1102 (147) 1216 (222) 1183 (154) 
Except for sex, all data are presented as mean (standard deviation); BD= Bipolar Disorder; BPRS= Brief Psychiatric Rating Scale; HDRS= Hamilton Depression 
Rating Scale; YMRS=Young Mania Rating Scale. a Scores for BD patients are significantly greater than those for healthy individuals and unaffected first-degree 



























N = 57 
 
 
N = 55 
Unrelated Healthy 
Individuals 
N = 25 
BD Patients 
 
N = 17 
Healthy 
Relatives 
N = 15 
Unrelated Healthy 
Controls 
N = 21 
BD Patients 
 







37.9 (13.0) 37.5 (12.0) 40.1 (11.1) 44.4 (12.3) 36.53 (16.0) 38.1 (13.4) 44.1 (10.4) 36.0 (11.3) 
Sex (Male/Female) 
 
31/26 31/24 16/9 6/11 9/6 12/9 14/10 5/5 
Clinical Features 
HDRS total score a,b 2.3 (2.4) 1.1 (1.5) 0.1 (0.5) 6.8 (6.5) 0.06 (0.2) 0.1 (0.5) 3.3 (3.8) 0.1 (0.3) 
YMRS total score a,b 0.9 (1.3) 0.3 (1.0) 0.3 (0.6) 2.4 (3.5) 0.0 (0.0) 0.1(0.7) 0.8 (2.3) 0.0 (0.0) 
BPRS total score a,b 24.9 (1.8) 24.8 (1.1) 24.4 (0.7) 26.4 (4.2) 
 




113.7 (15.2) 101.5 (12.5) 118.7 (20.2) 119.5 (21.6) 111.8 (17.2) 116.9 (14.5) 112.5 
(14.1) Correctly identified 
faces, % 
89.8 (11.1) 89.66 (10.5) 92.9 (6.5) 90.9 (7.9) 89.1 (9.6) 93.3 (6.6) 89.4 (8.8) 90.8 (6.5) 
Response time, msb 1159 (237) 1150 (185) 1125 (285) 1240 (249) 1088 (169) 1097 (128) 1265 (236) 1078 (121) 
Except for sex, all data are presented as mean (standard deviation); BD= Bipolar Disorder; BPRS= Brief Psychiatric Rating Scale; HDRS= Hamilton Depression 
Rating Scale; YMRS= Young Mania Rating Scale. a Scores for BD patients are significantly greater than those for healthy individuals and unaffected first-degree 








Figure 6-1 Analysis of variance maps (axial sections presented in the standard space of Talairach and Tournoux with the z dimension shown 
numerically on the top left corner of each image) showing anatomical locations of the main effect of group (bipolarpatients, healthy 
relatives and healthy individuals) on activation in the affective relative to neutral facial expressions condition. Also shown are plots of the 
mean andstandard error of the weighted estimates of neural responses extracted from these areas for Healthy Controls (HC), Healthy Relatives 






Figure 6-2 Main effect of genotype, ANK3 rs9810490, ANK3 rs10994336 and CACNA1C rs1006737 on facial affect labelling task in the 
affective relative to neutral facial expressions condition. Also shown are plots of the mean of the mean signal intensity (reported as a 








Figure 6-3 Group by ANK3 rs9810490, ANK3 rs10994336 and CACNA1C rs1006737 interaction on facial affect labelling task in the affective 
relative to neutral facial expressions condition in healthy controls (HC), healthy relatives (RELs),and Bipolar Disorder (BD) patients. Also 






7.    Discussion 
 
7.1 Introduction 
This chapter synthesizes the main findings and highlights, the strengths and limitations of 
the studies comprising chapter 3, chapter 5 and chapter 6 (Chapter 3. Neural correlates of 
emotional processing in Bipolar Disorder: a voxel-based meta-analysis of functional 
magnetic resonance imaging studies; Chapter 5.The effect of ANK3 bipolar-risk 
polymorphisms on the working memory circuitry differs between loci and according to 
risk-status for bipolar disorder; and Chapter 6. FMRI investigation on the effect of 
CACNA1C and ANK3 risk genes on brain regions during processing of facial affect labelling 
task in Bipolar disorder, their healthy relatives and healthy individuals). Finally,this 
chapter will conclude by discussing directions for future research. 
7.2 Summary of the main findings 
The main aims of this thesis were to (1) synthesise data from functional magnetic resonance 
imaging (fMRI) studies exploring brain regions underpinning facial affect processing in 
Bipolar Disorder (BD) by using meta-analytic techniques and (2) delineate the functional role 
of the CACNA1C and ANK3 risk genes on neural circuits relevant to BD. For the latter 
purpose, I used fMRI data to examine the effect of three genetic variants within the 
CACNA1C (rs1006737) and ANK3 (rs10994336 and rs9804190) risk genes on the neural 
correlates of (a) working memory and (b) facial affect labelling in BD patients, their healthy 
relatives and healthy individuals. In reference to the aims of this thesis, the following 
findings are presented: 
1. The two meta-analyses included in chapter 3 aimed to show the common and distinct 
pattern of activation between BD, Major Depressive Disorder (MDD) and Schizophrenia (SZ) 
during processing of facial emotional tasks by using a meta-analytic technique: the 
Activation Likelihood Estimation (ALE). Briefly, this technique allows the data-mining and 
coordinate-based meta-analysis of fMRI results by employing a probabilistic approach (Laird 
et al., 2005). ALE estimates the probability that at least one activation focus from a 
collection of experiment truly lies at a speciﬁc voxels' location by use of Gaussian 





analyses not only elucidated the neuronal underpinnings of facial affect processing in BD but 
also delineated brain activation maps of MDD and SZ, disorders that overlap in terms of 
clinical symptoms (Fischer & Carpenter, 2009; Judd et al., 2002; Angst et al., 2010) and 
genetic risk factors (International Schizophrenia Consortium, 2009; Lichtenstein et al., 2009; 
McGuffin et al., 2003) with BD. 
In BD, my results are in line with prior fMRI studies (Chen et al., 2011)and showed increased 
activation of emotional regions, including parahippocampus and amygdala, and decreased 
activation in the ventral prefrontal cortex (VPFC), area considered important for the 
cognitive control of emotions (Hariri et al., 2003). Moreover, it is noteworthy that the 
overengagment of the emotional systems was also found in MDD but not in SZ patients 
which showed, however, decreased activation.  
In the direct comparison between BD and MDD I found that BD patients showed increased 
activation in the parahippocampus and amygdala compared to MDD and also decreased 
activation in the dorsal anterior cingulate.  
Compared to SZ, BD patients showed increased activation of the pulvinar thalamus and 
decreased activation in the posterior associative cortices.  
Taken together, these results underscore the engagement of common and disease-specific 
brain regions between BD, MDD and SZ suggesting that further examination of brain 
differences between these disorders may shed light to mechanisms differentiating BD from 
MDD and SZ.  
2. (a) The fMRI study investigating the main effect of two risk single nucleotide 
polymorphisms (SNPs) located in the ANK3 gene, the rs10994336 and the rs9804190, and 
the group by genotype interaction for each SNPs during a working memory task, described 
in chapter 5, lead to two significant results:  
i) For healthy individuals, I found that the two SNPs within the ANK3 risk gene affect 
different regions of the working memory circuitry. For the ANK3 rs10994336 I found 
decreased activation in the ventral visual cortex, including the middle and inferior temporal 





prefrontal cortex, including the middle and inferior frontal gyri. These regions are both part 
of the superordinate cognitive control network (Niendam et al., 2012) but they subserve 
different functions.  
The prefrontal cortex plays an important role in regulating executive function, such as 
working memory, cognitive flexibility and planning (Elliot et al., 2003). The increased 
activation observed in this region in carriers of the ANK3 rs9804190 risk-allele may be a 
reflection of the inefficient use of the prefrontal networks and therefore a deficit in the 
executive functions. In keeping with this interpretation is the evidence from a study by 
Roussos et al. (2012) which showed that healthy individuals carriers of the ANK3 rs9804190 
risk-allele underperformed in several executive function tasks.  
On the other hand, the ventral visual cortex is involved in the processing of visual stimuli, 
implicit or explicit, and the decreased activation in this area is in line with a previous study 
by Ruberto et al. (2011) which found that the ANK3 rs10994336 risk-allele was associated 
with decreased sensitivity in target detection. 
ii) BD patients and their healthy relatives carriers of either the ANK3 rs10994336 or the 
ANK3 rs9804190 risk-allele showed increased activation in the ventral anterior cingulate 
cortex (ACC) compared to healthy individuals. Additionally, BD patients carriers of the ANK3 
rs10994336 risk-allele also showed increased activation in the posterior cingulate cortex 
(PCC) compared to healthy individuals. Both regions have extensive reciprocal connections 
to  multiple cortical and subcortcal regions (Hagmann et al., 2008; Paus et al., 2001) and 
they are key components of the default mode network (DMN), one of the most studied 
resting-state networks (Buckner et al., 2008; Raichle et al., 2001).  
In healthy individuals, it has been consistently reported that the regions that are part of the 
DMN, including the ventral ACC and the PCC, are supposed to be deactivated during 
cognitive demanding tasks, and highly metabolically active during rest (Leech et al., 2011; 
2014; Mazoyer et al., 2001). Therefore, the hyperactivation in the ventral ACC and PCC 
observed in this study in BD patients carriers of either risk-alleles support the evidence of a 
failure to deactivate the DMN network that therefore may interfere with the regions that 





fMRI study by Allin et al. (2010) that found a failure to deactivate the PCC in euthymic BD 
patients while performing a paced verbal fluency task. Finally, the same pattern of 
hyperactivation in the ventral ACC observed in healthy relatives carriers of the ANK3 
rs10994336 risk-allelemay suggest a possible neurobiological marker for the familial risk of 
the BD condition.  
2. (b) The fMRI study investigating the functional role of the three SNPs within the CACNA1C 
(rs1006737) and ANK3 (rs10994336 and rs9804190) genes on four predefined volume of 
interests (VOIs) during processing of facial affect labelling task reported in chapter 6 
showed: 
i) The three genetic polymorphisms regardless of group influenced key regions of the facial 
affect processing network with increased activation in the amygdala, fusiform gyrus, inferior 
occipital gyrus and VPFC for the CACNA1C rs1006737 and ANK3 rs10994336 risk-alleles and 
decreased activation in the same regions for the risk ANK3 rs9804190 allele. Together these 
findings add to the growing literature that showed stronger effects of these genes at the 
level of brain processing of emotional and cognitive information (Krug et al., 2010; Jogia et 
al., 2011; Bigos et al.,2010; Roussos et al., 2012).    
ii) BD patients had decreased activation in the VPFC compared to healthy individuals and 
their healthy relatives. This result is in keeping with prior evidence which showed decreased 
VPFC activation in BD patients while processing emotional tasks (Altshuler et al., 2008; 
Foland et al., 2008; Jogia et al., 2008; Foland-Ross et al., 2012). Taken together these 
findings suggested that the dysfunction in the VPFC is a trait related feature of BD and 
represent a dysfunction of the cognitive control mechanism exerted by the VPFC over the 
amygdala (Jogia et al., 2008). 
iii) In healthy relatives and healthy individuals the risk variants within the CACNA1C 
rs1006737 and ANK3 rs10994336 independently increased the activation in the VPFC. The 
implication of these findings has been linked to a compensatory mechanism of the top-
down cognitive control system (Jogia et al., 2012) that it has been interpreted as the ability 





contrast, the ANK3 rs9804190 risk-allele has been associated with decreased activation in 
the VPFC in the two groups. 
7.3 Strengths and limitations 
7.3.1 Strengths 
This thesis has multiple strengths and advantages. Firstly, the two meta-analyses included in 
this thesis synthesized the results of fMRI studies conducted by independent researchers 
and therefore helped to identify neural patterns that are consistent and specific for BD, 
MDD and SZ. Consequently, they provided a clearer picture of the neural regions 
underpinning facial emotional processing in these psychiatric disorders.  
Secondly, the two fMRI studies described in chapter 5 and chapter 6 of this thesis are 
among the first to report evidence about the different functional impact of genetic 
polymorphisms within the CACNA1C and ANK3 risk genes for BD during processing of 
cognitive and emotional tasks in BD patients, their healthy relatives and healthy individuals.  
Thirdly, the participants that I used for all the fMRI analyses performed in this thesis were 
matched for age and sex in order to increased the homogeneity of the sample. Indeed, 
several studies in BD reported that both sex (Barret et al., 2008) and age (Weisenbach et al., 
2014) have an effect on brain activation during processing of cognitive and emotional tasks.  
Fourthly, the observed differences in brain activation during processing of cognitive 
(Chapter 5) and emotional (Chapter 6) tasks cannot be attributed to differences in accuracy 
or intellectual ability as the groups (healthy individuals, BD patients and healthy relatives) 
were comparable in terms of these measures.  
 
Fifthly, BD patients included in this thesis were in euthymic state and therefore the results 
may underline the trait deficits of the disease rather than state related effects.  
 
Finally, the results from the two imaging genetics studies included in this thesis suggested 
that by harnessing the information in the human genome is possible to uncover insights into 
the neurobiology of BD which in turn may point to new targets for the development of more 





role in the regulation of the voltage-gated ion channels that, in the light of my findings, 
seem to be important for the proper development and function of neural circuits that 
regulate emotions and cognition, especially in BD patients. The voltage-gated ion channels 
are widely and selectively distributed in the brain and therefore it is not surprising that 
alterations in ion channel activity may be the underlying cause of the dysfunctions in the 
specific brain regions observed in my two imaging genetic studies. It has been shown  that 
the activation of these channels influences neurotransmitter release, neuron excitability, 
gene transcription, and plasticity (Imbrici et al., 2013) and their activation or inhibition can 
alter the extracellular levels of several neurotransmitters, including dopamine, serotonin, 
glutamate, and GABA, which are notoriously implicated in psychiatric disorders (Aldana and 
Sitges, 2012; Mele et al., 2012). Therefore, discovering the important role of the CACNA1C 
and ANK3 genes at the level of brain function might be of interest in finding neurobiological 
mechanism underpinning the clinical symptoms observed and experienced in BD as well as 
in developing novel molecules acting as selective ion channels blockers and consequently in 
finding better treatments for BD. 
7.3.2 Limitations 
In this section I will report some limitations related to the results included in this thesis.   
Firstly, the two meta-analyses included in chapter 3 present some methodological 
limitations that needed to be acknowledged: (a) I accepted the results of individual studies 
as reported and not weighted based on the threshold of significance used in each original 
study, (b) although most patients were remitted when scanned the level of patients' 
symptomatology varies in the studies included, (c) in the majority of the studies included, 
patients were medicated and were prescribed combinations of psychotropics and therefore 
the impact of medication on the results cannot be easily evaluated, (d) sex differences have 
not been explored, (e) most of the original studies examined multi-episode BD patients 
therefore the results of my meta-analyses could not be generalized to the initial stages of 
mood disorders, (f) it would be desirable to evaluate a range of study-wise factors that may 
influence both the nature and the topography of the results. These factors may include 
clinical information about age of onset or illness severity, task performance and details of 





used in individual source studies, which precludes separate analyses per task type because 
of small sets sizes, and finally the two meta-analyses provided an estimate of the probability 
of differential activation in brain regions when comparing diagnostic groups and not the 
mean activation difference in these regions. Therefore, traditional measures of 
heterogeneity and publication bias that are based on the effect size of group differences are 
not applicable.  
Secondly, the relatively small sample size in the three groups included in chapter 5 and 
chapter 6 might have masked differences of small effect sizes. The small sample size 
together with the rarity of one of the alleles for each genotype, brought me to consider the 
heterozygotes together with the homozygotes of each genotype. Therefore, the results of 
my thesis did not show the effect of carriers of just one risk-allele (heterozygotes) on 
cognitive and emotional circuits.   
Thirdly, the three investigated variants, the ANK3 rs9804190, the ANK3 rs10994336, and the 
CACNA1C rs1006737, are located in the intron of the genes and therefore not causing an 
amino acid substitution. As mentioned in chapter 6, it still not clear the effect of these non-
coding regions on neural activation and therefore more studies are needed to fully 
characterize the mechanism by which alterations in CACNA1C and ANK3 expression result in 
brain function changes.  
Fourthly, although the BD patients used in this thesis were in remission, they all have been 
treated with different psychotropics and therefore I cannot conclusively exclude a possible 
effect of medication. However, Keener et al. (2007) have reported that medicated BD 
patients showed similar pattern of activation compared to healthy individuals but more 
research exploring the effect of psychotropic medications in brain function and structure is 
needed.  
Finally, I cannot exclude that the effects of the three three genetic variants observed in 
Chapter 5 and Chapter 6 could be due to other, yet unknown, genetic loci, in linkage 






7.4 Future direction 
The studies and the results discussed in this thesis point to new avenues of enquiry in BD. 
This section aims to highlight a variety of research directions that need to be pursued to 
advance our understanding on this disorder. 
As mentioned in the limitations, in this thesis I was unable to investigate the effect of 
carriers of only one dysfunctional copy of each genetic variant (heterozygotes) within the 
CACNA1C and ANK3 genes on brain regional activation during cognitive and emotional tasks.  
Therefore, by increasing the sample size I will be able to divide the groups according to the 
three genotypes. This will be useful for extending my results and to provide more insight on 
the functional impact of these genes on brain activation.  
Evidence from GWAS studies reported the involvement of several other risk genes for BD, 
including NCAN (Cichon et al., 2011) and ODZ4 (Green et al., 2013; Mühleisen et al., 2014). 
Therefore the examination of these genes on neural activation in BD patients could be a 
future research objective in order to identify the most relevant risk genes for BD. Moreover, 
it will be interesting to also explore the epistatic genetic effects of those genes to identify 
possible interactions that may contribute to the diathesis of BD.  
The BD sample included in this thesis was in clinical remission and therefore I investigated 
the effect of ANK3 and CACNA1C risk genes on trait-related functional dysfunctions in BD. It 
would be interesting to explore the effect of these candidate genes in acute affective states 
(manic and depressive) to identify state related functional differences. It has been 
consistently shown that specific affective states might altered different brain regions while 
processing of cognitive or emotional tasks (Phillips et al., 2007; Townsend et al., 2012). 
However, evidence about the impact of specific genetic variants on BD in different affective 
states is still at its infancy. 
GWAS studies reported a highly significant polygenic component of BD risk, involving up to 
thousand of common alleles with very small effect (Sklar et al., 2011; Ferreira et al., 2008; 
Mühleisen et al., 2014). Therefore, the scientific interest is now shifting towards the 
exploration of the aggregate effect of common genetic variants (alleles) in the context of a 





polygenicity. The main reason is because with a polygenic approach, and therefore with the 
ensemble of genetic markers resulted significant in GWAS studies, it will be possible to 
increase the explanatory power of a given phenotype even in small samples (Dudbridge et 
al., 2013). The first successful application of polygenic score analysis to GWAS data was in 
schizophrenia (Purcell et al., 2009; Ripke et al., 2014). Notably, the recent study by Ripke et 
al. (2014) reported that the variance explained by the polygenic risk score (PRS) in 
schizophrenia is exponentially higher (18%) compared to the variance explain by a single 
SNP, e.g the CACNA1C gene (0.3%). Moreover, the PRS has also been used in correlation 
with neuroimaging measures. Specifically, two fMRI studies employed PRS for predicting 
brain regional dysfunctions, one in SZ (Walton et al., 2013) and the other in individuals with 
familial risk for a mood disorder (Whalley et al., 2012). Particularly, the study by Whalley et 
al. (2012) showed that increased polygenic risk-allele load for BD was associated with 
increased activation in limbic regions previously implicated in BD, including the ACC and 
amygdala, during a verbal fluency task. Finally, the clinical relevance of the polygenic scoring 
might be potentially striking especially with the discovery of even more genetic markers 
associated with a given disease. As the cost of sequencing decreases, the clinical utility of 
the DNA sequencing is currently undergoing intensive investigation as a tool for precise 
diagnosis, risk prediction, and therapeutic guidance (Biesecker et al., 2014). Specifically, 
some studies have already proven the clinical importance of the combination of established 
genetic risk variants in the discrimination of cases from controls, especially for prostate 
cancer (Aly et al., 2011; Zheng et al., 2008). Therefore, it is plausible that in the near future, 
the PRS may have the potential to improve the efficiency of health care system by helping to 
develop personalized treatments as well as preventive strategies also in common psychiatric 
diseases.  
Finally, as described in chapter 5 and chapter 6, the two tasks employed in this thesis, the N-
back and the facial affect labelling tasks, engage a large network of interconnected regions 
(Owen et al., 2005; Phillips et al., 2003). Therefore, it would be pertinent that future fMRI 
studies will focus their attention on investigating the association of genetic variants within 
the CACNA1C and ANK3 genes on multiple rather than isolated brain regions. With this 
regard, the dynamic casual modelling (DCM) method (Friston et al., 2003) might be useful 
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Appendix 1:  Original paper on:" Risk and resilience in bipolar disorder: rationale and 

























































Appendix 2:  Original paper on:"Common and distinct neural correlates of emotional 
processing in Bipolar Disorder and Major Depressive Disorder: A voxel-based meta-
analysis of functional magnetic resonance imaging studies." European 


































































Appendix 3: Original paper on: "Evidence of diagnostic speciﬁcity in the neural correlates 
of facial aﬀect processing in bipolar disorder and schizophrenia: a meta-analysis of 









































































Appendix 3: Original paper on: “The effect of ANK3 bipolar-risk polymorphisms on 
the working memory circuitry differs between lociand according to risk-status for bipolar 
disorder." American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2015; 
9999: 1–9. 
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